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I am pleased to issue the ‘Clinical Guidelines for Opioid 
Substitution Treatment’ on behalf of the Primary Care division 
of the HSE. The Guidelines arise from a recommendation 
in the ‘Introduction to the Opioid Treatment Protocol’ to 
develop joint guidelines against which future audits could be 
measured.
The HSE established a working group, chaired by Mr Joe Doyle 
from the Social Inclusion Office, comprising representatives 
from the College of Psychiatrists of Ireland, the Irish College 
of General Practitioners, the Pharmaceutical Society of Ireland 
and HSE Addiction Services. The group reviewed existing 
national and international guidelines, consulted with key 
stakeholders and staff working in the service and considered 
submissions in detail. Expert opinion from Professor Michael 
Farrell, Director of the National Drug and Alcohol Research 
Centre at the University of New South Wales, was obtained 
both during the process and on completion.
The resulting document represents a significant step forward 
in delivering evidence based approaches to enhance the 
quality and safety of care that the HSE Addiction Service 
provides. I wish to commend the Working Group for their 
hard work over a significant period of time and in particular 
to thank Mr Joe Doyle for his effort and commitment to 
completing this work.
John Hennessy 
National Director of Primary Care
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The HSE established a clinical guideline working group 
towards enacting two specific recommendations in the 
Introduction of the Opioid Treatment Protocol (2010) report. 
These recommendations were to develop joint guidelines 
that would enable benchmarks against which future audits 
could be measured and to move to less urine testing (with an 
elimination of supervision) and a greater clinical focus on the 
use of the results of drug testing samples.
The committee was comprised of representatives from the 
College of Psychiatry of Ireland, the Irish College of General 
Practitioners, the Pharmaceutical Society of Ireland, HSE 
Addiction Service Managers, and chaired by the National 
Social Inclusion Office. The committee drew on relevant 
guidelines, such as the UK guidelines ‘Drug Misuse and 
Dependence: UK Guidelines on Clinical Management’, the 
NICE guidelines on Methadone and buprenorphine for 
the management of opioid Dependence, the Eurometh 
Methadone Guidelines, and the relevant ICGP Guidelines. 
Expert opinion was sought during the drafting process and 
key stakeholder groups were consulted at two points of 
the drafting process (chapter 2 drug testing and when a 
composite draft was finalised). The committee considered 
each submission in detail and adapted the Guideline 
accordingly. 
The Guidelines are based on the principles that people who 
use drugs have the same entitlement as other patients to the 
services provided by the HSE. Service users have a right to be 
heard, listened to and taken seriously and should be consulted 
and involved in all matters and decisions that may affect their 
lives. The Guidelines have been developed in order to outline 
evidence-based care to standardise and improve the quality 
and safety of care to the patient.
The main illicit opioid used in Europe is heroin, which may 
be smoked, snorted, or injected. A range of other synthetic 
opioids are also illicitly available, such as Oxynorm/
Oxycontin, codeine, fentanyl, methadone, and buprenorphine. 
In 2011, eleven European countries reported that 10% or 
more of their first-time opioid clients entering specialised 
treatment were using opioids other than heroin.
In Ireland, Opioid Substitution Treatment (OST) refers 
to the provision of both methadone and buprenorphine/
buprenorphine-naloxone. At the end of 2014, there were 9764 
people in receipt of OST in HSE Addiction Clinics and GPs, 
compared with 9,116 in 2013. There were 726 new first time 
patients in 2014, compared to 552 first time patients in 2013. 
There were 468 people in receipt of OST in prisons, compared 
to 539 in December 2013. There were 159 new first time 
patients in prisons, compared to 169 in 2013. 1 
1 Most recent information on drug treatment, visit http://www.
hrb.ie/health-information-in-house-research/alcohol-drugs/
ndtrs/ . For interactive tables on drug treatment, visit http://www.
drugsandalcohol.ie/ 
The involvement of the community pharmacists in the 
dispensing of methadone has continued to expand over the 
past decade. At the end of December 2013, there were 6,265 
(69%) patients receiving their medication in 628 pharmacies, 
compared with 3,740 (58%) patients in 329 pharmacies at 
the end of 2003.
Drug use has a detrimental impact on individual service users, 
their children, families, and society in general. Drug-related 
mortality rates in Ireland are among the highest in the EU. 
National and international evidence consistently shows that 
drug treatment is effective. The Research Outcome Study in 
Ireland (ROSIE) shows drug treatment leads directly to less 
involvement in crime and to improvements in employment 
and training (Comiskey et al., 2009). OST has proven to be 
effective: the focus should now shift to optimising outcomes. 
These Clinical Guidelines are the first national guidelines 
applicable in HSE treatment clinics, as well as in primary 
care settings; they update and replace the 2008 ICGP 
guidelines: Working with Opiate Users in Community Based 
Primary Care and will provide guidance on the treatment of 
opioid dependence in Ireland. The Guidelines are targeted 
at clinicians and patients in the management of Opioid 
Substitute Treatment (OST), but also for the community and 
voluntary services that are supporting people’s treatment and 
rehabilitation. 
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OST plays an intrinsic role in supporting patients to recover 
from drug dependence. Assessment and recovery care-
planning is an ongoing process and, once stabilised on OST, 
collaborative and active care planning (e.g. using mapping 
tools and motivational approaches) to consider options across 
a wide range of personal recovery goals is an important part 
of a recovery-orientated culture. Treatment should seek to 
maximise outcomes across a range of domains, including drug 
and alcohol misuse, health, and psychosocial functioning.
There are currently 1,000 people working in the addiction 
services. The Guideline is based on the assertion that 
interventions must be carried out by trained and competent 
people, with a clear understanding of the impact of 
problematic drug use. Investment in upskilling key 
competencies and the provision of professional support and 
supervision is essential. 
It is hoped that the Guidelines will now set the parameters 
for audit process. The involvement of service users in this 
process will be crucial, as will the completion of a brief 
instrument, such as the Treatment Outcome Profile, to provide 
important information on the performance of individuals and 
on the overall performance of the service (in line with the 
Introduction of the Opioid Treatment Protocol). The updated 
and revised National Drug Treatment Reporting System 
(NDTRS) form will also inform on service provision; covering 
data on key working and case management, interventions 
carried out, information on detoxification, and the condition of 
the service user at discharge.
I would like to thank the drafting committee for their patience 
and commitment to developing this multi-stakeholder 
guideline. Thanks also to the numerous individuals and 
stakeholder groups for submitting feedback at various stages. 
Finally, I would like to gratefully acknowledge the significant 
contributions of Aoife Davey in drafting and editing this 
document.
Joseph Doyle 
Chairperson
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1.1 Key Points
 » Opioid Substitute Treatment (OST) 
plays an intrinsic role in supporting 
patients to recover from opioid 
dependence.
 » OST should be provided at the lowest 
level of complexity, matching the 
patient’s needs, and as close to the 
patient’s home as possible.
 » Service users should be fully involved 
in the development of their care plans, 
setting appropriate treatment goals and 
reviewing their progress in treatment. 
 » It is good practice to involve service 
users in the design, planning, 
development, and evaluation of 
services.
 » One of the special features and 
strengths of drug treatment and 
rehabilitation in Ireland is the valuable 
partnership between statutory drug 
treatment services and the community/
voluntary sectors which comprise 
significant service provision in some 
areas.
 » Services should be proactive, with 
regard to their engagement with 
family members, but there should be 
recognition that they have separate 
and distinct needs from service users.
 » A good therapeutic alliance is crucial 
to the delivery of any treatment 
intervention.
1.2 Principles underpinning good 
governance for addiction services 
incorporating OST
Treatment and rehabilitation models available 
in Ireland have primarily been determined by 
how services developed locally; often being 
influenced by factors such as geography, 
community acceptance, and the available 
health provision infrastructure. 
Whatever the local treatment system model, 
the following principles should apply: 
 » Clinical governance: The principles of 
good clinical governance are outlined in 
the HSE document Achieving excellence 
in clinical governance – towards a culture 
of accountability (2010). See Appendix 1 
for the HSE Guiding Principles of Clinical 
Governance.
 » Standards: All health services should 
implement the Standards for Safer Better 
Health Care (2012); continuing to improve 
the day-to-day experience and outcome 
for patients and their families and begin to 
demonstrate compliance with them. Quality 
in Alcohol and Drug Services (QuADS) 
has been embedded within the National 
Standards for Safer Better Health Care.
 » Partnership: Local statutory, community 
and voluntary-based services should work 
with primary care providers to ensure 
service provision meets the changing needs 
of communities within defined resources. 
Drug use trends and potential treatment 
populations can change rapidly. Local service 
providers need to work together to ensure 
services respond appropriately.
 » Competencies: All agencies should have the 
necessary competencies to respond to the 
complex issues associated with substance 
use.
 » Involving service users: Involving service 
users as active partners in their drug 
treatment is essential and is associated with 
better outcomes. Service users should be 
fully involved in the development of their 
care plans, setting appropriate treatment 
goals and reviewing their progress in 
treatment. It is also good practice to 
involve service users in the design, planning, 
development and evaluation of services, and 
in advocacy and support groups linked to 
local drug treatment. Service users may also 
be involved in peer education schemes e.g. 
to reduce the risk of overdose and blood-
borne viruses.
 » Involving families/carers: Services 
should be proactive with regard to their 
engagement with family members/carers, 
but there should be recognition that they 
have separate and distinct needs from 
service users and may even have needs 
that conflict with them. At all stages in the 
continuum of care, family members should 
be offered the opportunity to engage with 
supports for themselves. Family or guardian 
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Chapter 1: Guiding principles of Opioid Substitution Treatment (OST)
involvement should be the norm in the 
treatment of under-18 year olds.
 » Informed consent: The HSE National 
Consent Policy2 means the need for consent 
extends to all interventions conducted 
by or on behalf of the HSE on service 
users in all locations. Consent must be 
obtained before starting treatment or 
investigation, or providing personal or social 
care for a service user or involving that 
individual in teaching and research. This 
requirement is consistent with fundamental 
ethical principles, with good practice in 
communication and decision-making, and 
with national health and social care policy. 
The need for consent is also recognised in 
Irish and international law.
1.3 Therapeutic Alliance
Forming a therapeutic alliance is a consistent 
predictor of engagement and retention of 
clients in drug treatment. The initial time 
devoted to the development of an early 
therapeutic alliance is vital. 
2 For national consent advisory group policy 
documents see www.hse.ie
The key competencies of developing a 
therapeutic alliance are: 
 » The ability to engage a service user 
appropriately while demonstrating 
satisfactory levels of warmth
 » The ability to build trust, and to be able to 
adopt a personal style consistent with and 
engaging with the service user
 » An ability to adjust the nature of the 
intervention according to the capacities of 
the service user
 » An ability to deal with and recognise the 
importance of discussion and expression 
of client’s emotional reactions, particularly 
intense emotions, while also working with 
the patient’s motivation
 » The ability to engage a service user 
appropriately while demonstrating 
satisfactory levels of understanding (Roth 
and Pilling, 2007)
Other factors identified in ensuring effective 
therapeutic alliance include: taking a non-
blaming, non-judgmental stance, use 
of motivational dialogue, being a good 
listener, being in good psychological health, 
and developing a helping alliance and a 
collaborative relationship with the service user 
(Wanigaratne, 2005). 
Equally, an awareness of factors that 
reduce the possibility of forming a positive 
therapeutic alliance is important. These 
might include rigidity, impatience, criticism, 
inappropriate self-disclosures, being distant, 
aloofness, being distracted, and making 
inappropriate use of silence (Wanigaratne, 
2005).
1.4 Information sharing
It is important to maintain public confidence 
in the confidential nature of personal 
health information while, at the same 
time, optimising use of such information. 
Identifiable information about patients must 
not be given to others unless the patient 
consents or if disclosure without consent 
can be justified.3 The National Protocols 
and Common Assessment Guidelines to 
Accompany the National Drugs Rehabilitation 
Framework (NDRIC, 2011) provides a 
set of protocols for interagency working 
arrangements. This is the Framework within 
which addiction services operate.
3 Reasons for non-consensual disclosure: 
• If a court or tribunal orders to disclose medical 
information, or when obliged by law or Public 
Health Regulations.
• If there is a need to protect children under the 
‘Children First Guidelines’
• If there is a substantial and immediate risk to 
the service user or another person’s welfare. 
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2.1 Key Points
 » All drug users entering treatment and rehabilitation should have a care plan based on 
assessed need, which is regularly reviewed.
 » All drug users entering treatment and rehabilitation should have full risk assessments to 
evaluate immediate health concerns, mental health issues, and risks to children.
 » The needs of all drug users should be assessed across the domains of drug and alcohol 
use, health (physical and psychological), offending, and social functioning (including 
housing, employment and relationships).
 » Key working is a basic delivery mechanism for interventions in addiction services.
 » Psychosocial interventions, which address assessed needs, are a fundamental part of drug 
and alcohol treatment.
 » Psychosocial interventions are the mainstay of treatment for the use of cocaine and 
other stimulants, cannabis, and hallucinogens.
 » Psychosocial interventions can also address common associated or co-occurring mental 
disorders, such as depression or anxiety.
 » Self-help and mutual aid approaches have been found to be highly effective for some 
individuals and service users seeking abstinence should be signposted to them.
 » Contingency management (CM), CRA/CRAFT/ACRA and family and couples interventions 
should be offered, where appropriate.
2.2 OST as a component of 
rehabilitation
OST is considered a key component in the 
treatment of opioid dependence and plays an 
important role in rehabilitation and recovery. 
Well-delivered OST provides a platform of 
stability and safety that protects people and 
creates the time and space for them to move 
forward in their personal recovery journeys. 
OST has an important and legitimate place 
within recovery orientated systems of care. We 
need to ensure OST is the best platform it can 
be, but focus equally on the quality, range, and 
purposeful management of the broader care 
and support it sits within (Strang, 2012, p.5).
2.3 OST within an integrated care 
plan
Given the diversity of the supports that may 
be required during rehabilitation, it is unlikely 
that one service alone could meet all the 
needs or goals of an individual. Depending 
on the complexity of need, an individual may 
require supports from statutory, voluntary and 
community services. The care planning and 
case-management process (of the National 
Drugs Rehabilitation Framework) is intended 
to co-ordinate the services being received 
and to identify, through assessment, which 
supports should be sought. The service user’s 
needs and input should be central to the 
development and ongoing implementation of 
an individual care plan. 
A care plan should be fully drawn up within 
the first three months of treatment and 
should clearly document the patient’s aims 
and goals for treatment and outline the 
range of treatments required to achieve the 
user’s goals. A formal care plan review should 
be undertaken every 3 months and when 
a change in a service user’s circumstances 
makes it necessary. The date of next care plan 
review should be explicitly stated in the care 
plan at the end of the care planning session 
and at the end of each subsequent case 
review. Patients should be provided with a 
copy of their care plan.
OST should be provided with a range of 
medical and psychosocial interventions.4 
4 As outlined in the National Drugs Rehabilitation 
Framework (2011).
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The recognised system for substance misuse 
services to share information in order to 
develop shared care plans is outlined in the 
NDRIC National Protocols and Common 
Assessment Guidelines (2011).
2.4 Psychosocial interventions: 
matching treatment to service user 
need
Following a comprehensive assessment, it is 
important to match a treatment programme 
to the needs identified with the service user 
in their care plan. The severity of needs will 
determine the length and type of treatment 
required. Evidence supports the effectiveness 
and efficiency of reserving more intensive 
services for service users with more severe 
problems. 
The effectiveness of treatment may not be 
based on the number of counselling sessions 
received but on the provision of targeted 
interventions directed towards the specific 
problem identified with the service user. 
Service users with more severe alcohol and 
drug problems or who are more depressed 
tend to do better in highly structured, 
behaviourally orientated treatments.  
Service users’ needs should be addressed 
in a ‘stepped care approach’: less intensive 
interventions initially, and then ratcheting up, 
depending on the complexity of issues, degree 
of dependence, co-morbidity, and polydrug 
use identified (Figure 1).
Stepped-care model for the treatment of substance misuse problems
Psychotherapy Drug free/maintained
Cognitive-behavioural  
(relapse prevention) and counselling
Reducing drug use/maintenance
Cognitive-behavioural 
(motivational 
interviewing)
Stable/continuing to use
Behavioural 
approaches
Chaotic/severe problems
Source: Wanigaratne and Keaney, 2002 
Figure 1: Stepped-care model for the treatment of substance misuse problems
All interventions should be delivered by people 
who are qualified and accredited in delivering 
the intervention. They should also receive 
appropriate line management supervision to 
ensure competency and that the interventions 
being provided are appropriate to their role.
2.5 Psychosocial interventions
For opioid, polydrug and alcohol users, 
psychosocial interventions may be provided 
in combination with pharmacological 
intervention. There is evidence that the 
effectiveness of methadone maintenance is 
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enhanced by the provision of psychosocial 
interventions.5  
For stimulant use, including cocaine, and for 
cannabis use, there is no effective substitution 
agent. Hence, the mainstay of treatment is 
evidence-based psychosocial intervention. 
The NICE guidelines (2007) on psychosocial 
interventions in alcohol and drug use 
identify a number of formal psychosocial 
treatments as having high quality evidence 
base. The Community and Voluntary sector, 
in partnership with the HSE, have been 
important innovators and deliverers of 
psychosocial interventions and have adapted 
their programmes to suit emerging drug 
trends. These include brief interventions, drug-
related advice and information, advice and 
support for social problems, harm reduction, 
complementary and alternative therapies, 
cognitive behaviour therapy (CBT)/coping 
skills (CBCS), motivational interviewing (MI), 
relapse prevention, dialectical behaviour 
therapy (DBT), node-link mapping, 
contingency management, counselling and 
psychotherapy, community reinforcement 
approach, family interventions, family 
therapy, strengthening families programme, 
behavioural couples therapy (BCT), and 
mutual aid/self-help approaches (AA, NA and 
SMART Recovery).
5 Amato et al., 2004.
Many drug users also have considerable 
co-morbid problems, particularly common 
mental health problems, such as anxiety and 
depression. There is evidence that a range of 
evidence-based psychosocial interventions, as 
described in relevant NICE guidelines, can be 
beneficial. 
There is a growing body of evidence indicating 
that a significant percentage of clients who 
present for substance abuse treatment are 
dealing with the impact of some form of 
trauma. A report commissioned by SAMHSA6 
states that two-thirds of individuals, 
presenting to substance use treatment, 
report childhood abuse or neglect, and 
75% of women in treatment programmes 
report having being sexually abused. In 
addition, the report states that “there is a 
high probability of drug or alcohol relapse 
when trauma is not addressed and no 
alternative means of coping with the pain are 
provided”. SAMHSA has developed treatment 
guidelines7 that recommend all services 
working with individuals presenting with 
substance use issues be trauma informed. A 
‘trauma-informed’ system is one in which all 
components of a given service system have 
been reconsidered and evaluated, in light of a 
basic understanding of the role that violence 
6 Jennings, 2004.
7 Harris & Fallot, 2001.
plays in the lives of people seeking mental 
health and addictions services. 
2.6 Key steps involved in the 
integrated care pathway
The key steps involved in the integrated care 
pathway for rehabilitation, as outlined in the 
National Protocols and Common Assessment 
Guidelines to accompany the National Drugs 
Rehabilitation Framework (NDRIC, 2011), are: 
1. A drug and alcohol screen in line with the 
HSE SAOR model of screening and brief 
intervention.
2. An initial assessment to determine 
the seriousness and urgency of the drug 
problem. Depending on the outcome, a 
service user may be offered a further service 
within the assessing agency and/or be 
referred on to a more appropriate service. 
The type of intervention/support required 
may vary from a counselling session to 
inpatient detoxification or a combination 
of service interventions (See Appendix 2 for 
assessment templates).
3. A comprehensive assessment is 
appropriate for service users with more 
complex needs (See Appendix 2 for 
assessment templates). It will identify the 
services to be involved in the shared care 
plan. It should be ongoing and include the 
following: 
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a. Identification of all drug and alcohol 
use and measurement of severity.
b. Assessment of other domains, including 
psychological, physical and legal 
problems, as well as social issues, such 
as training, family support, and housing 
services.
c. Specific attention will be required for 
people who experience both mental 
health and substance use problems. 
It is essential that the assessing 
agency is competent in identifying 
possible mental health issues and is 
proactive in referring the service user 
for assessment of their mental health 
needs, where necessary.
Regarding the assessment of young 
people, in addition to the above, 
 » Assessment should be comprehensive 
and multidisciplinary, and may include 
Child and Adolescent Mental Health 
Services (CAMHS), social services, and 
youth probation services.
 » All domains of functioning should be 
assessed, including developmental 
needs, educational and language 
attainment, and emotional and physical 
health and safety.
 » Assessment of strengths and 
weaknesses of the family system is also 
vital.
4  Implementation of the care plan to 
support an individual rehabilitation 
pathway  This is a holistic, documented 
care plan between the service user and 
service provider based on SMART (Specific, 
Measurable, Attainable, Realistic and 
Time-bound) objectives. Care plans should 
document and enable review of service user 
needs, goals, and progress in four specific 
areas: Drug and alcohol misuse, Health 
(physical and psychological), Offending, 
and Social functioning (including housing, 
employment and relationships). The care 
plan should be brief and readily understood 
by all parties involved and should be a 
shared exercise between the service user 
and the service provider. It should explicitly 
identify the roles of specific individuals 
(including the service user) and services in 
its delivery. It should be reviewed routinely 
(every 3 months) and when a change in 
a service user’s circumstances makes it 
necessary (See Appendix 3 for care plan 
templates). 
5  Risks need to be assessed at all stages. 
These may include risks related to overdose, 
unsafe injecting practices, and unsafe sex. 
Wider risks may include self-harm, child 
protection, suicide ideation and intent or 
harm to others, domestic violence and risk 
related to crime and debt intimidation to 
individuals and families. 
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3.1 Key points
 » Good communication between 
the patient, the prescriber, the 
pharmacist, and other members of 
the interdisciplinary team is crucial in 
providing optimal treatment.
 » Carers should be active partners in drug 
treatment, where consent is given.
 » Patients should be made fully aware 
of the risks of their medication and 
of the importance of protecting 
children from accidental ingestion. 
Prescribing, supervision, and dispensing 
arrangements should also aim to 
minimise risks to children.
 » Supervision of Methadone has been 
proven to reduce deaths related to 
overdose of methadone.
 » Supervised consumption needs to be 
available for all patients for a length 
of time appropriate to their needs and 
risks. 
 » Ongoing assessment and care planning 
is central to the treatment process.
3.2 Aims and objectives of OST 
When deciding whether to prescribe, the 
clinician and the patient should use a care 
plan to document treatment goals and 
outcomes within the rehabilitation process 
(see Appendix 3 for care plan templates). This 
is within the context of promoting a process 
of change in drug taking that can incorporate 
overcoming dependence and:
 » reduce drug use
 » reduce risk-taking behaviour
 » reduce morbidity and mortality
 » reduce offending
 » promote stabilisation and onward 
progression 
 » improve health
 » improve quality of life; functioning as 
a productive member of society and 
becoming personally fulfilled
For some people, it will include becoming drug 
free.
3.3 Legislative requirements for 
Prescriptions and requisitions and 
initiation of OST
3.3.1 Methadone
The Methadone Protocol8 applies to medical 
prescribers and pharmacists. Adequate 
understanding of the law relating to 
prescribing and dispensing for drug users is 
vital. This includes the Misuse of Drugs Acts 
1977, 1984 and 2015 and the subsequent 
orders and regulations, such as the Misuse of 
Drugs Regulations 1988 (S.I. No. 328 of 1988) 
(as amended), which are applicable to OST 
prescribing and dispensing. It is an offence to 
supply methadone other than in accordance 
with these regulations.
In a community-based practice, OST can 
only be supplied to a patient if it has been 
prescribed by their OST Protocol Scheme GP 
or their locum on the standard methadone 
prescription form (see Appendix 4 for a 
8 The Methadone Protocol is the system in place 
to implement and support the Misuse of Drugs 
(Supervision of Prescription and Supply of 
Methadone) Regulations 1998 (S.I. No. 225 of 
1998). 
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sample prescription form).9 Level 2 prescribers 
contact the HSE Chief Liaison Pharmacists 
and GP Coordinator when first prescribing 
opioid replacement therapy for a patient, 
in order for a suitable pharmacy to be 
organised. Pharmacists must also comply 
with the requirements of the Pharmacy Act 
2007 (as amended) and the Regulation of 
Retail Pharmacy Businesses Regulations 2008 
(S.I. No. 488 of 2008). The Pharmaceutical 
Society of Ireland has published guidance for 
pharmacists on the safe supply of Methadone 
from community pharmacies.10 
All patients who are prescribed methadone 
need to be listed with the Central Treatment 
List (with the exception of patients prescribed 
methadone for palliative care or pain relief, 
9 Statutory Instrument 323 of 2014 amended 
the Misuse of Drug Regulations 1988, as 
amended. Among other things, it removed the 
handwriting requirements in relation to certain 
details on prescriptions for controlled drugs 
specified in the Schedule to the Misuse of Drugs 
(Supervision and Prescription and Supply of 
Methadone) Regulations 1998 (S.I. No. 225 of 
1998) i.e. Methadone. This amendment removed 
the handwriting requirement from Regulations 
13(1)(f) and 13(1)(g) for Methadone 
Prescriptions only; including the name and 
address of the person for whom the treatment 
is issued; the dose; preparation; form; strength; 
and total quantity in words and figures. The SI 
took effect on 11 July 2014.
10 See www.thepsi.ie/gns/pharmacy-practice/
practice-guidance/Guidance_on_the_Medicines_
Safe_Supply.aspx
when notification is to the Controlled Drugs 
Department in the Department of Health).
3.3.2 Buprenorphine/Naloxone 
The Department of Health Expert Group 
on the Regulatory Framework, for products 
containing buprenorphine/naloxone and 
buprenorphine-only for the treatment of 
opioid dependence (2012), sets out several 
recommendations for its use, including the 
appropriate cohort of patients for its use 
and when it may not be suitable for use.11 
(See Appendix 5 for the recommendations 
regarding appropriate patient cohort).
Staff of the Central Treatment List maintain, 
separately, a record of people receiving 
buprenorphine/naloxone, currently referred 
to as the ‘Suboxone List’ (this is an informal 
agreement in anticipation of the inclusion 
of buprenorphine/naloxone in the relevant 
legislation). 
Approval from the Primary Care 
Reimbursement Service (PCRS) for each 
patient is currently required before 
buprenorphine products can be reimbursed in 
a community setting.
11 Increased phased access to buprenorphine/
naloxone is currently being progressed by the 
HSE in the context of its service plan for 2016.
3.4 Provision of information to the 
patient 
3.4.1 Prescribers
Once a decision has been made to prescribe 
OST, patients should be informed of the 
rationale for treatment, the expectations 
placed on them (such as daily attendance for 
supervised doses), and what they can expect, 
either verbally or by a written consensual 
agreement. 
The patient should be informed of:
 » What will happen during treatment
 » The risks during induction
 » The dangers of using benzodiazepines 
and other Central Nervous System (CNS) 
depressant drugs 
 » The planned rate of dose increase and 
rationale for this
 » Risks to children of ingesting prescribed 
medication and the importance of safe 
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storage must be emphasised at the first 
appointment and repeatedly thereafter12
 » That assessment of compliance with these 
safety measures will form part of the 
decision-making regarding dispensing and 
supervision arrangements 
 » The use of the Patient Information Leaflet 
(PIL) from the manufacturers of OST may 
be useful and can be downloaded from 
www.hpra.ie or www.medicines.ie
3.4.2 Pharmacists
Prior to commencing supply to an OST 
patient, the pharmacist should discuss with 
the patient any issue that either deems 
significant, including:
 » The patient’s privacy
 » The patient’s and pharmacist’s expectations 
from the service 
 » Risks associated with giving methadone or 
other medicines to another person
12 See Adfam (2014) ‘Medications in drug 
treatment: tackling the risks to Children’ and 
Adfam (2015) Medications in drug treatment: 
tackling the risks to children one year on. 
These reports outline the clear danger to 
children when OST medication is stored or 
used incorrectly by their parents; giving case 
studies where children accidentally ingest OST 
medication, or are actively given them by their 
parents and carers.
 » Risks to children of ingesting prescribed 
medication
 » Risks associated with storing methadone 
incorrectly 
 » General information about their OST 
therapy: including directions of use, any 
common side effects, the action to be taken 
if a dose is missed, interactions with alcohol 
and other drugs, e.g. benzodiazepines, 
cautionary notices about driving or 
operating heavy machinery, and methods 
for safe disposal
In addition, pharmacists should be cognisant 
of patients’ wider medical and healthcare 
needs and provide holistic pharmaceutical 
care. The pharmacist should be available and 
offer to discuss any relevant issues with the 
patient, at each dispensing. 
Liaison Pharmacists should be contacted for 
advice on unusual situations such as OST for 
use abroad/ restrictions on carrying controlled 
drugs in some jurisdictions/ possible 
availability of treatment outside Ireland, and 
assistance when a patient is to receive OST in 
dual locations e.g. moving from a hospital to 
go home for weekend leave (and then return 
to hospital).
There should be a mechanism whereby 
the treatment provider records that the 
information regarding safety measures 
with OST is imparted to the patient.
3.4.3 Involvement of family/carers 
Depending on the relationships between a 
service user and their carers, and bearing in 
mind the patient’s right to confidentiality, 
information should be exchanged between 
clinicians and carers in so far as it is possible 
and practicable. Carers should be active 
partners in drug treatment, where consent is 
given. This principle holds for all treatment 
settings (addiction clinics, community setting, 
and prison).
Carers should be offered specific 
information and advice on: 
 » The risks from Blood Borne Viruses (BBVs) 
and overdose and, if appropriate, should be 
advised on vaccination
 » Risks to children of ingesting prescribed 
medication and the importance of safe 
storage
 » Training around overdose prevention and 
management
It is recommended that practitioners:
 » Make themselves accessible to family 
members and carers with the consent of the 
service user
 » Assess and take account of the needs of 
family members and carers, including the 
welfare of dependent children, siblings, and 
vulnerable adults 
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 » Provide verbal and written information and 
advice on the impact of drug use and about 
treatment and the settings in which it may 
take place 
 » Provide information about self-help groups 
and other individual and group support for 
families and carers (such as the services 
directory on www.drugs.ie and the Family 
Support Network website at www.fsn.ie) 
 » Consider family or couple-based 
interventions
If families/carers have been offered, but 
not benefited from guided self-help and/
or support groups, and continue to have 
significant family problems, consideration 
should be given to providing or referring them 
for formal psychosocial interventions.
3.5 Communication between 
Prescriber, Dispensing Pharmacist 
and other relevant members of the 
multidisciplinary team
It is important that robust interdisciplinary 
policies and procedures are put in place 
to ensure information and required 
documentation or prescriptions can be 
accessed when required.
 » The relationship between the prescriber 
and the dispensing pharmacist is important. 
The dispensing pharmacist is often the 
member of the multidisciplinary team who 
interacts with the patient most frequently 
for the supervised consumption of their 
medication. It is essential that there is 
regular communication and/or meetings 
between the pharmacist, the prescribing 
doctor and any other relevant healthcare 
professional involved in a patient’s care. 
More frequent communications and/
or meetings may be required during 
the induction phase. These provide an 
opportunity to discuss patient care and 
any issues the pharmacist or medical 
practitioner deems necessary to ensure the 
patient receives an appropriate standard of 
care.
 » Communication between the pharmacist, 
prescriber, and other members of the 
multidisciplinary team is particularly 
important to ensure continuity of care 
for patients transitioning between 
environments, for example, transitioning 
between HSE addiction clinics, hospitals, 
prisons, and the community.
 » The name and address of the dispensing 
pharmacist should be written in the patient 
notes.
 » The pharmacist should dispense in line with 
the Pharmaceutical Society of Ireland’s 
Guidance for Pharmacists on the Safe 
Supply of Methadone.13
 » Pharmacists may, in respect of patient 
safety, decline to dispense the medications 
if they have concerns in respect of the 
medication dose.
Pharmacists should share relevant 
information with prescribers, for example: 
 » Non-attendance or difficulty with 
consuming a supervised dose. 
• When patients have missed scheduled 
pick-ups for three days or more, the 
prescribing doctor should be contacted, 
as the dosage may need to be modified. 
It is important, in some circumstances, 
(for example, during the induction phase) 
to contact the prescriber if any dose is 
missed, as there is a particular risk of 
overdose during this period. 
• After three days without a regular 
prescribed dose of opioid, patients may 
have reduced their tolerance to the drug 
and could be at risk of overdose if the 
usual dose is ingested. The risks of loss of 
tolerance are lower with buprenorphine 
than with methadone. 
13  See the PSI website for Guidance for 
Pharmacists on the Safe Supply of Methadone 
- http://www.thepsi.ie/gns/pharmacy-practice/
practice-guidance/Guidance_on_the_Medicines_
Safe_Supply.aspx
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• Where a patient has not picked up for 
more than three days, a pharmacist is 
normally unable to dispense the next 
day’s dose unless they have confirmed 
with the prescriber that it is safe to do so. 
Where possible, this should be reviewed 
and an assessment made on tolerance. 
In the interest of clarity, a consistent 
local policy should be developed. Efforts 
should be made to limit the impact on 
the patient of being without prescribed 
medication until a new prescription 
can be established. The patient should 
be asked about pick-up details and the 
clinician should check this aligns with 
the patient’s lifestyle, where appropriate. 
If the prescriber alters a dose, a new 
prescription must be received by the 
pharmacy specifying the new dose. 
 » If there are concerns about patients’ health 
or wellbeing 
 » If the patient attends the pharmacy in a 
state of intoxication i.e. under the influence 
of other drugs or alcohol. Pharmacists 
should be aware that a patient may have 
a greater risk of accidental overdose if the 
patient’s full dose is dispensed.  It is advised 
that the pharmacist contacts the prescriber 
to discuss the clinical situation and, if 
necessary, contact is to be made with the 
Liaison Pharmacist. If the prescriber alters a 
dose, a new prescription must be received 
which specifies the new dose.
When a patient misses an appointment 
with their prescribing doctor:14
 » It is the responsibility of the patient to 
attend for their prescription. Both doctors 
and pharmacists should inform patients 
that, if they miss their appointment and do 
not obtain a valid prescription, it may affect 
their treatment regime. 
 » A pharmacist may only supply 
controlled drugs to a patient on foot of 
a valid prescription and may only supply 
methadone to a patient if it has been 
prescribed on the standard methadone 
prescription form issued by their Methadone 
Protocol scheme GP.
 » The original prescription must be physically 
present and reviewed by the pharmacist 
prior to dispensing OST to the patient. 
However, it is important to ensure any 
impact on the patient’s ability to access 
their required medicine is minimised and 
all clinicians should act both in the best 
interest of patient and within the confines 
of legislation to achieve this.
3.6 Contingency management
Contingency Management (CM) operates 
by providing a variety of incentives in 
the form of privileges, such as take-home 
methadone, vouchers, prizes, or modest 
14  This can be particularly relevant for people 
entering and exiting the criminal justice system.
financial incentives. The most common form 
of CM in Ireland is the provision of take-
home methadone. CM  is used to modify 
a person’s drug use or to increase health 
promoting behaviours. It is contingent on each 
presentation, for example, a drug negative test 
(free from cocaine or non-prescribed opioids). 
Studies have found contingency management 
to be effective for people engaged in 
methadone maintenance programmes who 
are continuing to use illicit drugs. 
Criticisms of CM include the observations 
that rapid relapse, following discontinuation 
of this specific intervention, is common; 
that the availability of external incentives 
for abstinence is often limited if there are 
no competing reinforcers in the client’s 
environment; and that CM does not 
specifically address the issue of intrinsic 
motivation for change. Thus, CM can be used 
while transitioning clients to other forms of 
treatment in a stepped model of care. 
CM would normally be provided as part 
of a structured care or treatment plan 
in combination with other interventions 
provided by the keyworker/care-team/
clinician. This approach has been identified in 
the NICE guidelines as having the strongest 
scientific evidence base for the most effective 
outcomes.
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CM, in the form of take-home OST 
medication, is balanced against the need 
to have safe oversight of the use of OST 
medicine and the need to be aware of 
community safety from diversion of 
methadone. On balance, initiating treatment 
with supervised dosing, assessing response 
to treatment, and subsequently allowing 
unsupervised doses to patients who 
demonstrate stability appears to substantially 
reduce diversion, does not diminish efficacy 
and is supported by patient groups (WHO, 
2009). The risk of diversion of prescribed OST 
to the black market should be considered 
before take away doses are provided. Potential 
risks to children of ingesting OST medication 
and the availability of safe storage should also 
be considered. The patient should be advised 
of safe storage requirements.
3.7 Diversion of opioid substitution 
medication
The risk of diversion and accidental or 
intentional misuse increases in patients who:
 » Have suicidal ideation or cognitive 
impairment
 » Are homeless, living in a shelter, or 
transiently housed
 » Are actively addicted to alcohol, cocaine, 
benzodiazepines, or other drugs
The last group is at higher risk because they 
may sell their methadone in order to pay 
for their drug use, and are at greater risk for 
overdose.
The criteria for determining appropriateness 
for take-home doses are based on patient and 
community safety and on clinical stability, 
where clinical stability can be defined by:
1. Adherence with treatment directives 
2. No recent problematic drug or alcohol 
use
3. Stable housing
4. Stable dose of methadone (with 
allowances for occasional dose increases)
5. Emotional stability and good insight into 
safety issues
Contraindications to receiving takeaway doses 
of methadone
 » Repeated intoxication on presentation for 
dosing at the clinic/pharmacy
 » The patient has a child or children living in 
their household, and there are concerns that 
the child/children may be at risk of harm
 » Current chaotic and unpredictable 
behaviour
 » Assessed as at risk of self-harm
 » Current hazardous use of drugs (including 
benzodiazepines or alcohol) as this 
can increase risks of fatal overdose by 
respiratory depression
3.8 Supervised consumption
 » Supervision of methadone has been linked 
to a substantial reduction in deaths due 
to overdose of methadone (Strang et al., 
2010).
 » Supervision by an appropriate professional 
provides the best guarantee that a medicine 
is being taken as directed. In the majority 
of cases, the person supervising will be a 
pharmacist, however, in some specialist 
services, this is done through nursing staff. 
 » The patient must always be advised of safe 
storage of medicines at home.
 » No more than 6 days should be prescribed 
to take home, except for holidays (7 on 
occasions when Bank Holidays dictate). 
 » For take-away supplies for holidays, multiple 
prescriptions are required, with a direction 
to dispense unsupervised on specified dates.
 » In the stabilisation phase, which can take 
up to three months, consumption of OST 
should be supervised daily.
 » In the maintenance phase, a reduction 
from daily supervised consumption can 
be considered when the patient has 
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demonstrated ongoing stability and shown 
that they can safely manage take home 
opioid substitution medication. 
 » The key elements of ‘stability’ appear to 
include housing, employment, not being 
dependent on multiple drugs, and ceasing to 
inject after entering treatment. 
 » In the detoxification phase, a reduction 
from supervised consumption from 
the patient’s maintenance phase can 
be considered. This depends on clinical 
assessment based on patient need.
 » Where possible, the supervised dose should 
not be given to a patient in the presence of 
their child(ren).
See Table 1 for the suggested frequency of 
supervised consumption of methadone.
Chapter 3: Principles and key operational stages of pharmacological interventions for OST
Table 1: Frequency of supervised consumption of methadone (for non-prison 
setting and over-18s) 
Suggested frequency of supervised consumption
PHASE I
Pre OST (10 days prior 
to commencing OST)
N/A
PHASE II
Induction
Daily
PHASE III
Stabilisation
• Daily supervised consumption of methadone is recommended 
until the patient is stable.
• No more than 6 days should be prescribed to take home, except 
for holidays.
PHASE IV
Maintenance
• A reduction from daily supervised consumption can be 
considered when the patient has demonstrated ongoing stability 
and shown that they can safely manage take home doses. 
• Caution is needed with take home doses if there is a concern 
around alcohol or other drug use, as these can increase risks of 
fatal overdose by respiratory depression.
• As a guide, the following is suggested, depending on clinical 
assessment and patient need: 
 » Above 80mgs: Twice weekly supervision
 » Above 120mgs: Increased supervision should be considered.
 » No more than 6 days should be prescribed to take home, 
except for holidays.
PHASE V
Detoxification
• A reduction from supervised consumption from the patient’s 
maintenance phase can be considered.
• This depends on clinical assessment based on patient need.
• No more than 6 days should be prescribed to take home, except 
for holidays.
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3.9 Ongoing assessment of OST
It is important to note that through the five 
stages of OST, as outlined in this guideline, 
ongoing assessment and care planning is 
central to the treatment process. At all phases, 
treatment is delivered through active key 
working and care planning; this is underpinned 
by psychosocial interventions. 
In many cases, stabilisation on OST will be 
a key priority as an early step to recovery. 
For others, active support for detoxification, 
followed by relapse prevention, may be 
appropriate. However, assessment and 
recovery care-planning is an ongoing process 
and, once stabilised on OST, collaborative 
and active care planning (e.g. using mapping 
tools and motivational approaches), to 
consider options across a wide range of 
personal recovery goals, will be an important 
part of a recovery-orientated culture. For 
people to make informed choices through the 
assessment process, they need information 
and advice. As well as promoting clear 
pathways to recovery and abstinence, it is vital 
the nature of dependence is discussed and any 
risks of treatment and moving to abstinence 
are made clear. For collaborative recovery 
care-planning, people need balanced advice 
based on evidence, so they can weigh up their 
preferences and options in an informed way 
(Strang, 2012).
Treatment should seek to maximise outcomes 
across a range of domains, including drug 
and alcohol misuse, health, and psychosocial 
functioning. While drug treatment has been 
shown to be effective in reducing drug 
misuse, patients may not cease all illicit drug 
use. Clinicians will frequently be faced with 
decisions concerning what action to take if a 
patient is demonstrating limited progress on a 
treatment programme. In these circumstances, 
clinicians should consider optimising 
treatment by increasing the intensity of 
the programme rather than reducing it. 
Optimising treatment may include ensuring 
medication is provided within the optimal 
dose range; changing to another substitute 
medication if available; increasing key working 
or psychosocial interventions; and increasing 
supervised consumption. 
Once the care plan is complete (see 
Appendix 3 for care plan templates) the 
actions should be addressed and reviewed 
in regular one-to-one sessions. When a new 
action is identified, this should be added, 
with interagency communications being 
undertaken, as required. A formal review 
should be undertaken every 3 months (or 
more frequently if required). The date for the 
next review should be explicitly stated in the 
care plan at the end of the session and at the 
end of each subsequent case review. Clinicians 
are encouraged to systematically document 
progress in treatment under the five domains 
of care planning: Drug and alcohol misuse; 
Physical health; Mental health; Social 
functioning; and Criminal justice (see NDRIC 
National Protocols and Common Assessment 
Guidelines, 2011). 
3.10 Referral procedure for change of 
OST location
The outcomes for a referral to change 
treatment location is that there is agreement 
and clarity among service providers and 
service user regarding referral to another 
service, including steps and timeframes 
involved and that the patient:
 » Accesses appropriate services in line with 
agreed assessment/care plan/shared care 
plan goals/needs.
 » Is supported throughout the process, as 
required, and appropriate follow-up takes 
place.
 » Will be tracked and supported to minimise 
disengagement from services
The transfer from HSE addiction Clinic 
to HSE Addiction Clinic is done through a 
request to and from the clinical teams, usually 
facilitated through the GP Coordinator. 
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The transfer from pharmacy to pharmacy 
can be organised by the Chief Pharmacist 
using the Pharmacy Transfer Form (see 
Appendix 6). 
Transfer from GP to GP can be organised by 
the GP Coordinator.
At all times, to ensure a continuum of care, 
contact should be made with the previous 
prescribing dispensing site to check the last 
date of OST received and also to confirm any 
other medication that may be prescribed. 
The Central Treatment List should be informed 
of the change of treatment and dispensing 
location, as a new CTL card needs to be issued 
to the new community pharmacy.
Chapter 3: Principles and key operational stages of pharmacological interventions for OST
3.1 Key points
3.3 Legislative requirements for 
Prescriptions and requisitions and 
initiation of OST
3.6 Contingency management
3.2 Aims and objectives of OST
3.5 Communication between Prescriber, 
Dispensing Pharmacist and other relevant 
members of the multidisciplinary team
3.9 Ongoing assessment of OST
3.4 Provision of information to the 
patient
3.8 Supervised consumption
3.7 Diversion of opioid substitution 
medication
3.10 Referral procedure for change of OST 
location (not applicable to prison transfer)
1
3
6
A
2
5
4
7
B
Clinical Guidelines for Opioid Substitution Treatment (OST) 26
4.1 Key points
 » Methadone or buprenorphine, used at the optimal dose range, are both effective 
medicines for OST.
 » Dose induction with methadone should aim to achieve an effective dose, while also 
exercising caution about the inherent risks of too rapid an increase. 
 » Dose induction, with buprenorphine, may be carried out more rapidly, with less risk of 
overdose.
 » Clinicians should aim to optimise treatment interventions for patients who are 
not benefiting from treatment, usually by providing additional and more intensive 
interventions (pharmacological and psychosocial) that may increase retention and 
improve outcomes. 
 » Once stable on OST, at least one dose per week should be supervised. 
 » Methadone and buprenorphine are both effective in detoxification regimens. 
 » OST is a medical treatment, and should not be used punitively i.e. there should be no 
dose reduction as a sanction for ongoing illicit drug use.
 » Opioid detoxification should be offered as part of a care plan, including preparation and 
post-detoxification support in an appropriate setting to patients ready for and committed 
to abstinence.
 » Health professionals working in isolation must ensure they have an opportunity to 
discuss and review their work with colleagues working in the field, to maintain up-to-date 
good practice.
4.2 PHASE 1: ASSESSING 
DEPENDENCE
A prescription for substitute medication 
should normally only be considered if there 
is evidence of current dependence (ICD 10 
and DSM-5; download at http://www.who.int/
classifications/icd/en/ also http://www.dsm5.
org). ICD 10 has been developed by the World 
Health Organisation and are internationally 
accepted criteria for establishing dependence 
(see Table 2 below for quick reference guide).
In addition, opiate withdrawal symptoms 
can be assessed using the Objective Opiate 
Withdrawal Scale (OOWS) and the Clinical 
Opioid Withdrawal Scale (COWS).
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Table 2: Quick Reference to ICD10 
Criteria for Dependence
Physical
 » Withdrawal manifested by the 
characteristic withdrawal syndrome or 
by the use of substance to relieve or 
avoid withdrawal symptoms.
 » Tolerance is defined by either increased 
amounts used to achieve intoxication 
or other desired effect or diminished 
effects with continued use of the same 
amount of substance. 
Psychological 
 » Difficulty in controlling substance use; 
unsuccessful attempts to cut down or 
taking the substance in larger amount 
over a longer period than intended. 
 » Continued substance use, despite 
awareness of negative consequences of 
drug use.
Social 
 » A great deal of time spent in obtaining 
the substance use, using the substance, 
or recovering from the effects of 
substance use. 
 » Neglect of important social, 
occupational, or recreational activities.
Table 3: Objective and subjective signs of withdrawal from opioids 
Objective signs of opioid 
withdrawal
Subjective signs of opioid 
withdrawal
 » Yawning 
 » Coughing
 » Sneezing
 » Runny nose
 » Lachrymation
 » Raised blood pressure
 » Increased pulse
 » Dilated pupils
 » Cool, clammy skin
 » Diarrhoea
 » Nausea
 » Fine muscle tremor
 » Restlessness
 » Irritability
 » Anxiety
The signs listed above may also be useful 
objective signs
 » Sleep disorders
 » Depression
 » Drug craving
 » Abdominal cramps
4.2.1 General health assessment
All drug users should have a full health 
assessment completed prior to commencing 
OST. The aim of this is to identify unmet 
healthcare needs and improve the general 
health of the patient. 
The history and assessment should include:
 » Current and past medical history
 » Current prescribed and non-prescribed 
medications, including cigarettes, cannabis, 
alcohol, and non-prescription medicines
 » Psychiatric history and current symptoms.
 » Drug-related complications such as 
abscesses, venous thrombosis, septicaemia, 
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endocarditis, and constipation. Treatment 
and referral, as appropriate
 » Assessment of injecting practices and 
advice given
 » History of accidental and deliberate 
overdose
 » Presence of past infection with blood-borne 
viruses (including assessment of risks such 
as previous injecting or sharing or having 
tattoos), immunisations for hepatitis A 
and B, testing for hepatitis A, B, C, and 
HIV. Advice and information given prior 
to testing. Referral to specialist service, if 
required
 » Contraceptive history and cervical 
screening, menstrual and pregnancy history 
in women. Provision of contraception advice
 » Sexual health and history of sexually 
transmitted infections. Advice on safer 
sex and referral to the local sexual health 
service
 » Oral Health and referral to appropriate 
dental service
 » Assessment of diet and nutrition and advice 
given to improve same. Oral nutritional 
supplements may be prescribed if criteria 
for prescribing are evident. Note potential 
for diversion
 » All allergies and sensitivities
4.2.2 Physical Examinations, 
Assessments, Investigations and 
Vaccination
 » Assessment of the service user’s physical 
and mental health
 » Assessment of injection sites in all limbs 
and inguinal areas if injecting - or has 
injected previously 
 » Measurement of weight and height
 » Consider chest X-ray if appropriate and if 
considering tuberculosis
 » Urine for drug screening, also checking for 
glucose, infections, or pregnancy
 » Confirmatory drug testing to test for PH, 
specific gravity, creatinine levels to confirm 
integrity of the sample (see section on drug 
testing)
 » Blood pressure measurement
 » General impression of respiratory, 
cardiovascular, and other systems and if any 
symptoms in these areas 
 » Examination of the cardiovascular, 
respiratory systems, including chest x-rays 
and pulmonary function tests i.e. peak flow. 
Examination of gastrointestinal system, 
including the liver
 » Pregnancy testing
 » Blood borne virus screen to include 
Hepatitis A, B, C, and HIV (all notifiable 
infections)
 » Vaccination for Hepatitis A and B, and 
Tetanus
 » Other blood tests, as appropriate – liver 
function tests, thyroid function, renal 
function and haematological indices
 » ECG, if cardiac risk factors or QT 
prolongation risk
Services should include access to:
 » Needle exchange services, harm reduction, 
advice and information
 » Adequate doses of OST
 » Provision of structured psychosocial 
interventions 
Also, general measures:
 » Availability of injecting equipment and 
education to reduce sharing
 » Advice on accessing harm reduction services
 » Regular sexual health screening, particularly 
if involved in sex-work
 » Testing and vaccination for blood borne 
viruses offered to all drug users and their 
sexual partners
 » Testing should be repeated if exposure 
persists 
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Table 4: Infections for which people 
who inject drugs may be at increased 
risk
 » HIV infection
 » Hepatitis A
 » Hepatitis B (HBV)
 » Hepatitis C (HCV)
 » Tuberculosis (TB)
 » Skin and soft tissue infections caused 
by Staphylococcus aureus (including 
methicillin-resistant staphylococcus 
aureus, MRSA) and streptococcal 
infections (e.g. endocarditis, necrotising 
fasciitis)
 » Severe systemic sepsis (e.g. 
infections with Clostridium novyi, 
Bacilliusanthracis)
 » STIs other than infection or hepatitis 
(e.g. chlamydia infection, syphilis, and 
gonorrhoea)
Table 5: Health promotion for safer injecting behaviour
 » Use a sterile needle and syringe and clean equipment for each injection: ‘one needle – 
one syringe – one time’. Never share or borrow needles, syringes, or other equipment.
 » Be aware of, and prepared for, situations where it may be difficult to prevent infections. 
For example, if there is a social pressure to share utensils or if the situation is somewhat 
chaotic when preparing an injection. Enact strategies to reduce the likelihood of 
unintentional sharing of injecting equipment (such as using colour-coded or labelled 
syringes).
 » Encourage peers who do not inject not to start injecting. Encourage peers who do inject 
to use safe injection practices.
 » Wash hands before and after injecting; clean the skin with alcohol or another disinfectant 
before injecting; use a filter; avoid the use of dangerous injection sites, such as the neck 
and groin; avoid injecting under the skin or directly into a muscle; and clean all materials, 
including the table surface, with a disinfectant, following injection.
 » Rather than injecting, use non-injecting routes such as smoking or orally ingesting the 
drug. Foil or gelatine capsules can be used for these purposes.
 » Prevent overdose by using smaller amounts of drugs (especially after periods of 
abstinence or less intense drug use), by not using drugs while alone, and by recognising 
signs of overdose in injecting partners and calling for help immediately upon their 
recognition. Take care when using drugs from new or unknown sources, and avoid mixing 
drugs, such as alcohol, benzodiazepines, and opioids. Utilise supervised health facilities for 
hygienic injecting, if such services are available. 
Ref EMCDDA Prevention & control of ID amongst PWID
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4.2.3 Drug testing at assessment phase
 » There must be a diagnosis of opioid 
dependence before a patient is started 
on OST. This may be assessed through a 
range of different parameters and criteria, 
for example, written assessment, collateral 
history, physical evidence, past knowledge 
of the patient, and past history of OST 
treatment
 » The recommendation is that at least 
one random drug test is taken prior to 
commencement of OST. If the clinician is 
concerned about the validity of any of the 
above parameters, additional tests should 
be carried out. The frequency and type of 
test required is assessed on an individual 
basis
 » If the clinician is still uncertain of the 
diagnosis of dependence, additional drug 
screens may assist in the confirmation of 
the diagnosis, for example, 6-AM
 » If concerns remain, it is prudent to discuss 
the case with a specialist colleague
4.2.4 Referral to Level 2 GP/HSE 
Addiction Clinic
For a clinician to make a referral upon 
assessing dependence to a level 2 GP or to a 
HSE Addiction Clinic:
 » If clinically indicated, a referral is made to 
either the HSE Addiction service or the GP 
Coordinator
 » If and when the patient is initiated onto 
OST, it is the responsibility of the Addiction 
Clinic/Level2 GP to keep in contact with the 
referrer
 » This should be an ongoing communication 
within the care planning process
4.2.5 Linkage with the Central 
Treatment List (CTL) and National 
Waiting List (NWL) and the National 
Drug Treatment Reporting System 
(NDTRS)
On assessment, once the clinician is satisfied 
that:
 » The patient has the capacity to consent to 
the course of treatment
 » The patient’s needs can be appropriately 
addressed by the competencies of the staff 
at the treatment location
 » The patient is not already in receipt of OST. 
This can be confirmed by contacting the 
Central Treatment List (CTL)
Either the patient:
 » Commences OST, if there is a position 
available. Priority is given to pregnant 
women, under-18s, patients with HIV 
and serious illnesses, and those who have 
detoxed and recently relapsed
 » Or, if there is not a position available, the 
patient is placed on the Waiting List for the 
service (this is overseen by the National 
Waiting List Coordinator in the CTL)
The National Waiting List (NWL)
 » The person will remain on the NWL until 
the service is in a position to commence 
their OST. A NWL information sheet (see 
Appendix 7) should be explained and signed 
by the patient
 » The waiting time is determined by numbers 
and existing caps in clinics and Level 2 
GPs, and on the number of community 
pharmacy places available
 » Once a treatment place becomes available, 
the person exits the NWL and is registered 
on the CTL
The Central Treatment List
 » Once the decision is made to initiate OST: 
• The clinician must send a signed ‘CTL 
Entry Form’ (see Appendix 8) to the CTL 
(with the patient’s first and surname) 
and two signed recent passport sized 
photographs. The CTL is available 9-5 
Monday to Friday
• Further details include patient’s recent 
address, the treatment provider details, 
Chapter 4: Assessment of dependence and management of OST
4.1 Key points
4.3 PHASE II: INDUCTION PHASE
4.6 PHASE V: DETOXIFICATION
4.2 PHASE I: ASSESSING DEPENDENCE
4.5 PHASE IV: MAINTENANCE
4.4 PHASE III: STABILISATION
1
3
6
A
2
5
4
7
B
Clinical Guidelines for Opioid Substitution Treatment (OST) 31
and pharmacy details (pharmacy details 
can be provided at a later date)
 » The CTL issues a patient treatment card 
(for patients receiving OST in a community 
pharmacy), with a unique patient number, 
which is sent to the designated pharmacy 
and a letter is issued to the GP stating the 
activation date of the card.
 » The CTL records the patient details on the 
confidential CTL list.
The National Drug Treatment Reporting 
System (NDTRS)
 » Treatment demand data are collected from 
practitioners and agencies in Ireland that 
report to the National Drug Treatment 
Reporting System (NDTRS). 
 » Providers of addiction services must ensure 
compliance with the NDTRS; they must 
provide details on the NDTRS form for each 
new person coming for first treatment, and 
each previously treated client returning to 
treatment in a calendar year. 
 » The NDTRS reporting form can be 
downloaded at http://www.hrb.ie/health-
information-in-house-research/alcohol-
drugs/ndtrs/information-collected/.
4.3 PHASE II INDUCTION PHASE
Methadone is the drug of first choice in 
the treatment of opioid dependence and 
therefore should be available to everyone who 
requires it. If methadone and buprenorphine/
buprenorphine-naloxone are equally suitable, 
methadone should be prescribed as the first 
choice. See Appendix 9 for list of drug to drug 
interactions with methadone. 
4.3.1 Methadone Induction
Methadone:
 » Should be commenced by suitably trained 
level 2 GPs and HSE addiction Clinic 
prescribers.
 » Initial dose between 10-40 mg depending 
on patient assessment.
 » The initial dose should be maintained for 
at least 3 days to ensure that the effects of 
the methadone dose can be fully assessed.
 » Requires frequent monitoring and daily 
supervision of consumption.
 » Patients and their carers should be alerted 
to signs of an overdose.
 » Watch for drug interactions.
 » Dose increase should be done at a daily max 
of 5-10 mg and a weekly max of 20 mg.
Starting patients on too high a dose of 
methadone may result in toxicity and death. 
Conversely, too low a dosage may cause 
withdrawal, which may prompt patients to 
seek relief from other sources, such as illicit 
opiates and benzodiazepines.
The critical factor in response to methadone 
is the degree of tolerance to opioids. In 
individuals with low tolerance, a starting dose, 
deemed safe for the majority of patients, may 
prove toxic. In addition, the prolonged half-
life (as long as 55 hours in methadone-naïve 
individuals) and the slow bioaccumulation of 
methadone accounts for its insidious onset of 
overdose. During dose increases, serum levels 
accumulate over several days, even if the dose 
is kept the same. Therefore, a dose that is 
barely adequate on day 1 can be toxic by days 
3 to 5.
Concurrent use of benzodiazepines, alcohol, 
and other sedating drugs substantially 
increases the risk of death from methadone 
toxicity. The risk of fatal methadone overdose 
during the first 2 weeks of OST is estimated 
to be 6 to 7 times higher than that of heroin 
users who are not in treatment, and 98 times 
higher than that of patients on maintenance 
doses of methadone in treatment for longer 
periods (Caplehorn and Drummer, 1999). See 
section on drug related deaths.
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4.3.2 Buprenorphine/buprenorphine-
naloxone induction
Induction and stabilisation can be more rapid 
than induction with methadone treatment 
due to the safer profile of buprenorphine. 
Buprenorphine/buprenorphine-naloxone:
 » Can safely be inducted more rapidly than 
methadone.
 » Should be commenced by suitably trained 
level 2 GPs and HSE addiction Clinic 
prescribers.
 » Precipitated withdrawal occurs when 
buprenorphine displaces both methadone 
and heroin from opioid receptors. As it is 
only a partial opiate agonist, this results in 
rapid reduction in opiate effects, leading to 
severe withdrawal symptoms in the hours 
after ingestion. 
 » The first dose of buprenorphine/
buprenorphine-naloxone must not start 
until the patient is experiencing withdrawal 
symptoms; otherwise there is a risk of 
precipitated withdrawal. Withdrawal 
symptoms usually commence about 8 
hours after last dose of heroin, and at least 
24 hours after the last dose of methadone, 
however, this can vary from patient to 
patient.
 » The starting dose is usually between 4 mg 
and 8 mg daily.
 » The dose can be increased by between 2 to 
8 mg daily, usually 4 mg, until the patient 
is stabilised, up to a maximum per day of 
24 mg (buprenorphine/naloxone)/32 mg 
(buprenorphine alone), though lower or 
higher doses may be appropriate in some 
patients.
4.3.3 Drug testing at induction phase
 » Drug testing is one of a range of parameters 
used by clinicians within the induction 
phase. Other parameters include clinical 
review, patient self-report and collateral 
drug history. 
 » The recommendation is that at least one 
random drug test is taken per month, used 
in conjunction with the above parameters.
4.3.4 Frequency of supervision of drug 
consumption
 » Daily supervision is recommended.
4.4 PHASE III: STABILISATION
The aim of this phase is to achieve a dose 
that treats withdrawals, reduces cravings, and 
supports the patient in achieving a healthier 
lifestyle.
4.4.1 Methadone stabilisation 
 » This phase can take up to 3 months.
 » Should be undertaken by suitably trained 
level 2 GPs and HSE addiction Clinic 
prescribers.
 » Doses between 60-120 mg per day are 
usually required to stabilise a patient. While 
this is the usual dose range required, some 
patients may be stabilised on lower doses 
and some patients may need higher doses.
 » Any dose increase should be carried out at 
daily max of 5-10 mg and weekly max of 
20 mg.
4.4.2 Buprenorphine/buprenorphine-
naloxone stabilisation 
 » This phase can be shorter than methadone 
stabilisation; in the region of 4-6 weeks.
 » Should be undertaken by suitably trained 
level 2 GPs and HSE addiction Clinic 
prescribers.
 » Doses between 16 mg to 24 mg per day are 
usually required to stabilise a patient. While 
this is the usual dose range required, some 
patients may be stabilised on lower doses 
and some patients may need higher doses.
 » Any dose increase should be carried out at a 
daily max rate of 2-8 mg.
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4.4.3 Drug testing at stabilisation phase
 » Drug testing is one of a range of parameters 
used by clinicians within the stabilisation 
phase. Other parameters include clinical 
review, patient self-report and collateral 
drug history.
 » The recommendation is that at least one 
random drug test is taken per month, used 
in conjunction with other parameters.
4.4.4 Frequency of supervision of drug 
consumption
 » Daily supervised consumption of 
methadone is recommended until the 
patient is stable.15
 » No more than 6 days should be prescribed 
to take home, except for holidays.
 4.5 PHASE IV: MAINTENANCE
4.5.1 Methadone maintenance 
 » This phase can be undertaken by suitably 
trained level 1, level 2 prescribers, and HSE 
addiction Clinic prescribers. 
 » The correct maintenance dose is the one 
which relieves withdrawal symptoms, blocks 
15 With the exception that OST administration 
in prison should be dispensed for supervised 
consumption only.
opiate induced euphoria, and reduces or 
eliminates cravings over a 24 hour period.
 » Requirements for dose increases once 
the patient has stabilised are usually 
infrequent. However, should a dose increase 
be necessary, the patient may require 
more frequent review and monitoring until 
stability has been achieved again.
 » Level 1 prescribers may consider seeking 
advice from the referral agency (level 2 GP 
or HSE addiction clinic) when considering a 
dose increase. 
 » Any dose increase should be carried out at 
daily max of 5-10 mg and weekly max of 
20 mg.
 » Patients on long term prescriptions should 
be offered a care plan review regularly, 
usually at 3 monthly intervals and should 
be part of a broader programme of planned 
social and psychological support. 
4.5.2 Buprenorphine/buprenorphine-
naloxone maintenance
 » This phase can be undertaken by suitably 
trained level 1, level 2 prescribers, and HSE 
addiction Clinic prescribers. 
 » The correct maintenance dose is the one 
which relieves withdrawal symptoms, blocks 
opiate induced euphoria, and reduces or 
eliminates cravings over a 24 hour period.
 » Requirements for dose increases once 
the patient has stabilised are usually 
infrequent. However, should a dose increase 
be necessary, the patient may require 
more frequent review and monitoring until 
stability has been achieved again.
 » Level 1 prescribers may consider seeking 
advice from the referral agency (level 2 GP 
or HSE addiction clinic) when considering a 
dose increase. 
 » Any dose increase should be carried out at a 
daily max rate of 2-8 mg and not exceed a 
maximum single daily dose of 24 mg.
 » After a satisfactory stabilisation has been 
achieved, the frequency of supervision and/
or dispensing may be decreased. A benefit 
of buprenorphine over methadone is that 
dosing can be reduced to every second day 
e.g. a patient stabilised on a daily dose of 
8 mg, may be given 16 mg on alternate 
days, with no dose on the intervening days. 
This may be useful for patients who cannot 
attend a pharmacy for daily dispensing 
or who are completing a reduction/
detoxification and do not wish/need to have 
a daily dose. The dose given on any one day 
should not exceed 24 mg. 
 » Patients on long term prescriptions should 
be offered a care plan review regularly, 
usually at 3 monthly intervals, and should 
be part of a broader programme of planned 
social and psychological support. 
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4.5.3 Transfer onto buprenorphine/
buprenorphine-naloxone (referred to as 
“buprenorphine“) from methadone
 » A transfer onto buprenorphine from 
methadone should be undertaken by 
suitable trained Level 2 GPs and HSE 
addiction Clinic prescribers.
 » The dose of methadone should be reduced 
to and stabilised on 30 mg or less (the 
lower the dose of methadone, the less 
likelihood of precipitated withdrawal).
 » A transfer onto buprenorphine for 
methadone doses greater than 30 
mg, should only be undertaken in an 
intermediate or specialist service/inpatient 
hospital and in consultation with an 
addiction specialist.
 » The first dose of buprenorphine should be 
administered at least 24 to 36 hours after 
the last use of methadone and preferably 
with mild to moderate withdrawals (RCGP, 
2004).
 » Increasing the time interval between the 
last dose of methadone and the first dose 
of buprenorphine reduces the incidence and 
severity of precipitated withdrawal.
4.5.4 Transfer from buprenorphine/
buprenorphine-naloxone (referred to as 
“buprenorphine“) onto methadone
 » A transfer from buprenorphine onto 
methadone treatment is less complicated 
than vice versa. 
 » Methadone can be started 24 hours 
after the last dose of buprenorphine. As 
with all methadone induction, the initial 
starting dose should not exceed 40 mg 
per day (see section 4.3 on induction). It 
is recommended that patients transferring 
from 4 mg or less of buprenorphine should 
be started on low doses of methadone 
and titrated as appropriately. The doctor 
should review the patient several hours 
after the first dose of methadone to adjust 
subsequent doses accordingly. 
 » Factors to be considered when transferring 
a patient from buprenorphine to 
methadone are complications with 
antagonists and opioid based analgesics. 
In patients who have frequent overdoses, 
the use of buprenorphine may complicate 
resuscitation efforts with naloxone. 
Such patients should be transferred to 
methadone. Patients requiring frequent 
opioid analgesia for recurrent acute or 
chronic pain conditions may be better 
stabilised on full agonists, such as 
methadone.(Lintzeris et al., 2006).
 » Care should be taken when increasing the 
dose of methadone, as buprenorphine may 
diminish the effects of methadone for 
several days (blockade effect), and there 
should be adequate time to allow ‘wash out’ 
of buprenorphine prior to marked increases 
in methadone dose.
4.5.5 Drug testing at maintenance 
phase
 » Drug testing is one of a range of parameters 
used by clinicians within the maintenance 
phase. Other parameters include clinical 
review, patient self-report and collateral 
drug history.
 » The recommendation is that at least one 
random drug test be taken per month, used 
in conjunction with other parameters.
4.5.6 Frequency of supervision of drug 
consumption
 » A reduction from daily supervised 
consumption16 can be considered when a 
patient has demonstrated ongoing stability 
and shown that they can safely manage 
take home doses.
 » Caution is needed with take home doses if 
there is a concern around alcohol or other 
16 With the exception that OST administration 
in prison should be dispensed for supervised 
consumption only.
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drug use, as these can increase risks of fatal 
overdose by respiratory depression.
 » As a guide, the following is suggested, 
depending on clinical assessment and 
patient need: 
• Above 80 mgs: Twice weekly supervision
• Above 120 mgs: Increased supervision 
should be considered.
 » No more than 6 days should be prescribed 
to take home, except for holidays.
4.6 PHASE V: DETOXIFICATION
This is the period during which dose reduction 
and discontinuation of OST takes place 
following stability of drug use. According 
to NICE (2007), detoxification should be a 
readily available treatment option for people 
who are opioid dependent and have expressed 
an informed choice to become abstinent. 
Requests for detoxification should have a 
defined time frame for response.17 Patients 
who do not successfully detoxify should be 
offered appropriate access back in OST or 
other treatment.
In order to obtain informed consent, staff 
should give detailed information to service 
users about detoxification and the associated 
risks, including: 
 » The physical and psychological aspects of 
opioid withdrawal, including the duration 
and intensity of symptoms, and how these 
may be managed.
 » The use of non-pharmacological approaches 
to manage or cope with opioid withdrawal 
symptoms.
 » The loss of opioid tolerance following 
detoxification, and the ensuing increased 
17 The Introduction of the Opioid Treatment 
Protocol recommends that the outcome 
should be reviewed for three and twelve month 
outcomes as part of a service audit process.
risk of overdose and death from illicit drug 
use that may be potentiated by the use of 
alcohol or benzodiazepines.
 » The importance of continued support, 
as well as psychosocial and appropriate 
pharmacological interventions, to maintain 
abstinence, treat comorbid mental health 
problems, and reduce the risk of adverse 
outcomes (including death).
Staff who are responsible for the delivery and 
monitoring of a care plan should: 
 » Develop and agree the plan with the service 
user 
 » Establish and sustain a respectful and 
supportive relationship with the service user 
 » Help the service user to identify situations 
or states when he or she is vulnerable to 
drug use and to explore alternative coping 
strategies 
 » Ensure that all service users have full access 
to a wide range of services 
 » Ensure that maintaining the service user’s 
engagement with services remains a major 
focus of the care plan 
 » Review regularly the care plan of a service 
user receiving maintenance treatment to 
ascertain whether detoxification should be 
considered 
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 » Maintain effective collaboration with other 
care providers
 » Discuss access to naloxone. See section on 
Dealing with overdose emergency; naloxone
For a range of useful tools and schedules to 
support community detoxification, see the 
Community Detoxification Protocols (ALDP, 
2011).
Methadone or buprenorphine should be 
offered as the first-line treatment in opioid 
detoxification. Neither opioid medicine is 
more effective than the other in achieving 
good outcomes from detoxification. 
Detoxification should be carried out with the 
medicine on which the patient had stabilised. 
4.6.1 Methadone detoxification
If the patient has been stabilised on 
methadone, the dose can be reduced at a 
comfortable and acceptable rate to that 
individual. This should be based on client 
assessment and on client direction; for 
example, this could be around 5 mg every one 
or two weeks. Patients often prefer a faster 
reduction at the beginning, although there is 
no evidence to indicate the superiority of a 
linear or exponential dose reduction. 
4.6.2 Buprenorphine/buprenorphine-
naloxone detoxification
Buprenorphine doses can be reduced initially 
by 2 mg every two weeks or so, with final 
reductions being around 400 micrograms. 
Patients report being able to reduce 
buprenorphine doses more quickly than 
methadone. 
4.6.3 Drug testing at detoxification 
phase
 » Drug testing is one of a range of parameters 
used by clinicians within the detoxification 
phase. Other parameters include clinical 
review, patient self-report and collateral 
drug history.
 » The recommendation is that at least one 
random drug test be taken per month, used 
in conjunction with other parameters.18 
4.6.4 Frequency of supervision
 » A reduction from daily supervised 
consumption can be considered,19 
depending on clinical assessment and 
patient need. 
 » No more than 6 days should be prescribed 
to take home, except for holidays.
18 Note some residential services may require 
additional screening.
19 With the exception that OST administration 
in prison should be dispensed for supervised 
consumption only.
4.6.5 Symptomatic treatment of 
withdrawal
Prescribing symptomatically can reduce 
some of the physical effects of withdrawal 
(See Appendix 10 for drugs that may help 
symptoms in the end stages of detoxification). 
There is no systematic evidence that any of 
these medicines work to improve outcome 
but they may be useful for the clinician in 
situations where it is not possible to prescribe 
effective opioid substitution. Particular care is 
needed concerning the risks of polypharmacy 
and appropriate supervision and support 
should be paramount in such cases.
Lofexidine is a non-opioid alpha-adrenergic 
agonist and is not a controlled drug. It is 
an unlicensed medicine for use in opioid 
detoxification and is used predominantly 
within prisons and specialist treatment 
centres.
4.6.6 Relapse prevention
Addiction is a chronic relapsing condition and 
therefore relapse is common during treatment. 
For some patients, the period of relapse is 
short and they quickly regain stability again. 
This always requires careful re-evaluation and 
care planning. For some patients, this may 
require re-induction and stabilising.
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Within the context of the person’s care plan, 
it is important to put a relapse prevention 
programme in place to support the patient. 
This can include:
 » Identifying high-risk situations and triggers 
for craving
 » Developing strategies to limit exposure to 
high-risk situations
 » Developing skills to manage cravings and 
other painful emotions without using drugs 
or alcohol
 » Learning to cope with lapses
 » Learning how to recognise, challenge, and 
manage unhelpful or dysfunctional thoughts 
about drug/alcohol use
 » Developing an emergency plan for coping 
with high-risk situations when other skills 
are not working
 » Learning to recognise the ways in which 
an individual is ‘setting oneself up’ to use 
drugs/alcohol
 » Generating pleasurable sober activities and 
relationships
 » Improving quality of life and attaining a 
lifestyle balance
4.6.7 Naltrexone 
Naltrexone is an opioid antagonist which, 
when taken regularly, blocks a former opiate 
user from experiencing the effects of opiates. 
It can be helpful following detoxification in 
enabling a patient to maintain abstinence. In 
Ireland, naltrexone is licensed only for oral use. 
A depot formulation is available but it is not 
licensed for opioid treatment. Naltrexone may 
be useful adjunct to psychosocial treatment 
for suitably motivated patients, but not 
generally recommended where psychological 
support cannot be secured. For under-18s, 
Naltrexone should be considered in motivated 
young people, where there is community 
support from both addiction specialists and 
family.
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5.1 Key points
 » Drug testing may be used as an ongoing tool for monitoring illicit drug use and adherence 
with prescribed medications. It should always be used towards enhancing the treatment 
of the service user.
 » Most drug testing processes consist of two separate types of analysis: a screening test 
and a confirmation test.  
 » The clinical situation will dictate the type of testing (screening or confirmatory) and 
frequency of testing:
 » Once a patient reaches a stable point with OST, a reduction in frequency of drug testing 
is recommended.
 » Drug testing should be randomised where possible
 » Direct observation of urine specimen collection is not required in routine clinical practice. 
 » The use of oral fluid drug testing is an acceptable alternative to urine drug testing.
 » Drug testing results should be shared between treatment locations and agencies, with 
appropriate consent, to prevent the duplication of testing. 
 » Addiction services, including Level 1 and Level 2 GPs, nationally, should have access to an 
appropriately accredited laboratory for drug testing/confirmatory analysis.
 » Biological fluids should be handled with appropriate standard and transmission-based 
precautions.
 » The recommendations for frequency of testing are to be viewed as a minimum standard 
for all patients receiving OST. In certain clinical situations, some patients may find that 
more regular testing may help them reach and maintain stability.
 » Stability and safer prescribing of OST is assessed on a range of criteria, drug screening 
being one of those. There are limitations to the value of drug testing, and clinicians need 
to assess stability across a range of parameters.
5.2 Objectives of drug testing
Drug testing should be viewed as an 
informative, supportive intervention in the 
management of OST. It should never be used 
as a reason for punitive action towards the 
service user. A combination of self-reporting 
and drug testing is more useful than either 
method alone. 
A selection of appropriate drug testing 
methods can enhance the treatment of those 
using drugs. It is important that patients are 
treated with dignity and respect at all times 
when obtaining a sample for drug testing.
5.3 Why and when drug testing can 
be useful
 » To assist in confirming drug use, although 
testing does not confirm dependence 
or tolerance and should only be used in 
conjunction with clinical assessment
 » To verify self-reporting of drug use
 » To minimise possible licit and illicit drug 
interactions
 » To confirm recent OST consumption
 » To support prescribing decisions
 » As a protective factor in relation to 
minimising risk of overdose
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Chapter 5: Drug Testing
 » To monitor illicit drug use
 » As a motivational tool to support recovery
 » To document periods of abstinence and 
evidence to support progress in treatment
 » To assist in contingency management 
interventions, e.g. deciding on takeaway 
doses
 » To re-evaluate treatment plans
 » To identify substance use disorders in 
pregnant women 
 » To facilitate other agencies in assessing 
progress in treatment e.g. criminal justice 
and child welfare agencies. This is on 
the understanding that drug test results 
should not be considered in isolation in 
determining progress. 
 » It may assist in detecting and monitoring 
emerging trends in substance use 
The rationale for drug testing and the results 
of those tests should be clearly delineated 
to those responsible for service user care 
to ensure cost-effectiveness and maximise 
usefulness. The service user should be 
informed of the reasons for this measure. 
Drug testing should be viewed as an 
informative measure, and not as a reason for 
punitive action towards the service user. 
Repeated positive urine drug test results 
imply a treatment plan may not be working 
effectively and that another approach should 
be considered. Efforts to reduce a client’s 
substance use by monitoring drug test results 
are most effective where open communication 
is practised between the person and the care 
team.
Drug testing to confirm drug use when a 
patient has already self-reported use is 
generally not cost-effective or regarded as 
necessary practice. A combination of self-
reporting and drug testing is more useful than 
either alone.
5.4 Choosing an appropriate drug test
Most drug testing processes consist of two 
separate types of analysis: a drug screening 
and a confirmation test. In most clinical 
situations, the most practical and cost-
effective option for screening purposes is the 
use of a randomised drug testing regime. 
Many licit and illicit drugs can be misused, but 
not all can be targeted by routine screening. 
Testing regimens generally target commonly 
misused drugs or drug groups. Where more 
specific testing is required, confirmatory 
analysis should be used.
See Appendix 11 for different matrices 
for drug testing, and Appendix 12 for the 
approximate durations of detectability of 
selected drugs in urine/oral fluid.
5.4.1 Drug Screen: 
The screening test is less time consuming and 
is designed to easily identify negative results. 
An immunoassay system is used, either in 
the laboratory or using point of care tests 
(POCT). With these tests, a negative result 
can be reliably accepted as negative. However, 
although a positive result is reliable, the 
chance of a false positive cannot be ruled out 
due to possible cross reactions. 
The most convenient drug screening test 
used in general practice is a urine POCT. This 
dipstick test provides immediate results. The 
advantages of this type of testing are that it is 
less time consuming than other tests and it is 
designed to easily identify negative results.
Cross reactivity: Care should be taken when 
interpreting immunoassay screening results, 
as some over-the-counter codeine-containing 
products, or prescribed opioid based 
medication, will give an opioid positive result. 
If a patient has used ecstasy or New 
Psychoactive Substances (NPS), they may test 
positive for amphetamines.
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Routine Point of Care Tests (POCTs)
Presently most routine POCTs include the 
following: 
 » Opioid 
 » Methadone 
 » Cocaine
 » Benzodiazepines
 » Amphetamines
Some POCTs can include the following add on 
screens
 » EDDP
 » Alcohol
 » PH
 » Creatinine
 » THC
 » 6-AM
Availability of these POCTs will determine 
their clinical utility and can assist with 
assessment, clinical review, and verification of 
self-report. If relying on POCT alone, clinicians 
should ensure access to 6-AM20 and EDDP21 
tests.
The use of POCT should be guided by 
the Guidelines for Safe and Effective 
Management and Use of Point of Care 
Testing in Primary and Community Care 22 
It is recommended that practitioners comply 
with these guidelines. Staff performing tests 
should also be trained in reading results.
Routine Laboratory Tests 
 » Opioid 
 » EDDP
 » Cocaine
 » Benzodiazepines
 » Amphetamine
20 A 6-AM (6 – acetyl morphine) is used in the pre-
treatment assessment phase or if heroin use is 
suspected in the previous 24hrs, or if the patient 
disputes an opiate positive result.
21 EDDP is a methadone metabolite. Testing for 
EDDP shows that methadone has been ingested.
22 www.imb.ie/images/uploaded/documents/
Guidelines_for_Safe_and_Effective_
Management_and_Use_of_Point_of_Care_
Testing_in_Primary_and_Community_Care.pdf 
www.icgp.ie/go/library/catalogue/
item/01147110-CDA5-40AC-
883E5C8D06A6A9E8/ 
www.thepsi.ie/Libraries/Practice_Guidance/
POCT_Guidelines_211209.sflb.ashx
 » Cannabis
 » Creatinine
 » 6-AM, Zopiclone and EtG screening are 
done on request
5.4.2 Confirmatory tests: 
A positive screen can be confirmed with a 
confirmatory test, conducted by an accredited 
laboratory. However, this should only be 
done where a clinical decision substantially 
affects the patient. A confirmatory test is 
always laboratory based and uses either 
gas or liquid chromatography coupled to 
mass spectrometry. These methods will 
unambiguously identify drugs and metabolites 
present in a sample. 
5.5 Procedures for drug testing 
Collection procedures for drug testing should 
be conducted in ways that preserve dignity. 
A correctly collected specimen is essential for 
obtaining an accurate test result. Guidance 
on written procedures for the collection and 
storage of biological samples, their dispatch 
to a laboratory, and the subsequent discussion 
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and management of reported results is 
referenced below. 23
The person responsible for specimen collection 
needs to ensure the following:
 » Confirming the identity of the service user 
 » Explaining clearly the collection procedure 
to the service user
 » Ensuring that the collection container is 
appropriate for the specimen matrix
23 See S.I. No. 492/2001 Transportation of 
Dangerous Goods Regulations. Samples sent 
to the laboratory of the HSE National Drug 
Treatment Centre, must be designated either 
Infectious or Diagnostic and packaged according 
to UN guidelines. Infectious (UN Hazard Class 
6.2 specifications) samples packaging consists 
of a primary receptacle (leak-proof, surrounded 
by absorbent material), which is inserted into a 
Secondary receptacle (leak-proof and shatter-
proof). Both receptacles must be placed in an 
approved outer package, bearing UN hazard 
class 6.2 markings. Only Dangerous Goods 
Safety Advisor (DGSA) approved couriers, with 
specifically designated vehicles and certified 
drivers, can be used to transport Infectious 
samples. 
Diagnostic (UN Hazard Class 6.0 specifications) 
samples must have the basic triple packaging 
system and UN diagnostic class markings but 
are not subject to transportation by specially 
designated vehicles.  
See World Health Organization guidelines 
document www.who.int/csr/emc97_3.pdf. Also, 
each local hospital laboratory will have its own 
policy document on this. This is an example 
from Letterkenny General Hospital www.hse.
ie/eng/services/list/3/hospitals/lgh/Specimen_
Transport_Policy.pdf
 » Labelling the specimen properly
 » Collecting a sufficient amount of the 
specimen
 » Ensuring that the specimen collection 
process reduces the risk of substitution, 
dilution, or adulteration
 » Storing the specimen according to 
the manufacturer’s or laboratory’s 
recommendations (e.g., appropriate 
temperature/protect from light) to maintain 
specimen integrity
 » Preventing loss of or tampering with 
specimen by storing it in a secure area 
 » Accurately recording information; and 
complying with appropriate dispatch and 
transport procedures
 » Following best practice in relation to 
disposal
 » Compliance with standard and 
transmission-based precautions24. Hand 
cleaning materials should be available to 
the patient after they have provided their 
sample.
24 See Standard Precautions Guidelines, HPSC 
(2009), http://www.hpsc.ie/hpsc/A-Z/
Respiratory/Influenza/SeasonalInfluenza/
Infectioncontroladvice/File,3600,en.pdf
5.6 Urine sample adulteration 
A false negative can be achieved by specimen 
dilution, addition of chemicals (salt, soap, 
bleach) or direct substitution with another 
sample. 
A false positive result can be achieved by 
direct addition of a drug to the sample or by 
substitution with one provided by a known 
drug user. In addition, pre-sample abstinence 
may produce a misleading negative result, 
while ingestion of drugs obtained licitly may 
mask those taken illicitly e.g. prescribed 
benzodiazepines masking the fact that there is 
illicit use also. 
The following are suggested practical steps 
that should be considered in your practice to 
limit the opportunities to tamper with a urine 
specimen: 
 » Using temperature and adulterant strips 
with the urine container
 » Checking the temperature strip on the urine 
containers as soon as collected
 » Prohibiting personal belongings in the 
bathroom
 » Ensuring that adulterants, such as soap, 
ammonia, or bleach are not readily available 
in the collection area when that patient 
provides specimens
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 » Reducing unsupervised access to hot water 
and hand dryers to prevent patients from 
heating specimens brought from elsewhere
 » Putting blue dye in the toilet
 » Using bathrooms within eyesight of staff to 
preclude use by more than one person at a 
time
 » Checking toilet before and after sample is 
given
 » Testing for pH, creatinine, or specific gravity 
if you are concerned about the integrity of 
a sample
5.7 Supervision of the provision of 
urine samples
Direct observation of urine specimen 
collection is not required in routine clinical 
practice. If there are concerns about the 
integrity of a sample, an alternative test could 
be considered e.g. oral fluid testing.
If a supervised sample is required for legal 
purposes, it is important to ensure that the 
patient has provided informed consent and 
that an appropriate level of chain of custody 
procedures is applied.
When taking samples from under-18 year 
olds, the obligations under the Children First 
Guidelines must be taken into consideration in 
all aspects of their care.
5.8 Testing for Alcohol
Alcohol is associated with significant 
morbidity and mortality, particularly when 
used in combination with other substances. A 
patient’s use of alcohol can be identified using 
their clinical history, examination, and by self-
reporting questionnaires. 
A range of biomarkers is available for 
detecting alcohol misuse. The most common 
and routine is breath alcohol which is 
measured using a breathalyser.
Ethyl glucuronide (EtG) is a direct metabolite 
of alcohol that can be detected in urine for 
up to 90 hours post ingestion and has the 
potential to become a useful marker of ‘binge’ 
drinking. Testing for this is only available in the 
laboratory.
5.9 Testing for Z-drugs
The proportion of people using these 
hypnotics has grown in recent years in Ireland 
and is of increasing concern in the drug using 
population.
If clinically indicated, specific drug tests for 
these drugs should be requested from the 
laboratory.
5.10 Testing for NPS
The use of NPS has increased significantly 
in recent years across the whole population 
but particularly in the drug using population. 
If clinically indicated specific drug screens 
for these tests should be requested from the 
laboratory.
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6.1 Key points
 » OST should be provided with a range of other medical interventions.
 » Psychosocial interventions can also address common associated or co-occurring mental 
disorders, such as depression or anxiety.
 » Common mental health problems are frequent in people accessing addiction services. 
Interventions may need to be provided in addiction services, in conjunction with 
Community Mental Health Teams (CMHTs). Those with severe mental health problems 
should have care integrated with acute community-based secondary mental health 
services. 
 » Reducing potential harm due to overdose, blood-borne viruses, and other infections 
should be a part of patient care.
 » All drug users should be offered testing and vaccination against hepatitis A and B, where 
indicated. This discussion should be documented in the patient’s record.
 » All drug users should be offered testing and appropriate treatment for hepatitis C and HIV 
infections.
 » Retaining patients in high-quality treatment is protective against overdose. This 
protection may be enhanced by other interventions, including training drug users and 
their families and carers in the risks of overdose, its prevention, and how to respond in an 
emergency.
 » Drug users who are also using alcohol in a problematic way should be offered alcohol 
treatments. 
 » Drug users who smoke tobacco should be offered smoking cessation interventions. 
6.2 Responses to continued drug and 
alcohol misuse for patients in OST
There is good evidence for the effectiveness 
of psychological treatments for substance 
use. Interventions such as motivational 
interviewing and relapse prevention appear to 
be effective across a range of substances.
A combination of substitute prescribing and 
psychological treatment is frequently more 
effective than medication or psychological 
treatment alone, particularly for opiate, 
benzodiazepine, and alcohol use.
Where no substitute prescribing treatments 
are available, with substances such as 
cannabis and cocaine, there is evidence that 
psychological treatment alone can be effective 
in changing a person’s substance-using 
behaviours.
Any form of psychological treatment can lead 
to better outcomes than no psychological 
treatment.
For cannabis users, MI, CBT, and family 
therapy appear to be the most effective.
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Table 6: Responses to continued drug or alcohol misuse when patients are on OST (adapted from Drug misuse and 
dependence, UK guidelines on clinical management, 2007) 
Scenario Risks Possible Reason Responses to consider
Opiate misuse
on top of OST
• Overdose 
• Blood-borne viruses 
and other infections if 
injecting
• Continued offending and 
involvement in drug-
misusing lifestyle
• Impairing engagement
• Inadequate 
dose
• Medication 
unsuitable
• Patient on 
reducing 
regimen
• Patient using 
heroin and/or 
other opiates 
on effective 
dose of OST
• Dose assessment, increase dose
• Change medication regimen
• Transfer patient to maintenance regimen
• Review psychosocial interventions
• Review contingency management, plus urine tests and supervised 
consumption
• Provide harm reduction interventions
• Address social functioning domains (including housing, employment 
and relationships) within a shared care approach
Crack cocaine 
and cocaine 
and/or other 
stimulants on 
top of OST
• Blood-borne viruses and 
infections if injecting
• More chaotic drug misuse
• Increased crime 
• Psychological problems
• Overdose
• Recreational 
use 
• Patient 
dependent 
on cocaine or 
crack cocaine 
• Review psychosocial interventions. 
• Review contingency management, plus urine tests and supervised 
consumption
• Provide harm reduction interventions
• Address social functioning domains (including housing, employment 
and relationships) within a shared care approach
• For stimulant users, the strongest evidence for effective 
psychological treatment is for CBT approaches, including 
motivational interviewing, relapse prevention, community 
reinforcement approach, and contingency management; suggests a 
combination of approaches as being the most helpful
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Scenario Risks Possible Reason Responses to consider
Alcohol* or 
benzodiazepine 
misuse with 
OST
* For alcohol, 
AUDIT is the 
recommended 
tool for screening 
for levels of 
alcohol risk 
• Alteration of methadone 
metabolism
• Deterioration of hepatic 
functioning in those with 
Hepatitis C 
• Street drinking with  
public disorder
• Presentation
• Overdose or ‘near misses’
• Drug Interactions
• Violent and aggressive 
behaviour
• Problematic 
use*
• Alcohol/benzodiazepine detoxification and/or reduction regimen
• For alcohol consider a breathalyser test
• Consider increased supervised consumption of opioid prescriptions
• Review key working
• Review psychosocial interventions (brief intervention in line with the 
SAOR model)
• Patient 
dependent*
• Alcohol/benzodiazepine detoxification and/or reduction regimen
• For alcohol consider a breathalyser test
• Increased supervised consumption of opioid prescriptions
• May need to transfer to specialist addiction service
• Review key work and psychosocial interventions
• For benzodiazepine users, a CBT approach appears to be effective in 
reducing drug use.
• For alcohol users, CBT (including motivational enhancement 
therapy), 12 step, and family therapy approaches appear to be the 
most effective
6.3 Mental health 
There is a high rate of psychiatric disorders 
among individuals misusing or dependant on 
drugs and alcohol.
 » A range of problems are seen, including 
anxiety, mood disorders, and personality 
disorders.
 » The coexistence of mental health and drug 
use problems is common, generally referred 
to as ‘dual diagnosis’ or ‘comorbidity’. 
Patients with comorbidity generally have 
poorer prognosis.
 » Comorbidity can be associated with 
negative factors, such as higher rates of 
relapse, increased hospitalisation, suicide, 
poverty, homelessness, and criminality.
 » The emergence of NPS use in recent years 
has increased the number of individuals 
presenting with mental health difficulties 
to services. A particular concern is the 
association between certain NPS and 
suicide (cathinone drugs).
 » It is important these patients receive 
appropriate assessment of needs and risk 
and treatments that are evidence based.
 » The Mental Health Act of 2001 specifically 
mentions that addiction to drugs or 
intoxicants is not a reason for involuntary 
admission to psychiatric care.
 » Patients with significant mental health 
issues should be prioritised for addiction 
treatment.
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6.3.1 Treatment for mental health 
problems
Practitioners in mental health and 
addiction services should be competent 
to manage patients with comorbidities. 
Substance use is associated with comorbid 
psychiatric disorders. Substance use may 
also contribute to and exacerbate mental 
illness. A multidisciplinary approach, with 
specialist practitioners and psychiatrists, and 
the availability of structured psychological 
interventions, is advised. Caution should be 
used when prescribing benzodiazepines to 
treat comorbid psychiatric disorders (see 
Appendix 13: Guiding principles for working 
with clients with co-occurring disorders).
Depression:
 » Depression is common and should be 
assessed and monitored closely.
 » A validated measure, e.g. the Hospital 
Anxiety and Depression Scale (HADS), 
can be used to inform assessment and 
monitoring.
 » Treatment can consist of psychological or 
pharmacological interventions or both.
 » Management of mild to moderate 
depression is the same as for non-drug-
using patients; sleep hygiene, individual 
facilitated self-help, cognitive behavioural 
therapy (CBT), structured physical activity 
programme, counselling, group-based peer 
support, antidepressants, referral for further 
assessment.
 » Management of failure to respond to 
first-line treatment or moderate to 
severe depression is with high intensity 
psychological interventions such as CBT 
or interpersonal therapy, pharmacological 
treatment, combined or collaborative care.
 » The choice of antidepressant depends on 
patient choice and patient preference, SSRIs, 
e.g. sertraline, or SNRIs, e.g. venlafaxine, 
being appropriate choices.
 » Citalopram and escitalopram are 
contraindicated for use with methadone 
due to the increase risk of QT prolongation.
 » Tricyclics (especially Dosulepin) should 
be avoided, as there is a high incidence of 
abuse.
 » The management of drug dependant 
patients with severe mental health issues 
is challenging in primary care. Refer 
to specialist mental health services if 
depression is severe or if the patient has 
failed to respond. 
 » If there is risk to life or severe self-neglect, 
then inpatient mental health care may be 
needed.
Anxiety:
 » Anxiety disorders, such as Generalised 
Anxiety Disorder, Panic disorder, 
Agoraphobia, Social Phobia Obsessive 
Compulsive Disorder, and Post-traumatic 
Stress Disorder are common.
 » Identify and assess the level of anxiety.
 » A validated measure relevant to the 
disorder, e.g. 7-item Generalised Anxiety 
Disorder (GAD-7), can be used for 
assessment and monitoring.
 » For management of mild anxiety, offer 
low-intensity psychological interventions; 
individual non-facilitated and facilitated 
self-help, psychoeducational groups, self –
help groups, trauma-focused CBT.
 » Management of failure to respond or severe 
anxiety is with high-intensity psychological 
interventions such as CBT, applied 
relaxation, or medications such as SSRIs or 
SNRIs, combined or collaborative care.
 » Caution should be used with prescribing 
benzodiazepines and/or pregabalin because 
of their abuse potential.
 » Refer to mental health services if anxiety is 
severe or refractory.
Psychosis:
 » Psychosis is characterised by a loss of 
connectedness with reality, e.g. the presence 
of delusions and hallucinations.
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 » It is important to distinguish between 
substance-induced and substance-related 
psychosis.
 » It is advisable to allow three to four weeks 
of abstinence before making a diagnosis of 
a psychiatric disorder.
 » Stimulants such as cocaine, ecstasy, and 
amphetamines are significant causes of 
psychosis and paranoia, however any 
psychoactive drug used to excess can cause 
these symptoms.
 » Use of NPS has also been implicated in the 
development of psychosis in individuals.
 » The main forms of psychosis that are not 
substance-induced are schizophrenia and 
bipolar disorder.
 » Substance use, particularly with NPS, 
with these disorders is common and can 
precipitate an acute episode.
 » The occurrence of substance induced 
psychosis in some individuals may indicate 
an ‘at-risk’ mental state, and they are at risk 
of developing schizophrenia.
If it is clinically indicated that psychosis is 
substance-related, and not substance-induced, 
consider referral for specialist psychiatric 
assessment.
Personality Disorders
 » Personality Disorders are long-standing 
and maladaptive patterns of perceiving and 
responding to other people and stressful 
circumstances.
 » The two subtypes most researched are 
Emotionally Unstable Personality Disorder 
and Dissocial Personality Disorder.
 » High-risk behaviour can persist, despite 
successful opiate treatment.
 » Patients with Personality Disorders can be 
offered the same range of treatment to 
those without Personality Disorders.
 » Management includes the use of limit 
setting and therapeutic contracts. 
Scheduling of brief, structured, and frequent 
visits may be helpful.
 » There is no specific pharmacological 
treatment for Personality Disorders.
 » Collaborative care planning with other 
service providers can be indicated.
6.4 Viral Infections 
6.4.1 Hepatitis A
 » Commonly transmitted by fecal-oral 
contamination.
 » Usually self-limiting and requires no 
treatment, unless occurring with another 
disease e.g. Hepatitis B or C.
 » Based on current evidence, it is 
recommended that injecting drug users are 
vaccinated against Hepatitis A.
 » The combined Hepatitis A and B vaccines 
may improve uptake.
 » Hepatitis A (acute) infection is a notifiable 
disease.  
See www.hpsc.ie/hpsc/NotifiableDiseases
6.4.2 Hepatitis B
 » May present with flu-like illness or may be 
asymptomatic in early stages.
 » May be discovered by abnormal liver 
function test results and subsequent 
positive Hepatitis B blood test.
 » Initial assessment of any drug user should 
include history of Hepatitis B vaccination 
and results of screening for Hepatitis B.
 » Vaccination for Hepatitis B should be 
carried out for all those at risk and records 
of these vaccinations should be kept.
 » Hepatitis B (acute and chronic) infection is 
a notifiable disease.  
See www.hpsc.ie/hpsc/NotifiableDiseases
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6.4.3 Hepatitis C 
 » Most patients are asymptomatic during 
early stages of infection, but others can 
suffer from nausea, fever, vomiting, or 
jaundice.
 » 20-30% of those infected will 
spontaneously clear the virus, 70-80% may 
become chronically infected.
 » Recent developments in non interferin 
based treatments has dramatically improved 
treatment outcomes. All chronically infected 
Hepatitis C patients should be referred for 
consideration for these new treatments.
 » Chronic infection can lead to cirrhosis, liver 
failure, and/or hepatocellular carcinoma.
 » When a patient tests positive for Hepatitis 
C antibody, further blood tests should be 
carried out. It is recommended that Hep C 
antigen and liver function tests should be 
done in primary care and community drug 
services. Patients who are antigen positive 
should be referred to specialist services 
for PCR blood testing, Fibro scanning, and 
consideration for treatment. 
 » Counselling prior to screening for Hepatitis 
C is no longer routine.
 » All patients who are at risk of contracting 
Hepatitis C should be given information 
and advice on the disease and how it is 
transmitted. 
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100 people exposed to hepatitis C
75 to 80 people develop 
chronic Hepatitis C
Some will remain 
well and never 
develop liver 
damage
Most people will develop 
some level of long term 
symptoms or signs of liver 
inflammation
In time many will develop cirrhosis of the liver 
(over an average 20 to 40 years) and 5% of 
those with cirrhosis will develop liver failure or 
cancer per year
20 to 25 people clear the virus 
within two to six months
Disease progression in Hepatitis C infection
6.1 Key points
6.5 Hepatitis A and B vaccinations
6.8 ECG Monitoring
6.9 Drug Related Deaths
6.2 Responses to continued drug and 
alcohol misuse for patients in OST
6.4 Viral Infections
6.7 Pain management for drug misusers
6.3 Mental health
6.6 Health implications for continued 
drug and alcohol use when patients are 
on OST
 » It is recommended that all drug users are 
screened for Hepatitis C, even if they are 
not intravenous drug users. 
 » Early detection and early referral of all 
active Hepatitis C cases to secondary care is 
now recommended. 
 » Patients who continue to inject drugs or 
misuse alcohol should not be excluded from 
treatment because of these behaviours.
 » Risks of concurrent alcohol use should 
be explained to all Hepatitis C positive 
patients. Alcohol has been shown to be a 
significant risk factor in the development 
of cirrhosis in patients who are chronically 
infected with Hepatitis C. 
 » Hepatitis C infection is a notifiable disease.  
See www.hpsc.ie/hpsc/NotifiableDiseases
Figure 2: Disease progression in Hepatitis C infection (Source: RCGP Hep C guidance)
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6.4.4 HIV
 » All service users should be offered education 
and prevention advice on HIV transmission, 
safe injecting, and safe sexual practises.
 » Among people who inject drugs, HIV is 
passed by sharing equipment used for 
intravenous drug use, as well as through 
unsafe sexual practices. 
 » Increased risk of HIV transmission in 
injecting drug users has been associated 
with injecting synthetic cathinones and 
homelessness. 
 » Some newly infected people experience 
flu-like symptoms, develop a rash, and/
or lymphadenopathy; others may have no 
symptoms.
 » All drug users entering OST should be 
offered a HIV anti-body blood test. Patients 
should be regularly reviewed for HIV risk 
behaviour and repeat tests offered, as 
clinically appropriate.
 » On site point of care and salivary antibody 
testing may be considered for screening at 
risk or hard to reach populations. All reactive 
test results must be confirmed using a 
laboratory-based confirmatory test, as a 
small number of people who are not HIV 
infected will produce a positive (reactive) 
result. The importance for confirmatory 
testing at an approved HIV testing 
laboratory needs to be emphasized to rule 
out the possibility of a false-positive result 
in the rapid HIV test and to confirm a true 
positive result.
 » PCR testing may be considered if a clinician 
has concerns about more recent infection 
 » All service users who are HIV infected 
should be referred to specialist hospital 
based services for ongoing monitoring of 
CD4/ viral load and antiretroviral therapy.
 » For chaotic /non-adherent service 
users, directly observed therapy may be 
considered.
 » Changes in drug use patterns may increase 
HIV transmission risks in certain categories 
of drug users. The Health Protection 
Surveillance Centre (www.hspc.ie) identifies 
high risk populations and targets areas for 
intervention. 
 » HIV infection is a notifiable disease. 
See www.hpsc.ie/hpsc/NotifiableDiseases
6.5 Hepatitis A and B vaccinations 
(Department of Health Immunisation 
Guidelines for Ireland 2012) see 
summary tables Appendix 15
 » Hepatitis A and B can be given as combined 
or separate vaccines.
 » Hepatitis A, if given on its own, is a single 
dose, with a booster at 6-12 months. This 
results in immunity beyond 10 years. 
 » Immunity against Hepatitis A is the same 
whether gained by combined Hepatitis A 
and B vaccine or Hepatitis A vaccine alone.
 » Immunity against Hepatitis A is the same 
whether gained by routine or accelerated 
schedule. 
 » The Hepatitis B vaccine requires a series of 
doses following the routine schedule (0, 1, 
6 months), or an accelerated schedule (0, 7, 
21 days, 12 months). 
 » If offering Hepatitis B vaccination on its 
own, it is recommended that individuals 
at risk of infection are offered a single 
booster once at 5 yrs. Measuring Hepatitis 
B immunity is not required before or after 
this booster.
 » The combined Hepatitis A and B vaccine 
requires a series of doses following the 
routine schedule (0, 1, 6 months), or an 
accelerated schedule (0, 7, 21 days, 12 
months). 
 » Testing for immunity after vaccination 
is recommended only for persons whose 
subsequent clinical management or 
occupational risk depends on knowledge of 
their immune status.
 » Such persons include immunocompromised 
people and sex or needle-sharing partners 
of HBsAg-positive persons.
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 » Testing should be performed 2 months after 
the last dose of vaccine.
 » About 10% of patients fail to respond 
adequately to three doses of the Hepatitis 
B vaccine. This is more common in those 
over 40 years of age, obese people, and in 
smokers. Poor response is also reported in 
alcoholics and in advanced liver disease.
 » Ideally, after the vaccination course, Anti-
HBs levels of >100mIU/ml would be 
achieved, levels >10mIU/ml are generally 
accepted as enough to protect against 
infection.
 » Both the Hepatitis B and Hepatitis A and B 
combined vaccines are inactivated and so 
are considered safe in pregnancy and for 
patients with HIV. These groups may not 
mount the same immune response, and 
may need further boosters.
 » It is recommended that vaccination should 
be offered to the children and sexual 
partners of those at high risk.
 » It is important that vaccination does not 
encourage relaxation of other measures 
designed to prevent exposure to blood 
borne viruses, for example, condom use and 
needle exchange.
 » All health workers should be vaccinated for 
Hepatitis A and B.
6.6 Health implications and 
interventions for continued alcohol 
and drug use when patients are on 
OST
6.6.1 Alcohol
Problematic alcohol use is a significant risk 
factor for drug users on OST due to:
 » It being a significant cause of death due 
to alcohol overdose, inhalation of vomit, 
hypoglycaemia, and accidents or violence
 » It increases the dropout rates from 
treatment
 » It increases risk of hepatic cancer in people 
with Hepatitis C
 » One third of patients receiving methadone 
have been identified as having a current 
drink problem.
The National Treatment Outcomes Research 
Study (Comiskey et al., 2009) found 24% 
of the cohort at the start of the study 
were drinking above Department of Health 
recommended limits, and 25% were doing so 
at the five-year follow-up. Some, 8%, were 
drinking at harmful levels.
About one-third of patients receiving 
methadone have been identified as having a 
current drink problem, and a further one-sixth 
have a history of a drinking problem. It follows 
that clinicians working with drug users require:
 » An awareness that alcohol misuse is not 
separate from misuse of other drugs 
 » Competence at detecting problem drinking
 » The ability to give harm reduction and 
educational messages regarding misuse of 
alcohol
 » The ability to manage alcohol misuse 
emerging alongside pharmacotherapies, 
such as substitute prescribing
It may be clinically helpful to think of different 
patterns of drinking associated with drug 
misuse: 
 » Drinking that is substantially independent 
of other drug misuse 
 » Drinking that is interchangeable with the 
use of other psychoactive drugs.
 » Drinking and other other drug misuse, as a 
supplement to a substitute prescription
Assessment of the cumulative effects of high- 
risk behaviours and polydrug use requires 
repeat assessment by an experienced clinician. 
Opiate users who are chronically intoxicated 
with alcohol are difficult to manage. Some 
strategies to deal with the problems are 
outlined in the section on responding to 
failure to benefit from treatment (section 
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Chapter 6: OST and associated health considerations
5.5). As the risks of prescribing opioids, in 
conjunction with high levels of alcohol use, 
need to be balanced against the benefits of 
retaining the patient in treatment, specialist 
competencies are required.
Interventions:
 » An alcohol screen and appropriate 
intervention in line with the HSE National 
Screening and Brief Intervention (SAOR) 
Programme; the level of brief intervention 
is dependent on the score someone 
receives. See http://www.hse.ie/eng/
services/Publications/topics/alcohol/
alcoholscreening.html for the SAOR 
Guideline Framework, alcohol screening 
tools, and support materials.  
 » The standard interventions for problem 
alcohol use and dependence apply for 
patients on OST (see Table 6). 
 » Consider a care plan towards alcohol 
detxification, either in-patient or out-
patient, psychological interventions, 
pharmacology to prevent relapse, and 
supplements to prevent vitamin deficiencies 
problems.
 » Minimise polypharmacy, particularly with 
benzodiazepines.
 » Provide posters with information on 
supports, such as Narcotics Anonymous, 
Alcoholics Anonymous, SMART Recovery 
etc.
6.6.2 Benzodiazepines and 
Z-compounds
Doctors should familiarize themselves with 
the recommendations of the Benzodiazepine 
Best Practice Guidelines, published by the 
Department of Health and Children in 2002.25 
These commonly prescribed drugs do cause  
tolerance and  dependence. Initiation should 
be avoided in substance misusers. For a range 
of useful tools and schedules to support 
community detoxification, see the Community 
Detoxification Guidelines (ALDP, 2015).
They are often taken in large quantities:
 » To enhance other drug effects
 » To help manage withdrawals from other 
drugs
 » As a form of self-medication for anxiety & 
mood problems
Actions:
 » Identify those who qualify as having a 
dependence on benzodiazepines.
 » Assess if they also may have anxiety or 
mood symptoms.
 » Avoid double prescribing, by liaising with 
their community GP.
25 www.drugs.ie/resourcesfiles/reports/DOHC_
Benzo_committee.pdf 
 » Prescribing to attenuate benzodiazepine 
withdrawal symptoms should only occur 
when there is evidence of dependence.
 » Clear treatment goals should be agreed and 
documented.
 » Regular patient review, and dispensing and 
supervision should follow a schedule similar 
to that for other drugs of dependence, 
including daily dispensing and supervised 
consumption.
 » Aim to convert other BDZ and sedative 
hypnotics into an appropriate dose of 
diazepam.
 » Aim for the lowest dose of diazepam that 
will prevent withdrawal symptoms.
 » To minimize diversion, prescribe in 2mg 
doses.
 » Only very rarely should doses of more than 
30mg diazepam per day be prescribed.
 » Patients that are likely to need in excess 
of this dose should be considered for 
referral for inpatient medically assisted 
detoxification, in either St. Michaels, 
Beaumont or Cuan Dara, IPU Cherry 
Orchard Hospital.
 » Aim to prescribe a reducing regimen for a 
limited period of time, reducing slowly, at a 
rate of 2-2.5mg every fortnight.
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 » OST dose should be kept stable throughout 
the benzodiazepine reduction period.
 » Consider adjunctive therapies where 
available.
Patients should be advised to:
 » Reduce their use of benzodiazepines to an 
equivalent dose of diazepam 10mg TDS/
QDS daily i.e. between 30 and 40mg of 
diazepam daily as an outpatient.
 » Not to take extra benzodiazepines while 
prescribed a benzodiazepine detoxification 
programme.
 » Benzodiazepine withdrawal symptoms 
include anxiety, agitation, insomnia, tension, 
sweating, and sensory and perceptual 
distortions.
 » That concurrent use of benzodiazepines and 
other opioids, including methadone and 
heroin, may increase the risk of sedation, 
respiratory depression, risk of overdose, and 
death.
 » That benzodiazepine use is associated with 
decreased reaction time and impaired 
motor co-ordination that may lead to 
accidents and injuries.
 » That any prescription above 30 mg 
diazepam daily, or consumption above the 
doses recommended in the SmPC and BNF 
for the individual medications, constitutes 
misuse for driver licensing purposes.
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Benzodiazepine
agonist drug
Half Life of Parent 
Drug (hours)*
Speed of onset Equivalence to 
diazepam 5mg**
Use
Chlordiazepoxide 5-30 Slow 15mg Anxiety
Diazepam 20-100 Rapid 5mg Anxiety/Insomnia
Loprazolam 4-15 Slow 0.5mg (to 1mg) Insomnia
Lorazepam 10-20 Intermediate 0.5mg *** Anxiety/Insomnia
Lormetazepam 11 Intermediate 0.5 (to 1mg) Insomnia
Nitrazepam 18-25 Rapid 5mg Insomnia
Oxazepam 4-15 Slow 15mg Anxiety
Temazepam 8-22 Intermediate 10mg Insomnia
Zaleplon 1 Rapid 10mg Insomnia
Zolpidem 2 Rapid 10mg Insomnia
Zopiclone 5-6 Rapid 3.75mg Insomnia
*Some variation between individuals 
**Equivalence as BNF and Clinical guidelines 
***Approximately equivalent oral dosage from other sources
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Anxiety symptoms
(can mimic symptoms the drug was first 
taken for and also appear on rebound as 
drug stopped)
Distorted perceptions
(usually a sign of drug 
withdrawal, rather than 
anxiety)
Major incidents
(occurs especially 
when high doses are 
stopped abruptly)
Psychological Physical
 » Anxiety
 » Panic attacks
 » Insomnia
 » Poor memory
 » Depression
 » Paranoia
 » Intrusive 
memories
 » Cravings
 » Nightmares 
 » Excitability
 » Agoraphobia
 » Social phobia
 » Obsessions
 » Rage, aggression
 » Irritability
 » Agitation
 » Tremor
 » Headache
 » Weakness
 » Dizziness
 » Nausea
 » Vomiting 
 » Diarrhoea
 » Constipation
 » Palpitations
 » Rashes
 » Tingling, 
numbness, 
altered sensation
 » Fatigue
 » Flu-like 
symptoms
 » Hypersensitivity to 
sound, light, touch, 
taste, etc.
 » Abnormal body 
sensation, e.g. 
itching, widespread 
pain & stiffness, 
blurred vision, 
paraesthesia, muscle 
twitching, tinnitus, 
burning sensations, 
etc.
 » Feeling self or world 
to be abnormal
 » Depresonalisation 
 » Fits (1-2% of 
patients, esp. if 
stopping high dose 
abruptly)
 » Delirium (rare)
 » Transient 
hallucinations 
(visual, tactile, 
auditory) or 
illusions (rare)
 » Psychosis (very 
rare)
(Guidance for the use and reduction of misuse of benzodiazepines and other hypnotics and 
anxiolytics in general practice, 2014)
6.6.3 Stimulants (cocaine & 
amphetamines)
 » The mainstay of treatment is psychological. 
There are no substitute pharmacological 
interventions recommended.
 » Give safe injecting advice where 
appropriate.
 » Consider careful management in patients 
who use cocaine while on OST, such as no 
take home doses.
 » Observe for significant psychiatric 
symptoms, as withdrawal may be associated 
with significant depression, and suicidal risk.
 » Be cautious when prescribing SSRIs, as toxic 
reactions have been described while cocaine 
or amphetamines continue to be taken.
 » Treatment of young people may require: full 
mental health assessment, treatment and 
careful monitoring, with close liaison with 
CAMHS or other mental health team.
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6.6.4 Cannabis
 » Withdrawal may precipitate sleep 
disturbance, irritability, cravings, weight loss, 
vivid dreams etc. and these may require 
brief symptomatic management
 » Prescribing benzodiazepines should be 
avoided.
 » Cannabis can exacerbate existing mental 
health problems and if there is any 
evidence of psychosis, a full mental health 
assessment is required.
 » Psychosocial interventions are 
recommended for young cannabis misusers.
6.6.5 Tobacco 
Most patients in drug treatment smoke and 
this is often the only drug dependence that 
is not addressed. This is despite smoking-
related diseases being highly prevalent in 
drug misusers, with a likelihood of causing 
premature death. Smoking may act as a 
cue for the misuse of other drugs that are 
consumed in the same way. Therefore, 
smoking may increase the risk of relapse into 
drug misuse. 
Smoking cessation in drug treatment 
Evidence suggests smoking cessation may 
be associated with improved drug treatment 
outcomes. Similar processes apply to smoking 
cessation treatment as to treatment for other 
types of drugs, such as coping with cravings 
and preventing relapse. Despite this, most 
drug treatment services do not offer smoking 
cessation. This may be because staff have not 
been appropriately trained, or believe it may 
interfere with drug treatment or are tobacco 
smokers themselves, or it may result from 
a lack of evidence and clinical experience of 
using smoking cessation treatments in this 
patient group. However, societal attitudes are 
changing and the smoking bans introduced 
across Ireland in 2004, and in the UK three 
years later, may increase the demand for 
treatment for tobacco dependence among 
drug misusers. 
Treatment options 
There is a large evidence base for the 
effectiveness of smoking cessation treatment 
in the general population and in prisons, with 
the best outcomes from a combination of 
behavioural support and pharmacological 
interventions, such as nicotine replacement 
therapies, bupropion, and varenicline. In the 
absence of evidence to the contrary, it seems 
likely that drug misusers will respond to the 
same treatments as the general population, 
although they may need more intensive 
options to achieve the same results. 
Given the high rates of smoking and the 
low quit rates in drug misusers, it may be 
reasonable to consider harm reduction 
approaches to smoking, such as replacing 
cigarettes with clean nicotine in the form 
of patches for some of the day. This may be 
particularly useful in alleviating the symptoms 
of tobacco withdrawal while a patient is in a 
residential or inpatient drug treatment facility. 
Clinicians should encourage patients to stop 
or reduce their smoking and refer them to 
smoking cessation services. See www.quit.ie.
6.7 Pain management for drug 
misusers
The most common causes of pain are back 
pain, arthritis, and headache; all increasing in 
prevalence with age. Acute pain commonly 
occurs in drug users, as they have a higher risk 
of physical illness and injury.
Pharmacological intervention is only one 
aspect of pain management and non-
pharmacological interventions such as CBT 
should be considered for drug users.
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Acute pain
 » Requires full analgesic management in 
patients who are dependent on opioids.
 » These patients may have a lower tolerance 
of pain and a higher tolerance of opioid 
analgesic effects.
 » For mild-moderate pain, non-opioid 
analgesia, education, and advice are first line 
responses.
 » For more severe pain, if opioid analgesia 
is indicated, treatment depends on 
whether patient is taking full opioid 
agonists (methadone), partial agonists 
(buprenorphine), or opioid antagonists 
(naltrexone). 
 » If the patient is dependent on full agonists 
(methadone), the opioid pain relief 
should be in addition to the usual opioid 
treatment dose and the amount of pain 
relief medication titrated against pain whilst 
monitoring respiratory function.
 » Sub-therapeutic doses should be avoided.
 » If the patient is dependent on a partial 
agonist (buprenorphine), specialist advice 
should be sought.
 » Opiate antagonists (naltrexone) will render 
opioid analgesia ineffective.
 » All patients and their carers should be 
informed of and understand the effects 
of OST and opioid blockade on pain 
management.
Chronic pain 
 » Studies show opioid dependent patients 
who develop chronic pain report lower pain 
thresholds than controls.
 » Doctors need to exclude physical 
comorbidities and mood disorders.
 » It frequently requires multi-disciplinary 
team assessment by medical, primary 
care (physiotherapy, occupational therapy, 
psychology), psychiatric, and pain service.
 » Ideally, there would be jointly agreed 
treatment plan, a single prescriber, 
dispensing arrangements to minimise over 
use and diversion, regular reviews, and a 
plan for managing non-compliance or if 
outcomes are not met.
 » Aim for acceptable balance between 
improved function and minimal side-effects.
 » Pain from terminal illness should be 
managed by palliative care team.
Pain and Substance Misuse: Improving the 
patient Experience, British Pain Society, 2006
6.8 ECG Monitoring
Methadone can prolong QTc interval, and 
increase the risk of cardiac arrhythmias. 
The risk increases with increasing doses. The 
current guidance is not uniform, and clinicians 
should consider identifying those with 
significant risk factors for QT prolongation, 
and performing a baseline ECG:
 » Patients on a dose over 100mg methadone.
 » Patients being prescribed other known QT 
prolonging medicines.
 » Patients with a personal or family history of 
significant cardiac disease.
 » Patients experiencing unexplained syncope 
or generalized seizures. 
6.9 Drug Related Deaths
The main causes of drug related deaths are: 
overdose, suicide, accidents and physical 
health complications of drug misuse. 
Concurrent use of benzodiazepines, alcohol, 
and other sedating drugs substantially 
increases the risk of death from methadone 
toxicity. One study found evidence of 
polydrug use in 92% of methadone-related 
deaths.
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6.9.1 Overdose
 » The induction period for OST and the early 
part of treatment are both associated with 
a high risk of overdose, as tolerance can be 
difficult to assess. 
 » Similarly, the period after leaving treatment, 
either after detoxification or with the 
sudden cessation of treatment, are 
associated with an increased risk of death.
 » The risk of overdose is especially high 
following release from prison if tolerance 
has been reduced, they have a history of 
intravenous drug use, and/or a long history 
of opioid dependence or polydrug use.
 » Those who are out of treatment are 
approximately three times more likely to 
die than those who are stable in treatment 
(Farrell and Barry, 2010).
6.9.2 Reducing drug-related deaths
 » Be aware of those most at risk.
 » Provide easy and timely access to 
treatment.
 » Retain people in treatment.
 » Provide education and training to drug 
misusers and their families, on the risks of 
overdose and how to respond effectively.
 » Advise on the dangers of combining drugs, 
especially alcohol and benzodiazepines.
 » Educate new patients on the risks of loss of 
tolerance.
 » Use appropriate supervised consumption in 
the early stages of OST.
 » Confirm satisfactory home storage 
arrangement and document this, especially 
when children are in the home.
 » Conduct or arrange a mental health 
assessment for anyone with a suicidal risk.
 » Liaise effectively with the prison regarding 
transfer of care.
 » Have an emergency protocol in place that 
covers the management of drug overdoses.
6.9.3 Dealing with overdose emergency; 
naloxone
 » Treat opiate overdose with standard 
resuscitation techniques and naloxone.
 » Naloxone is given 0.4-2.0 mg IV/IM/SC, and 
this can be repeated every 3-4 minutes up 
to a maximum of 10 mg.
 » The half-life of naloxone is much shorter 
than methadone or buprenorphine.
 » Patients should be helped to understand 
that they are at risk of life-threatening 
sedation when naloxone wears off.
 » This should be made clear to patients, 
especially in emergency departments and 
other situations where the patient may 
leave suddenly.
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7.1 Key points 
 » Effective, safe and responsive services for service users involve working together and with 
others in teams in primary care, in secondary care, or across both.
 » Interventions must be carried out by trained and competent people with a clear 
understanding of the impact of problematic drug use.
 » Appropriate communication and transfer of information between professionals is vital to 
ensure seamless care. In line with the HSE Consent Policy.
 » Assessment and evidence-based care provided by liaison or multidisciplinary team is 
appropriate in many cases.
 » Quality of treatment should be consistent, across the criminal justice system including 
prisons.
 » Drug users in hospitals will require interventions that facilitate their medical treatment 
and, if possible, improve their engagement with drug misuse treatment. 
 » Clinicians working with pregnant women should aim to support the woman in achieving 
drug stability in order to reduce the risk of neo natal abstinence syndrome (NAS). 
 » Young people are likely to require different interventions compared to adults, and 
healthcare professionals will require specific competencies to deliver these interventions.
 » Information sharing, governance, policies and practice should include guidance for 
clinicians working with the parents of under-18-year-old service users.
 » Older drug users are likely to have increased drug-related and non-drug-related health 
needs. Drug users in pain will have needs for pharmacological and other interventions 
similar to non-drug users.
7.2 Hidden Harm
Parental problematic substance use can 
and does cause serious harm to children at 
every age from conception to adulthood 
e.g., emotional and physical neglect, 
development of serious emotional and social 
problems, elevated risk of Foetal Alcohol 
Spectrum Disorders, and vulnerability to the 
development of substance use problems 
themselves in later life. This may add 
to potential intergenerational problems 
connected to substance misuse.
Two key features of this experience are: 
 » Children are often not known to services 
 » They may suffer harm in a number of ways 
through physical and emotional neglect, 
including exposure to harm and poor 
parenting
Not all parents who use substances experience 
difficulties with parenting and not all children 
exposed to parental substance use are affected 
adversely, either in the short or longer term.
Any issues raised through the assessment 
of family and child welfare (see Table 7) 
need to be managed in accordance with the 
Children First Guidelines: National Guidance 
For The Protection And Welfare Of Children 
(Department of Children and Youth Affairs, 
2011) and its supporting document, Child 
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protection and welfare practice handbook 
(Health Service Executive, 2011). See Appendix 
14. 
Table 7: Assessment of Family and 
Child Welfare
 » Effect of drug use on functioning e.g. 
intoxication, agitation
 » Effect of drug-seeking behaviour e.g. 
leaving children unsupervised, contact 
with unsuitable characters
 » Impact of parent’s physical and mental 
health on parenting
 » How drug use is funded e.g. sex 
working, diversion of family income
 » Emotional availability to children
 » Effects on family routines e.g. getting 
children to school on time
 » Other support networks e.g. family 
support
 » Ability to access professional support 
 » Storage of illicit drugs, prescribed 
medication, and drug-using 
paraphernalia. With consent, 
information should be gathered from 
other professionals, informing the 
patient and  preferably with their 
consent
7.3 Criminal justice system
7.3.1 Garda custody
Accurate assessment by the designated doctor 
of drug misuse in detainees, including the 
degree and severity of dependence and of the 
need for medical intervention is essential, as 
intoxication and withdrawal can put detainees 
at risk of medical, psychiatric and legal 
complications. 
To ensure the continuity of pharmacological 
treatment for drug users taken into custody, 
the Garda station must have access to a level 
2 GP prescriber to:
 » Contact the CTL to confirm if the detainee 
is receiving OST. The CTL is available 9-5 
Monday to Friday, telephone 01 648 8638.
 » If the person is in receipt of OST, contact 
the relevant Drug Treatment Clinic or GP/
Community Pharmacy to confirm details of 
the patient’s prescription and last received 
doses of OST and other medications. 
 » If the person is not currently in receipt 
of OST, it should be requisitioned from 
a pharmacy by the medical practitioner 
under whose care the methadone will be 
provided to the patient, using the standard 
methadone prescription form. 
The Irish College of General Practicers (ICGP) 
has published a protocol for managing OST in 
Garda stations (ICGP, 2015). It is important 
that doctors attending to patients in Garda 
stations confirm the last dose and date of 
dispensing. This information is accessible 
through the dispensing location, the CTL, and 
the patient. 
7.3.2 Drug Treatment Court
The Drug Treatment Court (DTC) programme 
provides an alternative to incarceration to 
people who have been found guilty of offences 
before the District Court, who are struggling 
with substance abuse. 
 » Referral occurs where someone pleads guilty 
or has been found guilty of an offence 
before the District Court, which would 
involve serving time in prison. 
 » The judge responsible for handing down the 
sentence will refer the person to the DTC 
programme, if there is a view in the Court 
that this could work.
 » It is eligible to people over the age of 18 
who have an address in the County of 
Dublin. 
 » It operates from the Chancery Street 
Courthouse. 
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It consists of a multi-disciplinary team who 
supports the DTC Judge. Participants attend 
daily at the City of Dublin Education and 
Training Board (CDETB) centre where they 
receive educational training for the purposes 
of obtaining FETAC qualifications. The CDETB 
staff also work with the participants on 
improving all aspects of their life and provide 
day to day support with recovery efforts. 
These efforts are underpinned by the DTC 
Liaison Nurse, who is employed by the HSE 
and who helps develop a treatment plan for 
each participant, tailored to their needs.
7.3.3 Probation orders
Conditions for drug and alcohol treatment 
can be included as conditions of a probation 
order or as part of a case management plan 
agreed with client/offender before coming out 
of prison on a post-sentence supervision order 
(which is the part of the sentence served in 
the community). 
7.3.4 Prison
As with drug misuse management in 
other settings, there is a need to integrate 
prescribing practice with psychological, 
medical, and social interventions Irish Prison 
Service Drug Treatment Services Review, 
Farrell, 2009; Amato et al., 2004). Integration 
with mental health and primary healthcare 
services is also very important in order to 
address the high levels of complex needs 
within the prison population. 
Prison can present opportunities, as well 
as challenges, to address a wide range of 
clinical needs of drug users. It is Irish Prison 
Service (IPS) policy to offer viral screening, 
vaccination, and appropriate referral to 
specialist services. STI, HIV and Hepatitis C in-
reach services have been developed in prisons 
where high need has been identified. See the 
IPS Drug Treatment Clinical Policy (2008).
 » The prevalence rates for drug use is Irish 
prisons greatly exceed those of the general 
population (Drummond et al, 2014). In 
2015, 1,467 patients were in receipt of 
methadone during the period (with 497 
individuals receiving methadone at the end 
of December 2015).
 » Any patient recorded on the CTL will 
have this treatment continued in prison. 
Clinicians need to liaise with community 
services and Gardaí to verify prescriptions 
and consumption and use appropriate drug 
screens to verify consumption of opioids.
 » Prisoners with addiction problems, 
not already established on OST in the 
community, will be assessed for opioid 
dependence with a view to providing 
appropriate drug treatment.
 » Initiation of methadone in prison is carried 
out in collaboration with community 
services to ensure that there is a treatment 
place available on release from prison.
 » The CTL must be notified if a patient 
is initiated on methadone, completes a 
methadone programme, or is discharged 
from a programme while in prison.
 » On committal to prison, community drug 
services should communicate in writing 
with prison healthcare staff outlining the 
current care plan for the patient. Similarly, 
on release from prison it is the responsibility 
of designated healthcare staff in each prison 
to ensure the community treatment service 
is informed in the form of a discharge letter 
as soon as possible. 
Although clinicians should regard drug misuse 
management in prisons as equivalent to 
any other setting, there are some particular 
differences that may need to be taken into 
account: 
 » The effects of incarceration itself on the 
individual; stress and anxiety.
 » Lower availability of drugs, leading to 
intermittent intoxication and withdrawal.
 » Less injecting behaviour, but when it does 
occur there can be a higher risk due to 
scarcity of injecting equipment.
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 » High volume and frequency of movement 
of prison population.
 » Risk of overdose on release due to 
diminished opioid tolerance.
 » Correlation between drug withdrawal and 
suicide in first week in prison. 
 » High value of drugs in relation to limited 
income of prisoners. 
 » The particular needs of prisoners in custody 
for very short periods of time. 
 » Efforts should be maximised to ensure 
continuation of community treatment on 
release even in circumstances of unplanned 
release.
7.3.5 Discharge from prison setting
 » The principle objective in preparing a drug-
misusing prisoner for release should be to 
prevent overdose; this is done by working to 
prevent relapse, facilitating continuation of 
treatment in the community, and linking in 
with supports and aftercare.
 » Post-release community drug treatment 
should be planned where possible; this 
means close liaison with community 
services and GP before discharge.
 » » The prison should contact the appropriate 
liaison pharmacist if a change of treatment 
location is required.
 » There needs to be contingency plans for 
when unanticipated release of prisoner on 
OST from prison takes place.
 » Re-induction onto OST prior to release can 
be considered for patients who are about to 
leave prison and have an identifiable risk of 
overdose who were not maintained on OST 
during their prison sentence if a community 
treatment place can be sourced.
7.3.6 Phases of OST within the prison 
setting; detoxification
In addition to the guidance provided under 
sections 3.11-3.15 (Phase I: Assessing 
dependence, Phase II: Induction, Phase III: 
Stabilisation, Phase IV: Maintenance, Phase 
V: Detoxification), the following clinical 
considerations for the prison setting should be 
taken into account.
Detoxification within the prison setting
 » As in all treatment settings, treatment exits 
should be negotiable and revisited. 
 » As in all other environments, treatment 
should not be discontinued punitively. 
 » Polydrug use is common and in cases of co-
dependence on any combination of alcohol, 
opiates, and benzodiazepines, more than 
one reduction regime may be needed.
 » Detoxification from more than one drug 
should not take place concurrently, with 
alcohol commonly the initial priority.
 » There is potential for rapid onset of 
withdrawal effects of opiates in prison and 
increased risk of suicide among drug users 
during early days of custody. 
 » Prisoners withdrawing from stimulant drugs 
should be treated according to clinical 
indications and should be observed for signs 
of psychological distress.
7.4 Opiate dependent patients in 
hospital
 » Hospitals are exempt by the Methadone 
Protocol. However, all hospitals should have 
appropriate policies and standard operating 
procedures for the provision of in-patient 
OST services. 
 » The objective of drug treatment in hospital 
is to stabilise drug misuse as quickly as 
possible and treat the drug related or non-
drug related condition.
 » On occasion, patients may wish to take 
the opportunity of a hospital admission to 
reduce their drug doses or even to detoxify 
fully. This may occasionally be useful, but, 
if unplanned, is likely to result in relapse on 
leaving hospital, which in turn exposes the 
patient to overdose risks. 
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 » Transfer of care on admission and discharge 
requires coordinated response by all 
professional staff. 
 » Planned admissions to hospital are 
preferable.
Substitute opioids or other controlled 
drugs should only be prescribed following 
an adequate assessment. The aims of this 
assessment are:
 » To enable treatment of emergency or acute 
problem or enable elective procedure to 
take place.
 » Confirm the patient is taking drugs; history, 
examination and urine analysis.
 » Identify the degree of dependence; opioid 
withdrawal signs may be observed.
 » Identify complications of drug misuse and 
evaluate risk behaviour; blood borne virus 
tests, nutrition, alcohol intake.
 » Consider psychiatric comorbidity.
For patients currently being prescribed 
methadone or buprenorphine, good 
communication between hospital and 
community is essential for safe patient 
care. Prescribing in these cases should be a 
relatively straightforward matter of continuing 
the usual dose of OST while in hospital. The 
OST dose needs to be independently verified 
through the CTL, the community pharmacist, 
and the patient’s methadone prescriber.
For patients not on OST, or where there 
is uncertainty about recent compliance, 
particular care must be exercised in initiating 
OST. 
Initial dosing schedule for opiate dependent 
patients admitted to hospital:
 » Only prescribe following assessment, as 
described above.
 » Polydrug and alcohol misusers may develop 
multiple withdrawal syndromes, so these 
may need to be differentiated to prioritise 
treatment.
 » Methadone may initially mask alcohol or 
benzodiazepine withdrawal symptoms.
 » Exercise particular care in cases of 
respiratory disease, head injury, and liver 
diseases.
 » Exercise care when prescribing additional 
drugs such as sedatives.
 » When it is appropriate to initiate opioid 
substitution in hospital to manage risk of 
withdrawal, methadone is usually preferred 
over buprenorphine.
 » Induction should follow the protocols 
previously described for induction (see 
section 3.10). However, close supervision in 
hospital may allow for a modified protocol.
 » Signs of intoxication, such as drowsiness, 
slurred speech, or constricted pupils indicate 
a need to discontinue the drug or reduce 
the dose.
 » Hospitals should contact community drug 
treatment services before prescribing 
buprenorphine products to ensure 
continuity after discharge as approval from 
PCRS is required before buprenorphine 
products can be reimbursed in a community 
setting for the treatment of opioid 
dependence (see section 3.3.2). 
7.4.1 Other drugs of misuse
Opioid dependant patients in hospital may 
commonly be taking other drugs and misusing 
alcohol.
 » The misuse of benzodiazepines or alcohol 
may lead to associated withdrawal 
symptoms and seizures.
 » Benzodiazepine prescribing should only 
be initiated once dependence has been 
established by history taking and by noting 
symptoms of withdrawal.
 » In the inpatient setting, it is appropriate 
to provide a slow withdrawal regimen over 
one to four weeks, with a starting dose 
of diazepam of no more than 30mg daily, 
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given in divided doses. For a range of useful 
tools and schedules, see the Community 
Detoxification Guidelines (ALDP, 2015).
 » Patients may also require concurrent 
detoxification from alcohol. 
 » Routine prescribing of benzodiazepines 
as hypnotics and as anxiolytics should be 
avoided while in hospital.
7.4.2 Discharge from hospital
For drug misusers not previously in treatment, 
attendance at the emergency department or 
hospital admission may present a window of 
opportunity to put them in touch with other 
services.
On discharge, the following information 
should be given:
 » General health promotion advice.
 » Contacts for further help, such as needle 
exchange, drug treatment services, or self-
help groups.
 » Advice on preventing overdose.
 » Advice on reducing the risk of blood-borne 
viruses and Hepatitis B vaccination.
 » Advice of loss of tolerance in hospital
If the patient was admitted on an opioid 
prescription from the community, this should 
be continued on discharge and prescribing 
responsibility transferred back to the GP or 
HSE addiction clinic. Planned discharge is 
best done in collaboration with local drug 
treatment service, the GP, and the community 
pharmacy. See section 3.8, Referral procedure, 
for change of treatment location.
On the day of discharge confirm the following 
for the community services:
 » Whether that day’s dose has been given and 
how much was given.
 » Any other drugs that the patient is being 
prescribed.
 » Patients should receive their dose on 
the day of discharge and contact should 
be made with their GP and community 
pharmacy to confirm that they have had 
that day’s dose.
 » Arrangements should be made in advance 
of discharge to ensure the patient has 
a place in a community pharmacy to 
receive their methadone and a place with a 
methadone prescribing GP.
7.5 Pregnancy and neonatal care 
Women who are pregnant or who may 
become pregnant are high priority for 
interventions to reduce drug use. Women 
may be more prepared to change drug using 
behaviour if they are pregnant. Substitute 
prescribing can occur at any time in pregnancy 
and carries a lower risk than continuing 
illicit drug use. It allows engagement and 
identification of health and social needs, and 
also offers opportunity for interventions and 
advice to improve outcomes.
All women with problematic substance use 
should be made aware of the benefits of 
antenatal care and advised to attend early 
in pregnancy. Research suggests that women 
who misuse substances have better outcomes, 
as do their infants, if they take up antenatal 
care early and they use services consistently 
throughout pregnancy. However, pregnant 
women, with substance misuse problems, 
can be subjected to social disapproval and 
judgemental attitudes. Discriminatory 
professional practice deters women from 
seeking help.
Drug using women of child bearing age should 
be offered pregnancy test, as amenorrhoea 
is common in female opiate users, and 
symptoms of opiate withdrawal may mimic 
early pregnancy.
If a pregnancy test is positive, a referral to a 
crisis pregnancy agency may be appropriate. 
Referral also may be appropriate to the Drug 
Liaison Midwife service connected to the 
three Dublin Maternity hospitals.
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Drug misusing women are often at risk 
of domestic violence and at high risk of 
antenatal and postnatal mental health 
problems. See the HSE Information Booklet 
‘Substance Misuse in Pregnancy’ (2009).26
7.5.1 Antenatal care
 » The objectives of management are to 
achieve pharmacological, social, medical, 
and psychological stability.
 » The dangers of sudden benzodiazepine or 
opiate detoxification should be highlighted.
 » Efforts should be made to engage drug 
misusing partners in ANC and treatment. 
 » Shared ANC with a GP may not be 
appropriate due to the complex needs and 
high risk pregnancy; ideally, a referral should 
be made to specialist maternity services.
 » Specialist Drug Liaison Midwives are 
employed by Addiction Services and are 
attached to the main Dublin Maternity 
Hospitals. For contact details, See the HSE 
Information Booklet ‘Substance Misuse in 
Pregnancy’ (2009).27
 » Where such a specialist service is not 
available, emphasis should be placed on 
arranging continuity of care, with an open 
channel of communication between all 
relevant parties.
26 Available to download at www.drugs.ie
 » Agencies should consider holding pre-birth 
case conferences early in the pregnancy if 
the child could be considered to be at risk 
when born to identify risk, goals, and the 
plan for discharge.
7.5.2 Prescribing for pregnant drug users
 » Opiate dependent pregnant women should 
not be required to reduce or come off OST 
in pregnancy. Such a detoxification may be 
inappropriate, as it may lead to unnecessary 
risks with the pregnancy.
 » The main objective is to achieve and 
maintain stability for the duration of 
pregnancy and after.
 » In particular, third trimester detoxification 
and dose reduction should not be 
encouraged, as there is evidence that even 
mild maternal withdrawal can be associated 
with foetal distress and stillbirth.
 » For those who continue to request dose 
reductions and detoxification, this should 
be commenced in the second trimester, 
with small frequent reductions e.g. 2-3mg 
methadone every 3-5 days, as long as there 
is no illicit drug use and no evidence of 
maternal withdrawal symptoms.
 » The metabolism of methadone is increased 
in the third trimester of pregnancy, 
therefore it may occasionally be necessary 
to increase methadone dose.
 » If illicit opiate use continues, all efforts 
should be made to stabilise the patient 
on a prescribed opiate, which may involve 
increasing the dose.
 » This may require referral to inpatient 
stabilisation services e.g. Cuan Dara in 
Cherry Orchard Hospital, and St Michael’s 
Ward in Beaumont Hospital.
7.5.3 Effects of drugs on the foetus and 
baby
Evidence has shown that the effects of 
different drugs can be broadly similar, non-
specific, and multifactorial e.g. intrauterine 
growth retardation, pre-term delivery, 
increased rates of low birth-weight, and 
increased perinatal mortality rate.
Opioids:
 » Heroin use can lead to increased rates of 
small for gestinal age babies and pre-term 
delivery.
Methadone:
 » There is an increased rate of Sudden Infant 
Deaths (SIDS) in methadone using women 
(with smoking as a recognised risk factor).
 » The relationship between methadone dose 
and neonatal withdrawal is controversial; 
a recent study in two Dublin maternity 
hospitals showed that incidence and 
duration of neonatal abstinence syndrome 
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were not affected by methadone dose 
and so should not be used as an incentive 
for patients to reduce their methadone 
dose during pregnancy. However, there 
are growing concerns about the effects of 
methadone on the developing visual system 
of the foetus and increased incidence of 
Pierre Robin syndrome in these babies. This 
needs further investigation.
Buprenorphine:
 » Buprenorphine is not licensed for use in 
pregnancy, however, research on women 
already taking this medication when they 
become pregnant does not demonstrate 
any adverse effects on the pregnancy or 
neonatal outcomes.
Cocaine:
 » Cocaine use can lead to higher rates of early 
pregnancy loss, third trimester placental 
abruption, increased rates of stillbirth, 
increased neonatal deaths, and Sudden 
Infant Deaths (SIDS).
 » Cocaine users should be advised to 
stop altogether, as there is no drug for 
substitution prescribing. See Table 6: 
Responses to continued drug or alcohol 
misuse when patients are on OST. For 
stimulant users, the strongest evidence for 
effective psychological treatment is for 
CBT approaches, including motivational 
interviewing, relapse prevention, community 
reinforcement approach, and contingency 
management. A combination of approaches 
is considered to be most effective.
Benzodiazepines:
 » Health risks of benzodiazepines in 
pregnancy have not been clearly 
established. Regular benzodiazepine use in 
pregnancy may be associated with neonatal 
abstinence syndrome.
 » The aim is to stabilise the patient on 
diazepam and then try gradual reduction if 
tolerated without restarting illicit use.
 » A woman on methadone should have her 
dose maintained while trying to reduce 
benzodiazepine use.
 » Women should be informed of SIDS 
precautions and safe sleeping practices.
Nicotine: 
 » Smokers have an increased incidence of 
threatened and spontaneous miscarriage, 
premature birth, low birth weight, perinatal 
death, SIDS etc.
 » Smoking cessation programmes are 
recommended for all pregnant women.
Alcohol:
 » Alcohol has known teratogenic effects.
 » Foetal alcohol spectrum disorder is the 
name used to cover all alcohol related birth 
defects.
 » The only certain way to avoid the risk of 
this is to abstain from drinking alcohol 
during pregnancy. See Table 6: Responses 
to continued drug or alcohol misuse when 
patients are on OST.
 » Pregnant women who drink alcohol at 
hazardous or harmful levels have high rates 
of comorbidity and social problems.
 » Pregnant women using alcohol should be 
offered brief and extended interventions to 
reduce alcohol intake.
7.5.4 Early neonatal care and 
withdrawals
New-born babies should not be removed 
from their mothers unless there is a clinical 
reason to do so. Practices, such as skin-to-
skin contact and breast feeding, should be 
encouraged. Neonatal withdrawal or neonatal 
abstinence syndrome can be associated 
with being on methadone maintenance 
therapy, even when a woman has been stable 
throughout her pregnancy.
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Women should be educated about neonatal 
abstinence syndrome early in the antenatal 
period.
Many babies will not need a paediatric review, 
but it is important to have access to skilled 
neonatal paediatric care.
Signs of withdrawal from opioids tend to be 
vague and multiple and tend to occur 24-
72 hours after delivery. Symptoms include 
high-pitched cry, rapid breathing, ineffective 
sucking, excessive wakefulness, hyper tonicity, 
and convulsions. Babies should not be 
discharged from hospital until 120 hours post-
delivery. Neonatal withdrawal can be delayed 
for up to seven to ten days if a mother was 
taking methadone and benzodiazepines in 
pregnancy. There is a need to see the baby 
regularly in first two weeks to check for 
delayed signs of withdrawals. 
Continuing support is required, including 
parenting advice and training, mental health 
advice, and intervention, where needed. There 
is a need to discuss SIDS and contraception 
with the woman.
7.5.5 Breast feeding
Taking methadone is not a contraindication 
to breast feeding. Breast feeding should be 
encouraged, unless the mother is HIV positive, 
using alcohol, cocaine or amphetamine type 
drugs. In addition, consideration should be 
given if the mother’s drug use is considered 
unstable regarding risks associated with falling 
asleep when breast feeding.
7.6 Young people 
A minority of people under-18 years use 
illegal drugs occasionally, and most of this is 
short term or occasional cannabis use. Drug 
dependence, especially opiate or stimulant 
dependence, and injecting drug use are 
uncommon. Young people with psychosocial 
problems, young offenders, young people with 
mental health problems, and those excluded 
from school are most likely to misuse drugs 
and alcohol.
Drug treatment goals are initially focused 
on reduction of immediate harm, addressing 
psychosocial and interpersonal factors which 
perpetuate substance use and then to try to 
move towards abstinence. Family Therapy 
has been found to be more effective than 
other treatments in engaging and retaining 
adolescents in treatment and reducing their 
drug use.
There is often potential for rapid 
improvements for those with a shorter history 
of substance use.
Although the evidence base for treatment 
in this group is not extensive, evidence and 
clinical experience suggests young people’s 
drug treatment is different from that of adults 
and should be provided separately (NICE, 
2007b).
Structured treatment by specialist 
multidisciplinary substance misuse treatment 
services, in collaboration with other children’s 
agencies is indicated for those with significant 
or complex substance misuse problems. This 
may occasionally involve pharmacological 
interventions.
Pharmacological treatment is required for a 
minority of young people who are physically 
dependent on alcohol, benzodiazepines, or 
opiates. Many of the medication options are 
‘off license’ for this age group. See Guidance 
for the pharmacological management of 
substance misuse among young people 
(Department of Health UK, 2009) 
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Policy and clinical governance issues are also 
different for this group, including: 
 » Consideration of the young person’s ability 
to consent to treatment and competence 
(or capacity to consent)
 » Involvement of those with parental 
responsibility 
 » Confidentiality and information sharing
 » Child protection needs 
 » Competence of clinician and multi 
disciplinary team in working with this group
 » Whether and how to involve other 
professionals 
 » Prescribing and drug licensing
 » Different legal, statutory, and policy 
framework for young people and families
In Ireland, anyone over-16 years old can 
consent to medical, dental or surgical 
procedures. However, the 1937 Constitution 
gives parents very substantial rights and 
other legislation makes it very clear that 
people aged 16–17 years are regarded very 
differently in law from those aged 18 years 
or over. Therefore, even if a 16-year-old does 
consent to an intervention, a doctor needs to 
document his or her assessment of this young 
person’s competence to give it. Every effort 
should also be made to get parents involved in 
all treatment decisions for 16-to-17-year-olds.
The Child Care Act 1991, the Children Act 
2001, and the Mental Health Act 2001 define 
a child as a service user under the age of 18, 
“other than a service user who is or who has 
married”.
A person with parental responsibility (or the 
courts) can consent on behalf of a child who 
lacks capacity to consent for themselves. 
Parents cannot override the competent 
consent of their child to investigations or 
treatments that are in their best interests. 
Legal advice should be sought if a competent 
child refuses treatment necessary to save life 
or avoid serious deterioration in health.
As per section 1.9, duties of confidentiality 
apply to children and young people just as 
much as to adults. In addition to the reasons 
for non consensual disclosure (see section 
1.4), information can be shared about a 
child or young person without consent when 
it is deemed to be in their best interest 
in situations where they do not have the 
capacity to make a decision about disclosure.
In addition to the guidance provided under 
sections 3.11-3.15 (Phase I: Assessing 
dependence, Phase II: Induction, Phase III: 
Stabilisation, Phase IV: Maintenance, Phase 
V: Detoxification), the following clinical 
considerations for under-18 should be taken 
into account.
7.6.1 Methadone induction for under-
18s
 » Induction onto methadone carries the same 
potential hazards as with adult patients, 
with iatrogenic overdose being the greatest 
concern.
 » Inpatient units may be useful 
for methadone stabilisation and 
commencement of therapy in those with 
unclear tolerance, comorbid problems, 
multiple drug use, poor family and social 
support, and for assessment of all other 
domains of functioning.
 » Care should be taken on assessment of 
tolerance and dependence in young people, 
as it is more uncertain in this group.
 » If the extent of physical dependence is 
unclear, consider withholding the initial 
starting dose of opiate until objective 
opiate withdrawal symptoms are witnessed.
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 » Dose induction is similar to that in adults, 
although care must be taken in assessing 
tolerance in relation to body mass.
 » Induction onto methadone is generally 
commenced at doses under 30mg a day and 
lower if tolerance is unclear.
 » Regular clinical review and dose titration in 
response to progress are good practice.
7.6.2 Buprenorphine/buprenorphine-
naloxone induction for under-18s
 » Buprenorphine/buprenorphinenaloxone 
induction should normally be commenced 
at 2 mg, and then titrated according to 
response.
 » All doses of buprenorphine must be 
carefully titrated and adjusted for height, 
weight and age.
7.6.3 Stabilisation for under-18s
Anecdotal evidence suggests stabilisation 
on to substitute medication with retention 
in treatment is greater if the young person’s 
parents are involved and supportive. 
Treatment in day care settings may initially 
allow greater compliance and encourage 
greater retention, particularly if parental 
support is less. In addition to opiate substitute 
medication, a care plan should include 
individual psychological work to support drug 
cessation and should also include very pro-
active case management of the care plan by 
the multidisciplinary team, with a nominated 
team member as the designated key worker.
7.6.4 Maintenance for under-18s
For under-18s, the maintenance phase should 
be short-term and should include individual 
psychological work to support drug cessation 
and a proactive case management of the 
care plan by the multi-disciplinary team and 
named keyworker.
7.6.5 Detoxification for under-18s
 » Some opiate dependant adolescents who 
have resilient personalities and good 
support may be suitable for detoxification.
 » Where physical dependence is not 
substantial, a symptomatic detoxification 
regime can be considered.
 » For those young people, who make a clear 
decision for immediate detoxification 
without a period of substitution treatment, 
lofexidine is an appropriate medication.
 » As with adult detoxification, young people 
who have been stabilised on OST, would 
usually undergo detoxification using the 
same medication.
7.6.6 Under-18s and benzodiazepine use
 » Most often characterised by episodic 
bingeing rather than daily use in young 
people.
 » Benzodiazepine maintenance prescribing is 
not recommended for this group.
 » If detoxification is required, it should be 
gradual and the length and severity of 
dependence should be taken into account.
 » Diazepam doses of 10mgs TDS are sufficient 
as a starting dose, even when previous 
reported use was higher.
 » Benzodiazepine dependence and withdrawal 
can be associated with self-harming and 
suicide, so monitoring of mental state is 
important.
7.6.7 Under-18s and co-morbid 
disorders
 » Psychological treatments are a mainstay 
of treatment but pharmacology may be 
required in certain cases e.g. ADHD or 
depression.
 » Treatment should be in conjunction with 
other professionals, including CAMHS. 
 » See the NICE guidelines on ADHD, 
adolescent depression, and early onset 
psychoses.
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7.7 Older current and ex-drug users
Evidence suggests that drug use continues 
throughout the lifespan and younger drug 
users mature out of their drug use. While 
there is little documented evidence about 
older drug users, the number of older heroin 
users accessing treatment is increasing and 
there are patients in their 40’s, 50’s, and 
60’s receiving OST. Prevalence of over 40’s 
accessing OST was 42% in 2015 (compared 
with 31% in 2013).
Older opiate users are likely to suffer from 
negative social consequences of long term 
of drug use such as unemployment, social 
exclusion, marginalisation, and homelessness. 
Dental deterioration is common. Older drug 
users may seem hostile or suspicious of 
change due to adverse past experiences; an 
understanding of their lifestyle difficulties 
is necessary to manage these attitudes 
constructively.
Older opiate users need all the usual screening 
and monitoring that a non-drug using patient 
would be offered, this should be appropriate 
to their age and general health. They may 
have special health needs caused either by 
complications of long history of drug (and 
alcohol) misuse, or by the problems associated 
with OST.
Complications Examples 
Related to long 
history of drug 
and alcohol 
misuse
Hepatic damage due to Hepatitis B, Hepatitis C and excess alcohol
HIV infection
Chronic airway disease
Chronic lung damage
Increased cardiovascular disease risk
Chronic venous and arterial damage
Poly-pharmacy Risk of drug interactions between methadone and medications used 
to treat other diseases
Normal ageing 
process
Hypertension
Diabetes
Chronic airway disease
Loss of cognitive function 
Chapter 7: Specific treatment situations and populations
7.1 Key points
7.5 Pregnancy and neonatal care
7.2 Hidden Harm
7.6 Young people
7.3 Criminal justice system
7.7 Older current and ex-drug users
7.4 Opiate dependent patients in hospital
7.8 Palliative care and life-limiting 
conditions
1
3
6
A
2
5
4
7
B
Clinical Guidelines for Opioid Substitution Treatment (OST) 69
7.8 Palliative care and life-limiting 
conditions 
Patients on OST are at risk of developing life-
limiting illness associated with drug abuse, 
for example, Hepatitis C, which may lead 
to cirrhosis and liver cancer. They may also 
develop life-limiting AIDS, but this is less 
common with antiretroviral treatment. 
Patients with a history of drug use may also 
engage in other behaviour which increases 
their risk of developing cancer e.g. tobacco 
related lung and head and neck cancers, 
cervical cancer. The problems that patients 
on OST with life-limiting illnesses have are 
similar to those outlined for older people on 
OST.
Patients with life limiting conditions may 
have palliative care needs which are addressed 
by their main health care team, or they may 
have complex palliative care needs, requiring 
referral to specialist palliative care services. 
Patients with life limiting conditions who have 
pain should be referred to specialist palliative 
care, as their pain may be difficult to manage. 
All health care staff caring for people with 
palliative care need competency in dealing 
with those needs.27 
27 See the HSE Palliative Care 
Competence Framework (2014)
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Appendix 1: Clinical Governance
The HSE places an important emphasis on quality and patient 
safety by developing an infrastructure for integrated quality, 
safety, and risk management in order to achieve excellence 
in clinical governance. Formalised governance arrangements 
ensure everyone working in the health and personal social 
services is aware of their responsibilities, authority, and 
accountability and they work towards achieving improved 
patient outcomes. E ffective governance recognises the inter-
dependencies between corporate and clinical governance 
across services and integrates them to deliver high quality, safe 
and reliable healthcare. 
The guiding principles of clinical governance are:
Patient First: Based on a partnership of care between patients, 
families, carers and healthcare providers in achieving safe, 
easily accessible, timely and high quality service across the 
continuum of care 
Safety: Identification and control of risks to achieve eff ective, 
efficient, and positive outcomes for patients and staff
Personal Responsibility: Where individuals, whether members 
of healthcare teams, patients or members of the public, take 
personal responsibility for their own and others’ health needs. 
Where each employee has a current job description, setting 
out the purpose, responsibilities, accountabilities, and standards 
required. 
De fined authority: The scope given to sta ff at each level 
of the organisation to carry out their responsibilities. The 
individual’s authority to act, the resources available and 
the boundaries of the role are confirmed by their direct line 
manager. 
Clear Accountability: A system whereby individuals, functions, 
or committees agree accountability to a single individual.
Leadership: Motivating people towards a common goal and 
driving sustainable change to ensure safe, high-quality delivery 
of clinical and social care. 
Inter-disciplinary working: Work processes that respect and 
support the unique contribution of each individual working 
member of a team in the provision of clinical and social care. 
Inter-disciplinary working focuses on the interdependence 
between individuals and groups in delivering services. This 
requires proactive collaboration between all members.
Supporting Performance: In a continuous process, managing 
performance in a supportive way, taking performance account 
of clinical professionalism and autonomy in the organisational 
setting. Supporting a director/manager in managing the service 
and employees, thereby contributing to the capability and the 
capacity of the individual and organisation, with measurement 
of the patients and staff experience being central in 
performance measurement, as set out in the National Charter 
(HSE, 2010).
Open culture: A culture of trust, openness, respect, and caring 
where achievements are recognised. 
Open discussion: of adverse events are embedded in everyday 
practice and communicated openly to patients. Staff willingly 
report adverse events and errors, so there can be a focus on 
learning, research, improvement, and appropriate action taken 
where there have been failings in the delivery of care. 
Continuous quality improvement: A learning environment 
and system that seeks to improve the provision of services 
improvement with an emphasis on maintaining quality in 
the future and not just controlling processes. Once specific 
expectations and the means to measure them have been 
established, implementation aims at preventing future 
failures and involves the setting of goals, education, and the 
measurement of results so that the improvement is ongoing
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Relevant clinical governance frameworks 
Members of some professions involved in drug treatment 
services are bound by their own governance frameworks: 
 » Doctors: The Medical Council is responsible for protecting 
the public by promoting and better ensuring high standards 
of professional conduct and professional education, training 
and competence among doctors. Doctors are legally obliged 
to enrol in professional competence schemes operated by 
postgraduate training bodies. The Irish College of General 
Practitioners (ICGP) also provides guidance for GPs. 
 » Nurses: The Nursing and Midwifery Board of Ireland, the 
regulatory body for the nursing profession, fulfils a range of 
functions, including: 
• Non-Medical Prescribing/Nurse Prescribing: The term 
non-medical prescribing refers to the prescribing of 
medication by health professionals other than doctors 
and dentists. Currently, only nurses/midwives are allowed 
to prescribe under strictly limited circumstances. The 
Introduction of the Opiate Treatment Protocol specifically 
recommends that “Nurse prescribing of controlled drugs 
should be explored and if possible developed further in line 
with international practice” (Farrell and Barry, 2010, p.36).
• Pharmacists: The PSI is an independent statutory body 
responsible for the effective regulation of pharmacy 
services and supervising compliance with the Pharmacy 
Act 2007.  All pharmacists are legally obliged to undertake 
Continuing Professional Development (CPD), which 
includes maintaining appropriate experience in the 
practice of pharmacy, keeping abreast of continuing 
education and professional developments, and undertaking 
appropriate CPD to their area of practice. 
• Psychologists: The Psychological Society of Ireland 
maintains the standards of practice in Psychology, set by 
its members.28
• Psychiatrists: The College of Psychiatrists of Ireland is the 
sole body recognised by the Medical Council and the HSE 
for Competence Assurance and Training in Psychiatry.29
• Counsellors: Individual counsellors and psychotherapists 
must be accredited members of one of the various 
counselling and psychotherapy representative bodies 
e.g. The Irish Association of Alcohol and Addiction 
Counsellors and/or the Irish Association for Counselling 
and Psychotherapy.
28  http://www.psihq.ie/overview-of-psi 
29  http://www.irishpsychiatry.ie/Home.aspx 
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Appendix 2: Assessment Templates
Example 1: ICGP Addiction Assessment Form (ICGP, 2011)
57
Appendix D
ADDICTION ASSESSMENT FORM
First Name:  ____________________
Last Name:  ____________________
Male             Female
D.O.B.
              Day   Month   Year
Community/Family
General Practitioner _________________
Address:  ___________________________
___________________________________
Tel:  _______________________________
Date of Assessment
                                    Day   Month   Year
Age first took drugs:  ________________
First Drug:  ________________________
Age first took opiates:  _______________
First Opiate:  _______________________
Current Opiate:  _____________________
Route:  ____________________________
How Long:  ________________________
How Much:  ________________________
How often in the past Month
Daily Every 2nd Day
2-3 Days  Weekends Only
If not daily, are you getting withdrawals
                                                  Yes/ No
Are you currently injecting       Yes/ No
Ever Shared                                Yes/No
Currently Sharing                      Yes/No
Substance Use
Substance Previous
Mth
Past Route Frequency Quantity
Heroin
Methadone
Morphine Tabs
Cocaine
Benzodiazepines
Tricyclic
Amphetamines
Ecstasy
Alcohol
Cannabis
Nicotine
Other Addictions
- Gambling
- Eating
Disorder
58
ICD 10 Criteria
Difficulty in controlling heroin intake
Has experienced withdrawal symptoms
Evidence of tolerance
Neglect of commitments
Persistent heroin misuse in spite of evidence of harmful effects
Currently in treatment Yes         No
Social History
Married Single      Separated/Divorced
Stable Relationship         Lone Parent
Living With:
Partner        Partner Taking Drugs
Parents       Parents Taking Drugs
Siblings      Siblings taking drugs
Living Alone       Living with children
Homeless
Living with other drug users
Family History of Alcohol   Yes/No
If Yes,  Mother         Father         Siblings
Mother Alive                        Yes/ No
If no, patient age at time of death          _______
Father Alive                          Yes/ No
If no, patient age at time of death         _______
Parents Together                   Yes/ No
If no, patient age at time of separation  _______
EDUCATION
Still at school                Yes/ No
Age left school              _______
Examinations Passed   ________
POST SCHOOL
Rehabilitation Course       Fas
Apprenticeship        CE Schemes
Third Level         Pre employment
Other
Employment Status
Full Time          Part Time
Unemployed
Student
59
SOURCE OF INCOME SOURCE OF FUNDING HABIT
Employment
Unemployment Benefit
Unemployment Assistance
Lone Parent Allowance
Disability Benefit
Supplementary Welfare
Other
Employment
Partner
Shop Lifting
Serious Robbery
Drug Dealing
Sex Worker
Other
FORENSIC HISTORY
Every in prison:               Yes/ No
On Probation:                  Yes/ No
Case Pending:                   Yes/No
Outstanding Warrant:      Yes/ No
HISTORY (PAST & PRESENT) OF PHYSICAL ILLNESS)
General Health Yes/ No  ________________________________________
Pregnant Yes/ No
DATE OF TEST
HIV status :             Never Tested                Positive               Negative
Hepatitis A status :  Never Tested               Positive               Negative
Hepatitis B status :  Never Tested               Positive               Negative
Hepatitis C status if known:  Never Tested               Positive               Negative
VACCINATIONS IF KNOWN
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Example 1: Addiction Assessment Form (ICGP, 2011)
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PSYCHIATRIC EVALUATION:
During the past 3 months you have felt:
Sad                           Yes/ No
Anxious                    Yes/ No
Frightened                 Yes/No
Guilty                        Yes/No
No Interest                Yes/No
Worthless                  Yes/No
Hopeless                                      Yes/No
Do you think life is worth living  Yes/ No
Do you think about suicide          Yes/No
If yes, have you planned to take your life
                                                      Yes/No
If yes, have you attempted to take your
life
                                                       Yes/
No
URINE INVESTIGATION
DATE
OF
SAMPLE
Opiates Benzodiazepine
Methadone Cocaine Amphetamines Tricyclic
PATIENTS GOALS & AIMS
Motivation on a scale of 1-5
61
MANAGEMENT PLAN
Refer to Central Services                               Yes/No
Treatment                                                       Yes/No
If yes,*Stabilisation
Detox in Patient
Detox out Patient
Slow reduction
Maintenance
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Example 2: Initial assessment used by Cork Kerry Substance Misuse Services, 2015
Service User Consent & Confidentiality Form
This consent & confidentiality form is designed to give you an understanding of: 
What happens to the information you give 
Who has access to the information you give
____________________________________________ Male  / Female 
[Clients Name: Block Capitals] 
Date of Birth ____________________________
1. I understand that by signing / marking this form below, I give consent to the recording of 
my personal information which is ordinarily confidential to the Service. Consent does allow 
that information to be discussed as a team.
2. I understand that I have the right to withdraw consent for the sharing of information at any 
time, except where there is a professional obligation for confidentiality to be extended (e.g. 
Child Protection, risk to self, risk to others, Court order). 
3. I understand that the information I provide is ordinarily not disclosed to people outside 
the Service without further written consent from myself or from my legal guardian, if I am 
under18 years of age.
4. I understand that my information / records are retained in electronic [computer] and, or 
paper form, and are the property of the service provider.
5. I understand that I have the right to access any information held in that record.
6. I understand that consent applies to the duration of this current assessment and, the service 
provided following on from this assessment.
7. I understand that attending this service requires appropriate behaviour.
8. I also understand that selected information from my records’ is also retained by the Health 
Research Board without the use of my name. 
9. All requests for a report for an external agency regarding my attendance at or my treatment 
with this service must be requested in writing with 10 working days advance notice. Such 
reports may require some additional consent.
Please note: In the event of the team becoming aware of information that would indicate that 
you, or someone in your care, or any other person, may be at risk, then staff of this Service have 
a professional responsibility to report that concern to a relevant authority. 
I CONFIRM THAT THE ABOVE CONDITIONS HAVE BEEN EXPLAINED TO ME AND THAT I FULLY 
UNDERSTAND AND AGREE TO THEM. 
Signature of Client: ________________________________ Date: ____/____/_______
DD/MM/YYYY
Signature of Staff: ________________________________ Date: ____/____/_______
DD/MM/YYYY
Consent Specific to Homeless Services Computer System(s) 
Signed ________________________________ Date ______________
 (Service User)
Signed ________________________________ Date ______________
 (Assessor)
Name of organisation:   _________________________________________
Project Worker:  _________________________________________
Contact telephone number:  _________________________________________
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Appendix 2: Assessment Templates
Additional Consent(s) Given 
Additional Consent(s)
For sharing my information with persons named below
I give consent to communicate with the below named people / service provider 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
Signed: ________________________     Date: _______________________
            [Client] 
Witnessed:______________________    Date:  _______________________
Additional Consent(s) Withdrawn
 Withdrawal of Additional Consent(s)
For sharing my information with the persons named below 
I withdraw consent to communicate with the below named people / service provider 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
Signed: ________________________     Date: _______________________
            [Client] 
Witnessed:______________________    Date:  _______________________
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Initial Assessment Form
General information
Name of Client: Male[HRB4] Female[HRB4]
Date of Birth[HRB6] Age[HRB5]
What is the reason for your referral/access to this service? [HRB14]
Alcohol Use      Illicit Drug Use      Licit Drug Use      Other      Homelessness 
TICK ALL APPROPRIATE BOXES
If  ‘Other ’   selected above give details ________________________________________ 
** It is of the utmost importance to the care plan that where relevant the appropriate annex are 
fully completed **
Current / Last / Most Recent Address:_________________________________________________
__________________________________________________________________________________
Phone Number____________________   Mobile Number________________
Agree to contact at above address: Yes    No      On mobile: Yes    No 
Living With [HRB7a] Alone    Parents/ Family    Friends    Partner(alone) 
   Partner & Children    Alone & Children    Foster Care    
   Other    Not Known    
Living Where [HRB7b] Stable accommodation    
   Institution (prison, clinic)    
   Homeless    
   Other unstable accommodation    
   Not known    
   Accommodation type:____________________________
Nationality[HRB10] _____________________________
Ethnicity: [HRB10a] White Irish    
   White Irish traveller 
   Any other white background    
   Black African Background    
   Any other Black Background    
   Chinese Background    
   Any other Asian Background    
   Other    
   Do not wish to answer this question    
Age left Primary or Secondary School  [HRB12a]__________________________
Highest Primary or Secondary Education level reached [HRB12b] ___________________________
Employment Status [HRB11]___________________________ Occupation _____________________
Source of Income _________________________________ Amount of Income __________________ 
What days do you work _______________________________________________________________
What hours do you work ______________________________________________________________
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G.P Name: _______________________________ G.P aware of Drug Use: Yes    No    
GP Address: __________________________________________________________________________
Medical Card: Yes    No    Applying for    
(Homeless Service Only) Medical Card Number  ___________________ Valid until _____________
Substance use in family: Yes    No    
Details ______________________________________________________________________________
No. of children  ___________________ Age Range: ________________________
(Homeless Service Only)  No. of current dependent Children ___________________________
Child Care/Welfare/Protection Concerns: _______________________________
Living with Substance Users/Gamblers/other addictions: Yes    No    
Details ______________________________________________________________________________
Current links with Agencies/External Professionals Involved: Yes    No    
Other services involved in care plan to date_______________________________________________
Next Of Kin 
Name of next of kin / emergency contact: _________________________________
Relationship of next of kin / emergency contact ____________________________
Next of Kin/Family aware of substance use: Yes     No    
Enter contact details of Next of Kin ____________________________________________________
Specific to Drug & Alcohol Services
Substance use, gambling, eating dx, histories [HRB14, 24a, 24b-28e]
Drugs used Route of 
transmission 
Frequency Quantity Duration of 
Use
Age 1st used Date Last 
Used 
Alcohol 
Cannabis
Hallucinogens
Benzodiazepines, 
Hypnotics & 
Sedatives
Prescribed
Street
Heroin 
Methadone
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Drugs used Route of 
transmission 
Frequency Quantity Duration of 
Use
Age 1st used Date Last 
Used 
Other Opiates
Cocaine 
Amphetamine
Ecstasy 
Over the counter
Drugs
Any  other drugs:
[i.e: Solvents / 
Gas Head-shop / 
Steroids’
Others……………….]
Drug of Choice:
Past
Present         
First Drug taken 
Drugs used Route of 
transmission 
Frequency Quantity Duration of 
Use
Age 1st used Date Last 
Used 
Gambling Forms of Frequency Amount Duration Age 1st  Last 
Gambled
Eating Disorders 
Appendix 2: Assessment Templates
1
3
6
A
2
5
4
7
B
Clinical Guidelines for Opioid Substitution Treatment (OST) 79
Risk Management  
Ever injected [HRB29b] Yes    No 
Age first injected [HRB29c] ________________________________
Ever shared [HRB30] Yes    No 
Injected in last month[HRB29a] Yes    No 
Shared in last month Yes    No 
If using I.V. needles how are they obtained ________________________________
If using IV needles how are they disposed ________________________________
HIV test Yes    No    Date Estimated _____________
HBV test  Yes    No    Date Estimated _____________
HCV test  Yes    No    Date Estimated _____________
Last vaccination date:  (Location) ________________________
 Date Estimated ________________________ 
Type of vaccination ________________________________
Place of vaccination ________________________________
Any History of STI’s Yes    No    
Unprotected Risk: Yes    No    
Justice / Legal 
Supports habit with: ________________________________
Most serious charge: ________________________________
Current charge Yes    No 
History of Assault Yes    No 
Details of convictions/Probation?
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
Harm Reduction Advise Given  
Needle Exchange time and places   Yes    No 
Safer sex Yes    No 
Drug Interactions’  Yes    No 
Other (give details)  _______________________________________________________________
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Previous Treatment 
Ever Treated for Substance Use/Gambling [HRB22] Yes    No 
Number of previous treatments __________________
Treatment Type(s)     ___________________
Longest time Drug/Gambling Free: __________________
Date Free From:
Date Free To:
Previous Treatment(s) Agency___________________________________________________________
Reason for leaving ____________________________________________________________________
Current methadone treatment?[HRB 21a, 21b] Yes    No 
Other Current Treatments/Medications Yes    No 
Details: ___________________________________________________________________________
Previous methadone maintenance Yes    No 
Any services currently involved in care provision Yes    No 
Other Relevant History
Any known Allergies [Medical or Any Other]
Past / Recent relevant medical history:
Currently Prescribed Medications
Any history of seizures  Yes    No 
If ‘Yes’ give details _______________________________________________________________
Ever seen by a Psychiatrist/Psychologist/Counsellor/Occupational Therapist: 
 Yes    No  
If ‘Yes’ give details 
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
Any Occupational Therapy  or Other diagnosis ________________________________________
History of Overdoses Yes    No 
Accidental Overdose _______________________________________________
Deliberate Overdose _______________________________________________     
History of Self Harm Yes    No 
History of Domestic Violence Yes    No 
History of suicidal thought Yes    No 
1
3
6
A
2
5
4
7
B
Clinical Guidelines for Opioid Substitution Treatment (OST) 81
Details ______________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
Treatment requested by Service User Yes    No 
Specify:  _____________________________________________________________________________
_________________________________________________________________________________ 
_________________________________________________________________________________ 
________________________________________________________________________________ 
Assessors Actions required following initial assessment not requiring comprehensive assessment 
• Children First / Child protection / Social work referral 
• Direct provision treatment[HRB 18a-1]
• Progress to opiate substitution protocols [HRB 18a-2]
• Refer on to other treatment provider[HRB 18a-3]]
• Psychiatric assessment or review [HRB 18a-4]
• Medical assessment [HRB 18a-6]
• Nursing viral screening or review[HRB 18a-6]
• Harm reduction psycho-educational group[HRB 18a-6]
• other / Involving placement on a list [HRB 18a-6]
• Referral to HAT / Homeless Action Teams 
• Key working toward another services provider ___________________________________
• Other _____________________________________________________________________
Assessors’ comments & Initial Care Plan 
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
Initial assessment completed by:
Signature__________________________________ Date  ___/___/___
Comprehensive assessment needed:  Yes    No 
Comprehensive assessment arranged  Yes    No 
Common assessment needed:  Yes    No 
Common assessment arranged  Yes    No 
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“Annex A” 
Housing information relevant to primary homeless services
Can you outline the main reasons for you 
becoming homeless on this occasion?
Have you been homeless before?
If yes, please give brief details
Have you ever slept rough?
If so when and for how long?
Are you registered with a Local Authority
If so please specify which Local Authority
Do you have any outstanding rent arrears 
with a Local Authority
Have you ever received a deposit 
from C.W.O towards private rented 
accommodation
Address of property/properties deposit was 
given for
*Date of receipt of deposit- approx
*Are you currently entitled to receive a 
deposit from Social welfare office 
Have you ever lived independently
Have you ever been in state care under age 
of 18 years? If so please specify type e.g. 
residential or foster care.
What are the main reasons for you becoming 
homeless? e.g. relationship, drug,alcohol 
issues, discharge from prison/hospital or 
other.
If you were evicted from accommodation 
could you outline the reason for the eviction
What difficulties would you say you have 
experienced in attempting to maintain 
accommodation in the past
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Name: Client No: DOB: 
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Southeast	Regional	Substance	Misuse	Services	
	
Insert	Service	Name	Here	
	
Comprehensive	Assessment	Medical	–	GP	&	Liaison	Nurse	Domain	
	
	
Consent	for	Medical	–	GP	&	Liaison	Nurse	Assessment	Checklist	
	
□	You’ve	explained	to	service	user	the	purpose	of	the	Medical	Assessment,	processes	and	he/she	fully	understands	the	assessment	
process.	
	
□	You’ve	explained	to	the	service	of	and	the	insert	service	name	Confidentiality	&	Information	Sharing	Policy:	
• This	information	is	confidential	within	the	Substance	Misuse	Team	for	the	purpose	of	working	together	to	promote	service	
users	wellbeing	and	provision	of	a	high	quality	service,	clinical	care	and	care	plan.	
• This	information	will	not	be	shared	without	first	discussing	the	need	for	sharing	and	getting	agreement	from	service	user	to	
share.	
	
□:		You’ve	reminded	the	Service	User	of	their		right	to	have	a	member	of	my	family/concern	person	present	with	during	this	
assessment	and	wish	to	include:	
						
										Name	of	family	member/CP:	________________________________	in	my	assessment.			□:	Declined	this	option	
	
	
□:		You’ve	reminded	the	service	user	of	their	right	to	change	their	mind	at	any	time	during	the	assessment	and	remove	consent.		
	
□:		Service	User	agrees	to	participate	in	the	Medical	Assessment	with	the	substance	misuse	service.			
	
□:		Service	User	states	they	are	not	under	pressure	to	take	this	Medical	Assessment.	
	
	
A	witness	should	sign	below	if	the	client	is	unable	to	sign	but	has	indicated	his	or	her	consent.	Young	people/children	may	also	
like	a	parent	to	sign	here	(see	notes).	
	
Signature		 	 	 	 	 	 	 Date		
	
Name	(PRINT)		
	
	
	
Confirmation	of	consent		
	
On	behalf	of	the	Insert	Service	Name	here,	I	have	confirmed	with	the	client	that	s/he	has	no	further	questions	and	wishes	the	
procedure	to	go	ahead.			
	
Staff		
Signature:	 	 	 	 	 	 Date						
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Southeast	Regional	Substance	Misuse	Services	
	
Insert	Service	Name	Here	
	
Comprehensive	Assessment	Medical	–	GP	&	Liaison	Nurse	Domain	
1.0 Client	&	Referral	Details	(Demographics)	
	
1.1	Date	of	
Assessment:	
	
	
_____D_______M_______Y	
1.1a	Assessor’s	Name:	
	
1.2		
Name:	
	
Last:	 	
	
	
1.2a	Client	Number	
	
First:	 	
	
1.3	Address:	
	
	
	
	
	
	
1.4	Phone	No.	
	
(Landline)	___________________________	
	
(Mobile)	____________________________	
	
1.4a	Which	is	best	to	contact	you?		Tick	one		
Landline				□																			Mobile						□	
1.5		GP	Name:	 	
	
	
Medical		
Card	No:			
	
	
1.6	Gender:	 Male							□							Female				□				 1.7		Date	of	Birth	
	
	
	
_____D/_______M/_______Y	
	
1.8	Next	of	Kin:	
	
	
	
	
1.8a		
Phone	
Number:		
	
1.9		Date	of	Referral:	
	
_____D_______M_______Y	
1.9a		Reason	for	referral:	
□	Alcohol						□Drugs	
□	Poly	Drugs				□	Other	
	
1.9b		Priority	Status:	
A:				Pregnancy		□												B:		Under	–	age		□		
C:	Femoral	Injectors:	(Groin/Neck)	□				D:	Self	Harm		□	
	
1.9c	Other	Reason	for	referral/Comments:	
	
	
	
	
Allergies:	
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2.0	Level	of	Problematic	Substance	Use	&	Severity	of	Dependency
2.1	Initial	Assessment	Screening	Result	and	Dependency	Severity	Score	(DSS)	
a. Date	of	AUDIT		Screening
_____D/_______M/_______Y	
Score:	
_________	
Extent	of	problem:	
□ Hazardous	Drinker					□	Harmful	Drinker					□	Dependent
Drinker	
b. Date	of	DUDIT	Screening
_____D/_______M/_______Y	
Score:	
_________	
Extent	of	problem:	
Male	6+		=	□	Harmful	Misuse			Female	2+	=	□	Harmful	Misuse	
Both	genders		25+	=	□	Heavily	Dependent	*	
c. Date	of	CUDIT	-	R	Screening
_____D/_______M/_______Y
Score:	
_________	
Extent	of	problem:	
□ Low	risk						□	Hazardous	Use
□ High	Use	–	Most	likely	Dependent	*
d. Date	of	the	Leeds
Dependency	Questionnaire	
(LDQ)	
_____D/_______M/_______Y	
Score:	
_________	
Dependency	Severity:	
□ Low					□	Medium					□	High
3.0	Current	Substance	Use	
3.1	Substance	Use	History	
What	substances	do	you	use	or	have	you	used,	including	alcohol.	Refer	to	Initial	Assessment	(2.7b)	for	first	substance	of	
choice	and	include	to	this	domain.	
Substance	Type/Age	at	first	use/order	
of	choice		
Route	of	Administration	 Use	in	last	30	days	
(tick	one)	
a. Alcohol
Specify	Type	
__________________	
□ Inject □ Smoke □ Eat/Drink
□ Sniff/snort						□	Sublingual								□	Rectal
□ Topical □ Not	known
□ Once	a	week	or	less
□ 2-6	days	a	week
□ Daily
□ No	use
□Not	know
b. Cannabis
Specify	Type	
__________________	
□ Inject □ Smoke □ Eat/Drink
□ Sniff/snort						□	Sublingual								□	Rectal
□ Topical □ Not	known
□ Once	a	week	or	less
□ 2-6	days	a	week
□ Daily
□ No	use
□Not	know
c. Amphetamine
Specify	Type	
__________________	
□ Inject □ Smoke □ Eat/Drink
□ Sniff/snort						□	Sublingual								□	Rectal
□ Topical □ Not	known
□ Once	a	week	or	less
□ 2-6	days	a	week
□ Daily
□ No	use
□Not	know
Name: Client No: DOB: 
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d.	Benzodiazepines			
Specify	Type	
	
	
__________________	
	
□	Inject														□	Smoke															□	Eat/Drink	
□	Sniff/snort						□	Sublingual								□	Rectal	
□	Topical												□	Not	known	
□	Once	a	week	or	less	
□	2-6	days	a	week	
□	Daily	
□	No	use		
□Not	know	
	
d.	Opioids	
Specify	Type	
	
	
__________________	
	
□	Inject														□	Smoke															□	Eat/Drink	
□	Sniff/snort						□	Sublingual								□	Rectal	
□	Topical												□	Not	known	
□	Once	a	week	or	less	
□	2-6	days	a	week	
□	Daily	
□	No	use		
□Not	know	
	
e.	Hallucinogens	
Specify	Type	
	
	
__________________	
	
□	Inject														□	Smoke															□	Eat/Drink	
□	Sniff/snort						□	Sublingual								□	Rectal	
□	Topical												□	Not	known	
□	Once	a	week	or	less	
□	2-6	days	a	week	
□	Daily	
□	No	use		
□Not	know	
	
f.	Cocaine	
Specify	Type	
	
	
__________________	
	
□	Inject														□	Smoke															□	Eat/Drink	
□	Sniff/snort						□	Sublingual								□	Rectal	
□	Topical												□	Not	known	
□	Once	a	week	or	less	
□	2-6	days	a	week	
□	Daily	
□	No	use		
□Not	know	
	
g.	Inhalants	
Specify	Type	
	
	
__________________	
	
□	Inject														□	Smoke															□	Eat/Drink	
□	Sniff/snort						□	Sublingual								□	Rectal	
□	Topical												□	Not	known	
□	Once	a	week	or	less	
□	2-6	days	a	week	
□	Daily	
□	No	use		
□Not	know	
	
	
h.	Tobacco	Products	
Specify	Type	
	
	
__________________	
	
□	Inject														□	Smoke															□	Eat/Drink	
□	Sniff/snort						□	Sublingual								□	Rectal	
□	Topical												□	Not	known	
□	Once	a	week	or	less	
□	2-6	days	a	week	
□	Daily	
□	No	use		
□Not	know	
	
3.2	Injecting	History	
Please	review	Initial	Assessment	for	Injecting	History	(2.9	–	2.10b)	which	includes	information	related	to	potential	abscess	
sites.	Follow-up	on	the	injecting	questions	in	order	to	give	the	service	user	the	opportunity	to	verify	information	from	Initial	
Assessment	and/or	to	provide	new	information.	
3.2a	Have	you	ever	injected?	
	□	Yes														□	No	
	
If	yes,		age	first	injected:	
	
	
	
3.2b	Have	you	injected	in	the	last	30	days?	
□	Yes										□	No			
OR	
□	Injected	in	the	last	year	but	not	last	30	days	
□Injected	but	not	in	the	last	12	months	
3.2c	Have	you	Shared	injecting	
Equipment:	(tick	one)	
□	Yes													□	No	
If	yes,	have	you	shared	in:	
□	last	30	days								□	last	12	months	
□	more	than	12	months	ago	
3.3.	Prescribed	Medication		
If	a	CA-	Alcohol	&	Drug	History	has	been	completed	please	review	this	assessment	to	avoid	duplication	
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Please	list	all	your	current	medication	and/or	recent	prescribed	medication	including	both	complementary	and	over	the	
counter	medications	
a.	Medication	Type:		
	
Reason:	
Commenced:	_____/______/______	
	
Completed:	_____/______/______	 Dosage,	Frequency	&	Route:		
Dispensing	Pharmacy	◊:	
	
Frequency	Dispensed	◊:	 If	not	taken	as	prescribed	How…	◊:	
	
Reason	for	non-compliance◊:		
	
	
Where	are	you	getting	this	medication?			¨	GP				¨	Chemist				¨		Family	member				¨			Friends							¨	Internet	
¨	Other	specify:		
b.	Medication	Type:		
	
Reason:	
Commenced:	_____/______/______	
	
Completed:	_____/______/______	 Dosage,	Frequency	&	Route	:		
Dispensing	Pharmacy	◊:	
	
Frequency	Dispensed	◊:	 If	not	taken	as	prescribed	How…	◊:	
	
Reason	for	non-compliance◊:		
	
	
Where	are	you	getting	this	medication?			¨	GP				¨	Chemist				¨		Family	member				¨			Friends							¨	Internet	
¨	Other	specify:		
c.	Medication	Type:		
	
Reason:	
Commenced:	_____/______/______	
	
Completed:	_____/______/______	 Dosage,	Frequency	&	Route:		
Dispensing	Pharmacy	◊:	
	
Frequency	Dispensed	◊:	 If	not	taken	as	prescribed	How…	◊:	
	
Reason	for	non-compliance◊:		
	
	
Where	are	you	getting	this	medication?			¨	GP				¨	Chemist				¨		Family	member				¨			Friends							¨	Internet	
¨	Other	specify:		
d.	Medication	Type:		
	
Reason:	
Commenced:	_____/______/______	
	
Completed:	_____/______/______	 Dosage,	Frequency	&	Dose:		
Dispensing	Pharmacy	◊:	
	
Frequency	Dispensed	◊:	 If	not	taken	as	prescribed	How…	◊:	
	
Reason	for	non-compliance◊:		
	
	
Where	are	you	getting	this	medication?			¨	GP				¨	Chemist				¨		Family	member				¨			Friends							¨	Internet	
¨	Other	specify:		
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3.4	When	was	the	last	time	you	misused	substances?	 
Alcohol	
¨ 				Today																											¨ 		Within	last	24	hours																															¨ 	1-2	days	ago																						¨ 	Within	the	week	
3.5			 Are	signs	of	intoxication/affected	present?																¨	YES																¨	No	
3.5a	 If	yes,	what	are	the	observed	(O)	and/or	self-reported	(SR)	physical	signs	below:	
¨	Smell	
	
O/SR		
	
¨	Enlarged	pupils		
	
O/SR		
	
¨	Slurred	or	loud	speech		
	
O/SR		
	
¨	Loss	of	Balance		
	
O/SR		
	
¨	Nausea	or	
vomiting		
O/SR		
	
¨	Quick	Mood	Changes	
(aggression)	
	O/SR		
3.6	 Are	signs	of	withdrawal	present?						¨	YES							¨	No				
3.6a	 If	yes,	what	are	the	observed	(O)	and/or	self-reported	(SR)	physical	signs	below:		
¨		Hand	tremors		
O/SR		
	
¨		Sweating	
	O/SR		
	
¨			Nausea	
O/SR	
¨	Visual	hallucinations 
O/SR	
	
¨	Seizures		(fits)	
O/SR	
ɣ	If	signs	are	present	for	withdrawal,	complete		
Withdrawal	Screening	for	Alcohol	–	CIWA-R	
Drugs	
3.7	 ¨ 				Today																											¨ 		Within	last	24	hours																															¨ 	1-2	days	ago																						¨ 	Within	the	week	
3.8	 Are	signs	of	intoxication/affected	present?																¨	YES																¨	No	
3.8a	 If	yes,	what	are	the	observed	(O)	and/or	self-reported	(SR)	physical	signs	below:	
¨	Small	Pupils	
O/SR		
	
¨	Running	Nose	
O/SR		
	
¨	Slurred	Speech	
O/SR		
	
¨	Glassy	Eyed	
O/SR		
	
¨	Goofing	off	
O/SR		
	
¨	Hyperactivity	
O/SR		
3.9	 Are	signs	of	withdrawal	present?						¨	YES							¨	No				
3.9a	 If	yes,	what	are	the	observed	(O)	and/or	self-reported	(SR)	physical	signs	below:	
¨		Anxiety	or	Jumpiness		
O/SR		
	
¨		Sweating	
	O/SR		
	
¨			Trembling	
O/SR	
¨	Irritability 
O/SR	
	
¨	Headaches	
O/SR	
ɣ	If	signs	are	present	for	withdrawal,	complete	
Withdrawal	Screening	for	Opiate	–	COWS	
Notes:	
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3.10	Current	Substance	Use	Key	Areas	of	Need	
List	needs	identified	from	the	initial	assessment	
Prioritise	
	
§_____________________________________________________________________________________			
	
	
	
§_____________________________________________________________________________________	
	
	
§_____________________________________________________________________________________			
	
	
§_____________________________________________________________________________________			
	
	
§_____________________________________________________________________________________			
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4.0	Current	and	Past	Medical	History	
	
(Before	completing	this	section,	ensure	you	have	review	of	Section	3.0	Physical	Health	of	the	Initial	Assessment	)		
Include	:		
• Physical	Disabilities:		
• Past	Hospital	Admissions	/	Investigations	
• Any	Past	Serious	Illness:		i.e.	Jaundice	/	TB	/	Asthma	/	Thrombosis	/	PE	/	Meningitis.	
• History	of	Seizures:		Frequency	/	Last	Seizure	/	Medication	/?	Diagnosis	
• Any	Family	History	of	Heart	Conditions	/	MI	/	Hypertension	/	Syncope	/	Pacemaker	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
1
3
6
A
2
5
4
7
B
Clinical Guidelines for Opioid Substitution Treatment (OST) 87
Appendix 2: Assessment Templates
Name: Client No: DOB: 
Rev515RN/RRC 	 Page	9	
 
	4.1	Current	or	Past	Medical	Key	Areas	of	Need	
List	needs	identified	from	this	section	of	Medical	Assessment	
Prioritise	
	
§_____________________________________________________________________________________			
	
	
	
§_____________________________________________________________________________________	
	
	
§_____________________________________________________________________________________			
	
	
§_____________________________________________________________________________________			
	
	
§_____________________________________________________________________________________			
	
	
5.0	General	Medical	History	–	Mental	Health	
	
(Before	completing	this	section,	ensure	you	have	review	of	Section	4.0	Psychological	&	
Mental	Health	Domain	of	the	Initial	Assessment)	
	
	
	
5.1	Insert	from	Initial	Assessment	Patient	Health	Questionnaire	-4	(PHQ-4):		Score:			
	
5.1a	If	the	score	is	6	or	more,	a	Hospital	Anxiety	Depression	Scale	was	a	required	action	post	Initial	Assessment.		Has	this	
been	completed	at	time	of	this	medical	assessment?			□	YES					□	NO		
	
If	yes:	HAD	Baseline	Score:	______________/	Date:	_____________	
	
If	no:	Complete	the	HAD	as	identified	in	Initial	Assessment	and	ensure	this	item	is	care	planned.	
	
5.1a	The	Patient	Health	Questionnaire	-4	(PHQ-4)	has	been	included	within	this	medical	assessment	in	the	event	a	re-
screen	is	required.	
	Patient	Health	Questionnaire	–	4(PHQ-4)		
(Ultra-Brief	Screening	for	Depression	&	Anxiety)	
(Developed	by	Drs.	Robert	L.	Spitzer,	Janet	B.W.	Williams,	Kurt	Kroenke	and	colleagues)	
Over	the	last	2	weeks,	how	often	have	you	
been	bothered	by	any	of	the	following	
problems?		
Not	
at	all	
Several	
Days	
More	than	Half	of	
the	Days	
Nearly	Every	
Day	
1	 Feeling	nervous,	anxious	or	on	edge	 0	 1	 2	 3	
2	 Not	be	able	to	stop	or	control	worrying	 0	 1	 2	 3	
3	 Little	interest	or	pleasure	in	doing	things	 0	 1	 2	 3	
4	 Feeling	down,	depressed	or	hopeless	 0	 1	 2	 3	
Sub	Total	 	 	 	 	
Scoring	guidance	-	Score	range	0-12:	score	of	6	or	more	is	an	indication	of	an	 	 	
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underlying	depression	&	anxiety.	
	
	
Total	
	
	
	
5.2		If	it	was	identified	in	the	initial	assessment	(Q4.1,	Q4.1a,	Q4.1b,	Q4.2	&	Q4.2a)	that	service	user	has	a	previously	been	
under	the	care	of	mental	health	services,	Follow-up	on	the	questions	in	order	to	give	the	service	user	the	opportunity	to	
verify	information	from	Initial	Assessment	and/or	to	provide	new	information.	Such	as	more	information	in	relation	to	
when/where?	
	
Previously	been	under	the	care	of	Mental	Health	Services?																		□	YES					□	NO																						When/	Where?	
	
	
	
	
	
	
5.3	Previous	Hospital	Admissions?																																																																□	YES					□	NO																						When/	Where?	
	
	
	
	
	
	
	
5.4	Insert	Initial	Assessment	Short	Screening	Self-Harm	Results:	Follow-up	on	the	questions	in	order	to	give	the	service	user	
the	opportunity	to	verify	information	from	Initial	Assessment	and/or	to	provide	new	information.	
	
		In	the	last	12	months	have	you	ever:	
Wanted	to	harm	your-self?	 □	Never															□	Sometimes																		□	Often								
Wanted	to	end	your	life?	 □	Never															□	Sometimes																		□	Often								
5.4a	Are	you	currently	having	self-harm	or	suicidal	thoughts?									□	Yes														□	No																			
	
5.4b	If	the	answer	to	5.4	was	Often	and/or	5.4a	yes,	a	full	Suicide	Risk	Assessment	was	a	required	action	post	Initial	
Assessment.		Has	this	risk	assessment	been	completed	at	time	of	this	medical	assessment?			□	YES					□	NO		
	
If	yes:	Risk	Assessment	Suicide	Baseline	Score:									Date:	_____________	
	
CURRENT	Risk	 ¨ 		(0-23)	Low	Risk	
Provide	Support	
¨ 	(24-50)	Moderate	Risk															
Intervention	required	
¨ 	(51	-75)		High	Risk	
Immediate	intervention	required		
Risk	Level	
12	month	ago	
¨ 	(0-23)	Low	Risk	
Explore	factors,	triggers	and	what	
helped	
¨ 	(24-50)	Moderate	Risk					
Explore	factors,	triggers	and	similarities	
patterns	and	interventions	&	supports	which	
were	useful	
¨ 	(51	-75)		High	Risk	
EXPLORE	&	identified	the	successful	
interventions	
	
If	no:	Complete	the	risk	assessment	as	identified	in	Initial	Assessment	and	ensure	this	item	is	care	planned.	
	
	
5.4c	The	Short	Screening	Self-Harm	has	been	included	within	this	medical	assessment	in	the	event	a	re-screen	is	required	
due	to	new	information	resulting	in	a	possible	baseline	change.	
	
In	the	last	12	months	have	you	ever:	
Wanted	to	harm	your-self?	 □	Never															□	Sometimes																		□	Often								
Wanted	to	end	your	life?	 □	Never															□	Sometimes																		□	Often								
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5.4d	Are	you	currently	having	self-harm	or	suicidal	thoughts?									□	Yes														□	No																			
	
5.5	Have	you	ever	self-harmed?	
	□	YES					□	NO	
	
	
	
If	yes	and	not	already	commenced,	
complete	a	full	risk	assessment.	
	
5.5a		In	the	past	(>3/12)	
□	YES					□	NO	
	
5.5b	How	many	times?	
	
	
	
5.5c	Recently	(<3/12)	
□	YES					□	NO	
	
5.5d	How	many	times?	
	
	
	
5.5e	Notes:	
	
	
	
	
	
	
5.6	Have	you	ever	taken	an	
Overdose?	
□	YES					□	NO	
	
Please	mention	whether	deliberate	
&/or	accidental	
	
5.6a		In	the	past	(>3/12)	
□	YES					□	NO	
5.6b	How	many	times?	
	
5.6c	Recently	(<3/12)	
□	YES					□	NO	
5.6d	How	many	times?	
	
5.6e	Notes:	
	
	
	
	
	
5.7	Have	you	ever	attempted	
suicide?	
□	YES					□	NO	
	
If	yes	and	not	already	commenced,	
complete	a	full	risk	assessment.	
	
5.7a		In	the	past	(>3/12)	
□	YES					□	NO	
5.7b	How	many	times?	
	
5.7c	Recently	(<3/12)	
□	YES					□	NO	
5.7d	How	many	times?	
	
5.7e	Notes:	
	
	
	
	
	
5.8			If	it	was	identified	in	the	initial	assessment	(Q7.4)	that	service	user	has	learning	difficulties,	Follow-up	on	the	questions	
in	order	to	give	the	service	user	the	opportunity	to	verify	information	from	Initial	Assessment	and/or	to	provide	new	
information.	
	
Learning	Disability	Identified:		□	YES					□	NO													□	Mild					□	Moderate		□	Severe				
	
5.8a	When	diagnosed?		
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5.9	Do	you	suffer	from	Depressive	Episodes?		
	
□	YES					□	NO	
	
	
	
If	yes	and	not	already	commenced,	complete	the	
Becks	Inventory	
	
5.9a	In	the	Past:	
	
	
	
	
5.9b	Currently:	
	
	
	
5.10	Do	you	suffer	from	Recurrent	Depressive	Disorder?																											□	YES					□	NO																					When	Diagnosed?		
	
	
	
	
	
5.11	Do	you	suffer	from	Schizophrenia?																																																								□	YES					□	NO																					When	Diagnosed?	
	
	
	
	
	
	
5.12	Do	you	suffer	from	Panic	Attacks	or	an	Anxiety	Disorder?																□	YES					□	NO																					When	Diagnosed?	
(This	relates	to	Past	&	Present)		If	yes	and	not	already	commenced,	complete	the	HAD	Scale	
	
	
	
	
	
5.13	Do	you	have	ADHD	or	a	Conduct	Disorder?																																											□	YES					□	NO																					When	Diagnosed?	
	
	
	
	
5.14	OTHER	RELEVANT	INFORMATION:	
	
	
	
	
	
	
	
	
	
5.15	Mental	Health	Key	Areas	of	Need	
List	needs	identified	from	this	section	of	Medical	Assessment	
Prioritise	
	
§_____________________________________________________________________________________			
	
	
	
§_____________________________________________________________________________________	
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6.0		 	BBV	Screening	History:	 	 	 (Y=	Yes, 	N=No,	DK	=	Don’t	know)	
Screening	
	
Screened	 Aware	of	Results	 Vaccinations	 How	Many	 Previous	Tx	or	
Referred	
Hep	A	 o	Y			Date………..	
Where………	
o	N	
o	DK	
o	Does	not	want	to	disclose		
o	Y								P	/	N	
Date………..	
Where………	
o	N	
o	DK	
o	Does	not	want	to	disclose		
o	Y				
o	N	
o	DK	
	
		
	 o	Y				
o	N	
o	DK	
	
	Date:	…………….	
Where……………	
Hep	B	 o	Y			Date………..	
Where………	
o	N	
o	DK	
o	Does	not	want	to	disclose		
o	Y								P	/	N	
Date………..	
Where………	
o	N	
o	DK	
o	Does	not	want	to	disclose		
o	Y				
o	N	
o	DK	
	
		
	 o	Y				
o	N	
o	DK	
	
	Date:	…………….	
Where……………	
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Hep	C	
	
	
	
	
	
o	Y			Date………..	
Where………	
o	N	
o	DK	
o	Does	not	want	to	disclose		
o	Y								P	/	N	
Date………..	
Where………	
o	N	
o	DK	
	
	
	
		
	 o	Y				
o	N	
o	DK	
	
	Date:	…………….	
Where……………	
HIV	
	
	
	
	
	
	
o	Y			Date………..	
Where………	
o	N	
o	DK	
o	Does	not	want	to	disclose		
o	Y								P	/	N	
Date………..	
Where………	
o	N	
o	DK	
	
	 	 o	Y				
o	N	
o	DK	
	
	Date:	…………….	
Where……………	
	
If	Client	has	not	been	screened	 Screening	offered				Y	/	N	 Accepted					Y	/	N	 Consent	Signed			Y	/	N	
	� 	Is	Hb	Titre	required?		Y	/	N	 Hb	Titre	offered						Y	/	N	 Accepted					Y	/	N	 Consent	Signed			Y	/	N	
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6.1	BBV	Screening	Key	Areas	of	Need	
List	needs	identified	from	this	section	of	Medical	Assessment	
Prioritise	
	
§_____________________________________________________________________________________			
	
	
	
§_____________________________________________________________________________________	
	
	
	
§_____________________________________________________________________________________			
	
	
§_____________________________________________________________________________________			
	
	
§_____________________________________________________________________________________			
	
7.0	Clinical	Observations	
 
Presentation:	
	
	
	Hair:			
	
	
Skin:		Colour/	Rashes	/	Bruising	/	Sclerosed	veins/Abscesses	/Needle	marks/Self-harm	
	
	
	
Oral	/	Dental:	
	
	
	
Tattoos	/	Piercings:	
Diet/Appetite	
	
	
	
Possible	Eating	Disorder:		Y/N			
Is	an	EAT	24	assessment	required?	Y/N	
Weight	loss	(MUST):		Y/N						
Blood	Pressure	
	
Pulse	 Temperature	 Allergies	
Height	 Weight	 BMI	
	
<	20,	Is	a		MUST	assessment	
required?		Y/N																	
BSL	(If	Diabetic)	
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Hearing	
	
	
	
Sight	/	Pupils	
Normal							
Constricted						
Dilated	
Elimination	/	Bowel		
Normal			
Constipated			
Diarrhoea	/	Loose	
Haemorrhoids	
Elimination	/	Bladder	
Normal								Anuria	
Poyuria	
Dysuria	
If	Pregnant							-	/	40	
	
EDD………………….	
	
First	antenatal	apt	
	
	Y/N					Date:……..…..	
	
	
Contraception:	Y/N											
	
If	Yes,	Type:		…………		
																												
Prescribed	by	Whom:	……….	
	
When:	___________	
	
Menstrual	Cycle:		Regular	/	Irregular	/	Amenorrhoea	
	
First	day	of	Last	Period……………..	
Pregnancy	Test	……..	…….…..	Y/N	
Result…P	/	N	
	
Referred	to:	__________																	Date:	
	
Urinalysis:		Y/N			
	
Result:		
Breathalysed:	Y/N	
	
Result:	
Bloods:						Y/N		
	
Haematology	/	Biochemistry		
Bloods:			Y/N								
	
Serology	/	BBV	Screening		/	Hb	Titre	
	
	
Examination	Notes	/	Doctor:	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Any	Relevant	Comments:	
	
Y	
	
Y	
	
Y	
	
Y	
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7.1	Clinical	Observations	Key	Areas	of	Need	
List	needs	identified	from	this	section	of	Medical	Assessment	
Prioritise	
	
§_____________________________________________________________________________________			
	
	
	
§_____________________________________________________________________________________	
	
	
	
§_____________________________________________________________________________________			
	
	
§_____________________________________________________________________________________			
	
	
	
§_____________________________________________________________________________________			
	
8.0	Outcomes,	Priorities	&	Conclusion	with	Service	User	
 
 
 
8.1.	Comprehensive	Medical	Domain	Outcome	Priorities	&	Conclusion	with	Service	User	
Have	you	discussed	the	outcome	of	the	AOD	Domain	with	the	service	user	and	agreed	identified	needs	below?	
□		Yes			□		No	
	
Medical/LN	Care	Plan	Goas	Identified	–	Priorities/Motivation	
	
§___________________________________________________________________________________			
	
	
§___________________________________________________________________________________	
	
	
§___________________________________________________________________________________			
	
	
§___________________________________________________________________________________			
	
	
	
§___________________________________________________________________________________			
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§___________________________________________________________________________________	
	
8.1a.	Have	risks	screenings	identified	where	full	comprehensive	risk	assessments	are	required?			□		Yes			□		Not	at	this	
time	
If	yes,	list	the	identified	comprehensive	risk	assessment(s)	required?		
	
	
	
	
	
8.2.	List	of	possible	services	required	&	onward	referrals	needed.			If	a	referral	is	required,	have	discussed	with	service	
user	the	reason	why	this	would	be	helpful		□	
	
Service	Type	 Reason	for	referral	 §Consent	given	to	refer	
	
	
	 □	Yes		□	Declined	
	
	 	 □	Yes		□	Declined	
	
	 	 □	Yes		□	Declined	
	
	 	 □	Yes		□	Declined	
	
	
	
§□	You	and	the	service	user	completed	and	signed	a	consent	form(s)	for	referral(s)	and	release	of	Medical	Domain	
Outcome,	if	appropriate.				
	
	
We	have	discussed	a	follow	up	plan	from	this	service	on	any	agreed	referrals	as	part	of	this	assessment	process?		
	
□	Yes							□	Declined	
	
	
Have	you	discussed	with	the	service	user	follow	up	information	to	be	provided	back	to	the	referring	agency	and	have	
agreed	the	information	to	be	feedback?		
	
□	Yes							□	Declined	
	
	
Have	you	offered	the	service	user	a	debrief	session?		□	Yes							□	Declined					
	
	
1
3
6
A
2
5
4
7
B
Clinical Guidelines for Opioid Substitution Treatment (OST) 92
Appendix 2: Assessment Templates
Name: Client No: DOB: 
Rev515RN/RRC 	 Page	20	
 
	
	
Signature	of	Service	User:	_____________________________			Date:	__________	
	
Print	Assessors	Name:		_____________________________________,			Liaison	Nurse	
	
Signature	Assessor	:______________________________	Date:________________	
	
(Substance	Misuse	Service	Only)	
	
Clinic	Doctor:	_______________________________	___Date:	________________	
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Appendix 3: Care plan templates
The following template structures are taken from the National Drugs Rehabilitation framework 
(2010). It is intended that there be one shared care plan for each service user, which will be 
monitored and reviewed by the case manager. 
Care plan template (for shared care plan).
This shared care plan can be split into separate sections, with various key workers taking 
responsibility for the implementation and review of these. Each row is completed and monitored 
by an individual key worker; the case manager oversees the entire plan.
Care plan template (service user and key worker)
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Recommendations re appropriate patient cohort 
of the Expert Group on the Regulatory Framework 
for products containing buprenorphine / naloxone 
and buprenorphine-only for the treatment of opioid 
dependence
3 3   In the interests of public health, and based on a clinical 
assessment, buprenorphine / naloxone may be most 
appropriate for use in the following cohorts of patients 
or in the following circumstances: 
3 3 1  Patients currently receiving treatment with 
buprenorphine / naloxone who should be maintained on 
buprenorphine / naloxone.
3 3 2  Patients with a specific medical need for whom 
methadone is contraindicated or not suitable, such as: 
• patients with prolonged QT intervals, 
• male patients with feminisation syndrome, 
• patients on neuroleptic medications which also affect 
QT interval 
• patients on high dose methadone treatment, who 
are also being treated with medicines which inhibit 
CYP450 enzymes (such as antiretroviral agents e.g. 
efaverinz or the anti-infective rifampicin etc.) and 
therefore are at greater risk of drug interactions or 
• patients diagnosed with HIV in order to facilitate 
alternative HIV treatment options.
3 3 3 Methadone-naïve patients or patients, including young 
patients, where detoxification is a primary goal of 
treatment, provided the prescriber is of the opinion that 
detoxification is a realistic goal for the patient.  
3 3 4 Patients being treated for codeine and other 
pharmaceutical opioid dependencies. 
3 3 5 Patients where, having regard to all of the patient’s 
circumstances, the prescriber is satisfied that there is 
clear evidence that the patient has been stable, socially, 
domestically and from a family perspective, for at least a 
period of six months, and particularly where the patient 
is in stable employment or education, and that the 
patient demonstrates a commitment to compliance with 
the treatment programme.
3 4 Buprenorphine / naloxone may not be suitable for the 
following categories of patients: 
• patients who are not stabilised on methadone, 
• patients who are poly-drug users,
• patients who are problem benzodiazepine users, and
• Patients with a history of non-compliance with 
treatment regimes
Appendix 5: Recommendations re appropriate patient cohort for buprenorphine / naloxone
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Appendix 6: Pharmacy Transfer Form
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Appendix 7: National Waiting List Information Sheet
1
3
6
A
2
5
4
7
B
Clinical Guidelines for Opioid Substitution Treatment (OST) 98
Appendix 8: Central Treatment List Entry Form
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Increase Methadone effects Decrease Methadone Effects
Anti-infection Antibacterial Ciprofloxacin
Clarithromycin
Erythromycin
Fusidic Acid
Rifampicin
Antifungal Fluconazole
Ketoconazole
Antiretroviral Delaviridine Abacavir
Amprenavir
Efarvirenz
Lopinavir/Ritonavir
Nelfinavir
Nevirapine
Ritonavir
Cardiac Ca++ channel blocker Verapamil
Corticosteroid Dexamethasone
Gastrointestinal Cimetdine
Omeprazole
Neurologic Anti-alcohol Disulfiram
Anticonvulsant Carbamazepine
Phenytoin
Migraine Dihydroergotamine
Opioids Buprenorphine
Naloxane
Naltrexone
Pentazocine
Appendix 9: Drug to drug interactions with methadone
1
3
6
A
2
5
4
7
B
Clinical Guidelines for Opioid Substitution Treatment (OST) 100
Appendix 9: Drug to drug interactions with methadonep.19
Increase Methadone effects Decrease Methadone Effects
Psychiatric Antianxiety Diazepam
Antidepressant Fluoxetine
Fluvoxamine
Moclobemide
Nefazodone
Paraxetine
Barbiturate Amobarbital
Butalbital
Pentobarbital
Phenobarbital
Secobarbital
Urologic Diruetics Spironolactone
Urinary
acidifiers
Vitamin C (in large doses)
Urinary 
alkalizers 
Sodium Bicarbonate 
Potassium Citrate)
Herbal drugs Cat’s Claw
Chamomile
Echinacea
Goldenseal
St. John’s Wort
Food Grapefruit Juice
Addictive drugs Alcohol (Acute Use) Alcohol (Chronic Use)
Cocaine 
Heroin
Tobacco
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Symptom Drug
Muscle cramps Quinine sulphate normally 200 to 300 mg at night
Gastrointestinal spasm/stomach cramps Hyoscine butylbromide (Buscopan) 10 to 20 mg qds pm
Diarrhoea Loperamide hydrochloride (Imodium) 4mg stat, then 2 mg after each loose 
stool (maximum of 10mg in 24 hours)
Nausea Metoclopramide hydrochloride 10 mg tds
Note: Domperidone is not suitable due to increased risk of QT interval 
prolongation in patients receiving Methadone.
Anxiety Propranolol 10 mg pm
Bone pain and headaches Paracetamol 1 g qds, or 
Non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen
400 mg tds after food 
Sedation Trazodone 100 to 150 mg nocte, or 
Diazepam 2 to 10 mg pm day and 10 mg nocte for 3 to 5 days
Appendix 10: Drugs that may help symptoms in the end stages of detoxification (RCGP, 2010, p.19)
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MATRIX ADVANTAGES DISADVANTAGES
Urine Available in sufficient quantities
Higher concentrations of parent drugs and/or metabolites than in blood
Availability of point-of-care tests (POCTs) 
Well-researched testing techniques 
Short to intermediate window of detection 
Easier to adulterate or substitute
May require supervised collection in certain clinical/legal situations 
Oral Fluid Non-invasive specimen collection 
Easy to collect
Reduced risk of adulteration 
Directly observed specimen collection
Parent drug rather than metabolite can be the target of the assay
Able to detect same-day use, in some cases
Detect residual drug in the mouth 
Limited specimen volume 
Possibility of contamination from residual drug in mouth that cannot be 
correlated with blood concentrations 
Short window of detection
In certain circumstances, a period of observation of 10-15 minutes is required 
before sampling 
Hair Longest window of detection
May be able to detect changes in drug use over time (from 7–10 days after drug use to 3 
months, depending on length of hair tested)
Directly observed specimen collection
Non-invasive specimen collection 
Easy storage and transport
Difficult to adulterate or substitute
Readily available sample, depending on length of hair tested 
Cannot detect use within the previous 7–10 days
Difficult to interpret results 
Few laboratories available to perform testing 
Difficult to detect low-level use (e.g., single-use episode) 
May be biased in respect of hair colour 
Specimen can be removed by shaving 
Sweat Detects recent use (fewer than 24 hours with a sweat swipe) or allows for cumulative 
testing with the sweat patch (worn for up to 7–14 days)
Non-invasive specimen collection
Difficult to adulterate
Requires little training to collect specimen 
Few facilities and limited expertise for testing 
Risk of accidental or deliberate removal of the sweat patch collection device
Unknown effects of variable sweat excretion among individuals 
Only a single sweat collection patch available so multiple analyses cannot be 
done if needed
Appendix 11: Different Matrices for Drug Testing, adapted from TAP 32 (SAMHSA, 2012)
1
3
6
A
2
5
4
7
B
Clinical Guidelines for Opioid Substitution Treatment (OST) 103
Blood Generally detects recent use
Established laboratory test method 
Expensive
Limited window of detection
Invasive specimen collection (venipuncture) 
Risk of infection
Requires training to collect specimen
May not be an option for individual with poor venous access 
Breath Well-established method for alcohol testing 
Readily available 
Used for alcohol 
Short window of detection 
May be difficult to obtain adequate sample especially with patients who are very 
intoxicated or uncooperative 
Appendix 11: Different Matrices for Drug Testing, adapted from TAP 32 (SAMHSA, 2012)
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Drug or is metabolite(s) Duration of detection in urine Duration of detection in oral fluid
Amphetamines including methyl amphetamine and MDMA 2 days
Between 24 and 48 hours for most 
drugs
Benzodiazepines:
 » Ultra-short-acting (half-life 2h) (e.g. midazolam)
 » Short-acting (half-life 2-6h) (e.g. triazolam) 
 » Intermediate-acting (half-life 6-24h) (e.g. temazepam, chlordiazepoxide) 
12 hours
24 hours
2-5 days
 » Long-acting (half-life 24h) (e.g. diazepam, nitrazepam) 7 days or more
Buprenorphine/buprenorphine - naloxone and metabolites 8 days
Cocaine metabolite 2-3 days
Methadone (maintenance dosing) 7-9 days
Codeine, Dihydrocodeine, Morphine 48 hours
Propoxyphene
Heroin is detected in urine as the metabolite 6 
acetyl morphine (6am)
24 hours
Cannabinoids 
 » Single use
 » Moderate use (three times a week)
 » Heavy use (daily)
 » Chronic heavy use (> three times a day)
3-4 days
5-6 days
20 days
Up to 45 days
Appendix 12: Approximate Durations of Detectability of Selected Drugs in Urine/Oral Fluid
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1. Employ a Recovery Perspective 
 » Recovery is a long-term process of internal change, including 
steps forward and sometimes steps backward. Recovery 
recognizes that internal changes proceed through various 
stages. 
 » Develop a treatment plan that provides for conti nuity of care 
over time.
 » Recognize that treatment may occur in different settings 
over time (e.g., residential, outpatient) and that much of the 
recovery process occurs outside of or following treatment. 
 » Devise treatment interventions that are specific to the tasks 
and challenges faced at each stage of the co-occurring 
disorder recovery process. 
 » Use sensible, step-wise approaches in developing and 
using treatment protocols. Consider markers unique to the 
individual’s culture. 
2. Adopt a Multi-problem Viewpoint 
 » People with COD generally have an array of mental health, 
medical, substance abuse, family, housing, and social 
problems. 
 » Services should be comprehensive to address these problems. 
 » Engagement, stabilisation, treatment, and continuing care 
are treatment phases that can enable the clinician to offer 
stage-appropriate treatment protocols. 
3. Address Specific Personal and Social Problems Early in 
Treatment 
 » Approaches may incorporate case management and 
intensive case management to help clients find housing or 
handle legal and family matters. 
 » Often, solving such problems is an important first step 
toward achieving service user engagement in continuing 
treatment. 
4. Plan for the Client’s Cognitive and Functional Impairments 
 » In relatively short, highly structured treatment sessions 
that focus on practical life problems, present interventions 
compatible with the client’s cognitive and functional 
impairments.
 » Careful assessment of such impairments such as alcohol 
related brain injury and a coordinated treatment plan 
consistent with the assessment are essential. 
5. Use Support Systems 
 » The mutual self-help movement, the family, the faith 
community, and other resources that exist within the client’s 
community can play an invaluable role in recovery. This can 
be particularly true for clients with COD, as many have not 
enjoyed a consistently supportive environment. 
 » Personal responsibility, self-management, and helping one 
another are the basic tenets of mutual self-help approaches. 
 » Mutual self-help principles, highly valued in the substance 
abuse treatment field, are now widely recognized as 
important components in the treatment of COD. 
The client with COD who successfully completes treatment 
must face the fragility of recovery, the toxicity of the 
past environment, and the negative impact of previous 
associates who may encourage drug or alcohol use and illicit 
or maladaptive behaviours. There is a need for groups and 
activities that support change. In this context, it is important 
that these clients receive support from families and significant 
others. There is also the need to help the client reintegrate into 
the community through such resources as religion, recreation, 
and social organizations.
Appendix 13: Guiding principles for working with clients with Co-Occurring Disorders (COD) (SAMSHA TIP 42)
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 » Professionals who are treating a person with a mental health 
or addiction problem must consider the welfare and safety 
of any children in that person’s family and/or children in 
regular contact with the person
 » Where there are concerns, these must be discussed and 
reported to the HSE Children and Family Services, as 
outlined in the standard reporting procedure
 » Professionals in the adult mental health and addiction 
services may find themselves assessing people who have 
a history of abusing or neglecting children. In such cases, 
the potential risk to any child with whom this person may 
have contact must be considered and communicated to the 
HSE Children and Family Services and to any other service 
involved in providing treatment or other assistance to the 
family
Where work with a family involves both the victim and the 
perpetrator of abuse, it is essential that efforts are coordinated 
and that information is shared between professionals. The 
child’s needs must remain paramount. All decisions taken in 
relation to parents/carers with a mental health or addiction 
problem of relevance to the child’s protection and welfare, such 
as a discharge back to their family or termination of treatment, 
must be communicated to the relevant HSE personnel.
Appendix 14: Roles and responsibilities of Mental Health and Addiction Services under Children First National Guidelines (Department of Children and Youth Affairs, 2011, p.25)
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Hepatitis B
Dose Volume Schedules 
(months unless stated)
Age 16 years 
and older
Engerix B 20mg 1ml 0,1,6
0,1,2,121
0,7,21 DAYS2 + 12
months
HBVAXPRO 10 10mg 1ml 0,1,6
0,1,2,121
Hepatitis A and B
Dose HAV/
HBV
Volume Schedules 
(months unless stated)
Age 16 years 
and older
Twinrix 720IU/ 20mg 1ml 0,1,6
0,7,21 DAYS2 + 12
1: When rapid protection is required   2: When very rapid protection is required
Appendix 15:  Summary Tables of Vaccinations for Hepatitis A and B
Anti-HBs Level Action Required
0 or <10 mlU/ml Non responder
Test for anti-HBc*
If anti-HBc negative, repeat full course of hepatitis 
B vaccine (use a different brand)
Recheck anti-HBs remains <10 mlU/ml, person is susceptible to 
HBV
10-99 mlU/ml Low response
If low level anti-HBs confirmed by 2 different assays, give booster 
dose if at increased risk (see page 12)
There is no need to retest for anti-HBs
100 mlU/ml or greater Good response
No need for further vaccine or anti-HBs 
Investigations 
* For those who are performing exposure-prone procedures, HBsAg testing should also be carried out.
HBsAg HBeAg Anti-HBe Anti-HBclgM Anti-HBc total Anti-HBs Interpretation
Neg Neg Neg Neg Neg Neg Susceptible to HBV
POS POS Neg POS/Neg POS/Neg Neg Acute HBV infection
Neg Neg Neg POS POS1 Neg Recent HBV infection (HBsAg window)
POS POS Neg Weak POS/Neg POS Neg Chronic HBV infection2
POS Neg POS/Neg Weak POS/Neg POS Neg HBeAg neg chronic HBV infection3
Neg Neg POS/Neg Neg POS POS/Neg Resolved HBV infection
Neg Neg Neg Neg Neg POS Response to hepatitis B vaccine
Notes
1  Anti-HBc detected in two assays
2  Follow up sample required to confirm chronic HBV infection
3  Follow up sample required and also HBV DNA viral investigations may be required
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